



# Baltic Statistics on Medicines 2010–2012



# Baltic Statistics on Medicines 2010-2012

Tartu 2013

**Edited by:**

**Estonian State Agency of Medicines**

Ly Rootslane, Ott Laius, Janne Sepp, Katrin Kurvits

**Latvian State Agency of Medicines**

Andis Seilis, Elma Gailīte, Dace Ķikute

**Lithuanian State Medicines Control Agency**

Dr Jolanta Gulbinovič, Renata Tomaševič, Vaida Stasevičiūtė

**Published by:**

Estonian State Agency of Medicines

1 Nooruse Street

50411 Tartu

Estonia

[info@ravimiamet.ee](mailto:info@ravimiamet.ee)

[www.ravimiamet.ee](http://www.ravimiamet.ee)

When using or quoting the data included in this issue, please indicate the source.

ISBN 978–9949–33–396–7 (print)

ISBN 978–9949–33–397–4 (pdf)



Printed by environmentally friendly printinghouse Ecoprint

# Contents

<b>1. Preface</b> .....	3
<b>2. Facts about the Baltic countries</b> .....	3
<b>3. Medicinal products regulation and pharmaceutical services in the Baltic countries</b> .....	8
3.1. Procedures of marketing authorisation of medicinal products in the Baltic states .....	8
3.2. Marketing authorization licences.....	9
3.3. Non-authorised medicinal products .....	9
3.4. Medicinal products mark-up.....	10
3.5. Generics market.....	13
3.6. Retail and hospital pharmacies and wholesalers .....	14
<b>4. Drug reimbursement systems in the Baltic countries</b> .....	17
4.1. Description of the reimbursement systems.....	17
4.2. Changes in the reimbursement systems .....	20
(during the period of 2010–2012)	
4.3. Reference price systems.....	22
<b>5. Materials and methods used in the Baltic Statistics on Medicines</b> ...	24
5.1. Data collection in the Baltic states .....	24
5.2. ATC/DDD methodology and interpretation of drug sales statistics .....	25
5.3. Factors affecting the interpretation of drug utilization data.....	26
<b>6. Cost of drugs as a share of total health care expenditure in the Baltic countries</b> .....	27
6.1. The medicinal products market .....	27
6.2. Sale of drugs according to the ATC main groups.....	28
(DDD/1000 inhabitants/day)	
6.3. Sale of drugs according to the ATC main groups (turnover).....	30
<b>7. Sales statistics 2010–2012</b> .....	33
<b>8. TOP 15 of prescription only medicines</b> .....	156
<b>9. TOP 15 of ATC 3rd groups</b> .....	157
<b>10. TOP 15 of over-the-counter medicines</b> .....	158
<b>11. Contacts</b> .....	159
<b>12. References</b> .....	160



## 1. Preface



**Kristin Raudsepp**  
Director General  
State Agency  
of Medicines  
Estonia



**Inguna Adoviča**  
Director  
State Agency  
of Medicines  
Latvia



**Gintautas Barcys**  
Director  
State Medicines  
Control Agency  
Lithuania

This book is a statistical summary of the medicines consumption data of the Baltic countries (Estonia, Latvia and Lithuania) in 2010–2012.

The national consumption statistics are published annually in all the Baltic countries; this is the first joint publication which provides comparative data illustrating the trends of interest and the national differences.

Medicines are classified according to the Anatomical Therapeutic Chemical (ATC) classification and the Defined Daily Dose (DDD) is used as a measurement – both of these are proposed by the World Health Organization (WHO) for the medicines consumption studies. These systems are coordinated by the WHO Collaborating Centre for Drug Statistics Methodology in Oslo.

The history of the Baltic countries has been quite similar during last 70 years. At the beginning of the 1940's all Baltic countries were occupied by the Soviet Union – during the Soviet period all the medicinal products were supplied centrally and the selection and availability of the products was similarly limited in all countries. When countries regained their independence in the early 1990's the national health care systems and marketing authorization procedures were developed with some differences between the countries. Since May 1st, 2004 all the three countries are Member States of the EU and their frame for regulating the pharmaceutical market is based on the same basic directives and regulations. Still, national differences

may be met in some areas. Over the 20 years of development the drug regulatory agencies have become stable organisations with all the possibilities to meet the developments in science, pharmaceutical industry and legislation.

Current publication gives the reader an overview of how the differences and similarities of our countries have influenced the drug use.

You will find the description of the reimbursement systems, an overview of the medicinal products market and other related subjects followed by the data on the consumption of the main groups of medicines.

The specialists of the State Agencies of all three countries were involved in compiling this publication and we hope that it is the beginning of a new tradition.



## 2. Facts about the Baltic countries

	Estonia	Latvia	Lithuania
Population (01.01.2013)	1 286 540	2 023 825	2 979 310
Total health expenditure (2011, euro)	921 mln	1 242 mln	2 121 mln
Total health expenditure per capita (2011, euro)	687.4	634	614.5
GDP per capita (2011, euro)	11 904	9 873	10181
Total health expenditure as a % of GDP (2011)	5.8%	6.2%	6.6%
Medicinal products turnover (2012, wholesale, VAT excluded, euro)	222 mln	260 mln	404 mln
Number of general pharmacies per 100 000 inhabitants (01.01.2013)	37	43	47
Number of physicians per 100 000 inhabitants (01.01.2013)	468	343	420
Total number of reimbursed prescriptions (2012)	7.6 mln	5.7 mln	12 mln
Currency (01.01.2013)	euro	Latvian lat 1 euro is equal to 0.7028 lats	Lithuanian litas 1 euro is equal to 3.4528 litas

## 3. Medicinal products regulation and pharmaceutical services in the Baltic countries

### 3.1. Procedures of marketing authorisation of medicinal products in Baltic States

The procedure of the marketing authorisation of the medicinal products in the Baltic States is following the European Union (EU) law as well as the EU and international guidelines. The procedures are similar in all EU member states. An application for a marketing authorisation for a medicinal product may be filed under the mutual recognition, decentralised, centralised or national procedure.

The **National Procedure** may be used when an application for the marketing authorisation of a product is filed for the first time in the EU. This procedure may also be applied to the 'extensions of marketing authorisations', wherein an application is filed, for example, for a new strength or pharmaceutical form of a product already approved nationally. After the evaluation of the application the product may be granted a marketing authorisation nationally.

The **Mutual Recognition Procedure (MRP)** makes use of a marketing authorisation already granted for the medicinal product by an EU Member State (or by Norway or Iceland). The Member State whose evaluation statement is used as grounds for recognising the marketing authorisation is known as the Reference Member State (RMS), while the member state recognising the authorisation is known as the Concerned Member State (CMS).

The **Decentralised Procedure (DCP)** may be applied for products that do not have a marketing authorisation in any Member State. This procedure will allow concomitant application for authorisations in both the RMS and the CMS. The process is conducted by the RMS while the CMSs participate in the evaluation of the application prior to the granting of the marketing authorisation in any of the Member States taking part in the process.

In the event that a marketing authorisation is recognised, the product will be granted a national marketing authorisation as soon as the national translations of its summary of product characteristics (SPC), package information leaflet (PIL) and labelling confirming to the SPC mutually agreed in the Mutual Recognition or Decentralised Procedure are ready and approved.

The **Centralised Procedure** is used when a marketing authorisation is applied within the entire EU area for the new biotechnological and other innovative medicinal products. Such marketing authorisation applications are filed with the European Medicines Agency (EMA). Applications for the marketing authorisation concerning the medicinal products for human use are evaluated by the Committee for Medicinal Products for Human Use (CHMP) and those for veterinary use by the Committee for

Medicinal Products for Veterinary Use (CVMP). Each Member State has nominated one regular member and one alternate member to each of these committees. Furthermore, five auxiliary members have been elected to each committee based on their scientific competence.

For each application the Committees will elect a rapporteur and a co-rapporteur from among their members to carry out the evaluation of the application with the aid of the resources made available by the medicines agencies of the Member States. Based on the reviews obtained, the committees will issue a scientific statement to be submitted to the EU Commission for the actual decision-making process. The marketing authorisation granted by the Commission is valid in every Member State.

### 3.2. Marketing authorisation licences

**Table 1. Marketing authorisations in January 2013**

	Estonia	Latvia	Lithuania	Centrally Authorised Products (CAP) in EU
Number of trade names	2848	2734	2850	780
Number of INN	829	1340	921	365
Number of products	3905	4542	5004	1821

### 3.3. Non-authorised medicinal products

As a general rule, the medicines used in all three Baltic states must have a marketing authorisation. Considering the relatively small size of the pharmaceutical market in all three countries, non-authorised medicines may be used exceptionally if there is no suitable authorised medicine in the register or if the authorised medicine is not available.

#### ■ ESTONIA

The use of the non-authorised medicines is permitted on the basis of applications from doctors (for ambulatory use per patient or for in-hospital use per medical institution for a maximum of 1 year) or from professional organisations (for a cohort of patients). The Agency assesses whether there are grounds for using a particular medicine and in justified cases may issue a permission for the use of a non-authorised medicine.

#### ■ LATVIA

In exceptional cases the State Agency of Medicines issues a permit to wholesalers for the distribution of the medicines authorised in other countries. The medicines wholesaler basis its request for the distribution of the non-authorised medicines on a request from a pharmacy or from a healthcare institution.

### ■ LITHUANIA

To ensure the availability of all the necessary medicines for the patients the use of the non-authorised medicines is permitted under exceptional circumstances. The non-authorised medicines may be used in the ambulatory care and at the hospital on the basis of a special application from a doctor with signed informed consent of the patient. The treating physician is responsible for prescribing, information and safe use of the non-authorised medicines.

### 3.4. Medicinal products mark-up

All Baltic states regulate the maximum value that wholesalers and pharmacies are allowed to add to their purchasing price (PP).

#### ■ ESTONIA

The level of maximum limits is required by law to allow the weighted average mark-up of 7–10% in wholesale and 21–25% in retail sale of pharmaceuticals and should be adjusted accordingly based on an annual market analysis by the Ministry of Social Affairs. In practice the applied mark-up may be lower than this maximum, which is frequent for the over-the-counter (OTC) pharmaceuticals. This is one of the commercial possibilities for the wholesalers and pharmacies to attract clients.

**Table 2. Wholesale mark-up scheme in Estonia**

Ex-factory price in €	Maximum mark-up (% of ex-factory price)
up to 1.60	20
1.61–2.88	15
2.89–6.39	10
6.40–12.78	5
over 12.78	3

**Table 3. Pharmacy mark-up scheme in Estonia**

Pharmacy purchasing price in €	Pharmacy mark-up coefficient (%)	Fixed pharmacy mark up in €
up to 0.64	-	0.38
0.65–1.28	40	0.38
1.29–1.92	35	-
1.93–2.56	30	-
2.57–3.20	25	-
3.21–6.39	20	-
6.40–44.74	15	-
over 44.74	-	5.11

A value-added tax (VAT) of 9% is applied for all pharmaceuticals and nutritional mixtures used for medicinal purposes. A standard value-added tax (VAT) of 20% is applied for other goods in Estonia. The value-added tax (VAT) was increased to 9% in the beginning of 2009, before that it was 5%.

#### ■ LATVIA

The principles for the determination of the price of the medicinal products are described in the legislation.

The maximum wholesale mark-up is determined by the following formula:

Maximum wholesaler's price = manufacturer's price x correction factor + correction sum in currency + VAT. The correction factor and correction sum shall be determined on the basis of the manufacturer's price (see Table 4).

**Table 4. Wholesale mark-up scheme in Latvia**

Manufacturer's price in €	Correction factor	Correction sum in €
up to 4.26	1.18	-
4.27–14.22	1.15	0.13
14.23 and more	1.10	0.84

The maximum retail mark-up is determined by the following formula:

Maximum pharmacy price = procurement price x correction factor + correction sum in currency + VAT. The correction factor and correction sum shall be determined on the basis of the procurement price (see Table 5).

**Table 5. Pharmacy mark-up scheme in Latvia**

Procurement price €	Correction factor	Correction sum €
up to 1.41	1.4	-
1.42–2.84	1.35	0.07
2.85–4.26	1.3	0.21
4.27–7.10	1.25	0.43
7.11–14.22	1.2	0.78
14.23–28.45	1.15	1.49
28.46 and more	1.1	2.92

The manufacturer's prices are declared to the State Agency of Medicines by the manufacturers twice a year and every time the prices are changed or a new product is placed on the market. The maximum retail prices are then calculated and published on the Agency's website for consumers and other interested parties.

The standard rate of value added tax (VAT) in Latvia is 21%. The reduced rate of 12% is applied to the medicinal products. The VAT for medicines in Latvia was increased twofold from 5% to 10% in 2010 and then to 12% in 2011.

### ■ LITHUANIA

Wholesalers and pharmacy maximum mark-ups of reimbursable pharmaceuticals is regulated by law and a combination of linear and regressive schemes is used.

In Lithuania VAT for reimbursed pharmaceuticals is 5 % and 21% for not reimbursed pharmaceuticals.

**Table 6. Wholesale mark-up scheme in Lithuania**

Ex-Factory Price in €	Maximum wholesale mark-up in %	Maximum wholesale mark-up in €
up to 1.86	14	-
1.87–2.89	-	0.26
2.90–5.63	9	-
5.64–7.24	-	0.51
7.25–15.51	7	-
15.52–19.74	-	1.09
19.75–263.28	5.5	
263.29 and more	-	14.48

**Table 7. Pharmacy mark-up scheme in Lithuania**

Pharmacy purchase price (PPP) in €	Maximum pharmacy mark-up in %	Maximum pharmacy mark-up in €
up to 2.37	22	-
2.38–2.89	-	0.52
2.90–4.42	18	-
4.43–7.24	-	0.80
7.25–7.90	11	-
7.91–21.72	-	0.87
21.73–144.81	4	-
144.81 and more	-	5.79

### 3.5. Generics market

#### ■ ESTONIA

Although there is no explicit regulation on the (mandatory) use of generics in Estonia (i.e. generic substitution), there are some regulative measures in place, directing doctors and patients towards the wider use of generics where these are available.

Doctors have to prescribe pharmaceuticals by their International Non-proprietary Name (INN) as the default option; if prescribing by the trade name, they have to document this in the medical record of the patient providing the justification and to mark “not to substitute” on the prescription.

If the pharmaceutical has been prescribed by the INN, the pharmacist has to offer different preparations to the patient, including the cheapest alternative for the patient. In discussion with the patient the most appropriate preparation is to be chosen.

The prevailing reference price system, establishing the reference price of a pharmaceutical as the basis for the reimbursed amount, is a strong incentive to accept substitution, as patients would have to pay the price difference between the reference price and the reimbursed amount on top of their statutory out-of-pocket payments.

#### ■ LATVIA

According to the Latvian legislation a physician may prescribe the medicinal product by the trade name and the pharmacist is allowed to substitute it with an analogue if the doctor has not forbidden this possibility on the prescription.

However in case of the first prescription of a reimbursed medicinal product the INN name of the medicinal product should be indicated on the prescription and the pharmacist has to offer different preparations to the patient, including the cheapest alternative for the patient.

#### ■ LITHUANIA

Several measures have been introduced in order to stimulate the use of generic medicines.

According to the Lithuanian legislation the medicines should be prescribed by the INN. The prescribing by the trade name is only allowed for the biological pharmaceuticals. Some medicines with narrow therapeutic window may be prescribed by the trade name after the decision of the specialists' commission. All pharmacies are obliged to provide data on prices to the patients via computer screens and are obliged to have the cheapest product in the store.

### 3.6. Retail and hospital pharmacies and wholesalers

**Table 8. Pharmacies and wholesalers in the Baltic states (as of January 1st, 2013)**

	Estonia	Latvia	Lithuania
<b>Retail pharmacies</b>	475 (including 166 structural units)	873 (including 96 structural units)	1404 (including 1130 structural units)
<b>Hospital pharmacies</b>	25 (including 2 structural units)	36 (no structural units)	50 (including 3 structural units)
<b>Wholesalers (incl. human and veterinary medicines distribution)</b>	58	58	143
<b>Wholesalers (only veterinary medicines)</b>	5	25	38

Structural unit is a separate pharmacy acting under the same activity licence as the main pharmacy.

#### ■ ESTONIA

In January 2013 there were 58 drug wholesalers in Estonia and 5 of them were specialised only in veterinary drugs. 18 wholesalers had both, human and veterinary products wholesale licences.

The total number of wholesalers in Estonia has been growing rapidly during the last five years, while the proportion of the veterinary wholesalers has been decreasing.

In 2012, 29 wholesale companies sold drugs to the general or hospital pharmacies or to other institutions. Over 90% of the medicinal products market was covered by the seven major wholesalers: Magnum Medical (29.5%), Tamro Estonia (27.7%), Apteekide Koostöö Hulgimüük (21.3%), Estonian Health Board (4.8%), Roche Estonia (3.4%), Oriola (3.3%) and Chirurgicus (2.3%).

**Table 9. Wholesalers of the medicinal products in Estonia**

	2009	2010	2011	2012	2013
<b>Wholesalers (human and veterinary medicines)</b>	40	44	46	50	53
<b>Wholesalers (only veterinary medicines)</b>	8	7	7	5	5
<b>Total</b>	48	51	53	55	58



At the beginning of 2013 there were 475 general pharmacies (including 166 structural units), 25 hospital pharmacies (including 2 structural unit) and 4 veterinary pharmacies in Estonia. 35% of the general pharmacies were situated in the bigger cities – Tallinn and Tartu.

**Table 10. Pharmacies in Estonia**

	2009	2010	2011	2012	2013
<b>Retail pharmacies</b>	496	486	477	469	475
<b>Hospital pharmacies</b>	28	26	26	24	25
<b>Veterinary pharmacies</b>	7	7	7	5	4

### ■ LATVIA

In January 2013 there were 58 drug wholesalers in Latvia. 6 of them had both, human and veterinary products wholesale licences, only one of those 6 was actually selling veterinary medicines.

Since January 1st, 2011 the licences for the distribution of veterinary medicines are being issued by the Food and Veterinary Service.

In 2012, 46 wholesalers of human medicines distributed medicines to the pharmacies, health care institutions, medical practitioners and other recipients. The remaining 11 wholesalers have either sold medicines to other wholesalers or exported them. Over 90% of medicinal products market was covered by the nine major wholesalers: Recipe Plus (35.0%), Tamro (21.4%), Magnum Medical (14.1%), Euroaptieka (7.1%), Oriola Rīga (4.6%), GlaxoSmithKline Latvia (2.8%), Medelens (2.5%), Vita-Farm (Baltfarma) (2.2%) and Jelgavfarm (2.2%). The market share of the other wholesalers covered 8% of the total market.

**Table 11. Wholesalers of the medicinal products in Latvia**

	2009	2010	2011	2012	2013
<b>Wholesalers (incl. human and veterinary medicines)</b>	40	50 (7)	57 (7)	57(6)	58 (6)
<b>Wholesalers (only veterinary medicines)</b>	23	23	24	24	25
<b>Total</b>	63	73	74	81	83

At the beginning of 2013 there were 896 retail pharmacies (including 94 structural units) and 41 hospital pharmacies in Latvia. 55% of all retail pharmacies are located in the 9 largest cities of Latvia – 34% in Riga, 5% in Daugavpils, 4% in Liepaja, 3% in Jelgava and Jurmala, 2% in Rezekne and Ventspils, 1% in Jekabpils and Valmiera.

**Table 12. Pharmacies in Latvia**

	2009	2010	2011	2012	2013
<b>Retail pharmacies (including structural units)</b>	896	882	880	873	873
<b>Hospital pharmacies</b>	41	38	38	36	36

### ■ LITHUANIA

In 2012, 40 out of 96 wholesalers sold medicines to the general or hospital pharmacies or to other institutions. The following 5 wholesalers cover 90% of the medicinal product market: UAB "EVD" (34%), UAB „Limedika“ (25%), UAB „Nemuno vaistinė“ (20%), UAB „Armila“ (6%) and UAB „Medikona“ (6%). The market share of the other wholesalers made up 9% of the total market.

**Table 13. Wholesalers of the medicinal products in Lithuania**

	2009	2010	2011	2012	2013
<b>Wholesalers (human medicines, including suspended licences )</b>	82	83	89	96 (7)	105 (9)

Hospital pharmacies are funded by the hospitals and do not dispense medicines to outpatients. Not every hospital has a hospital pharmacy for inpatients; however the majority of health care providers have ordinary community pharmacies on the premises.

**Table 14. Pharmacies in Lithuania**

	2009	2010	2011	2012	2013
<b>Retail pharmacies</b>	1515	1504	1483	1442	1404
<b>Hospital pharmacies</b>	58	56	55	54	50
<b>Veterinary pharmacies</b>	119	127	133	135	137

## 4. Drug reimbursement systems in the Baltic countries.

### 4.1 Description of the reimbursement systems

The structure of the reimbursement systems has similarities in Baltic states:

- Medicinal products are compensated for on the basis of the diagnosis.
- Reimbursement rates are divided according to the severity of the disease. There are Positive Lists of the products.
- For certain patient groups additional discounts are provided, for example children and the elderly.
- Medicinal products are compensated for according to the reference prices in case it exists.

Details of the systems are described below.

#### ■ ESTONIA

The Estonian health insurance relies on the principle of solidarity. The Estonian Health Insurance Fund (EHIF) covers the costs of health services required by a person in case of an illness regardless of the amount of the social tax paid for the person concerned. The Fund uses the social tax paid for the working population also for covering the cost of the health services provided to the persons who have no income with regard to work activities. The employers are required by law to pay social tax for all persons employed, the rate of this tax is 33% of the taxable amount, 20% of which is allocated for the pension insurance and 13% for the health insurance.

The purpose of the health insurance in Estonia is to cover the costs of the health services provided to the insured persons to prevent and cure diseases, finance the purchase of the medicinal products and medical devices, and provide the benefits for the temporary incapacity for work and other benefits.

Only the medicinal products included in the EHIF's list of medicinal products and authorised in Estonia are compensated for. Special reimbursement mechanism is available for the products not having a marketing authorisation in Estonia. Medicinal products are compensated for according to the reference prices and price agreements in case these exist; in other cases the refund is based on the product's retail price. At the manufacturing level there is statutory pricing (after the negotiations) for reimbursable pharmaceuticals. The process of pricing is incorporated into the procedure of reimbursement decision making. Medicinal products are compensated for on the basis of the diagnosis. Medicinal products intended for hospital use are compensated to health care providers if their cost is included in service fee.

Reimbursement rates for medicinal products for out-patient use:

**100% reimbursement** – pharmaceuticals for the treatment of choice of serious, life-threatening or epidemic diseases.

Patient shall make an own contribution of 1.27 EUR and in case there is a reference price or a price agreement, pay the sum that exceeds that price. Health Insurance Fund will cover 100% of the sum that exceeds 1.27 EUR and is within the reference price or price agreement.

**75% reimbursement** – pharmaceuticals for the treatment of choice of chronic diseases, threatening the quality of life.

The patient makes an own contribution of 1.27 EUR per prescription, pays 25% of the sum remaining between 1.27 EUR and the reference price/price agreement and everything exceeding the reference price/price agreement. The Health Insurance Fund shall pay 75% of the amount between 1.27 EUR and the reference price/price agreement.

**50% reimbursement** – all other pharmaceuticals in the Positive List.

The patient shall make an own contribution of 3.19 EUR, pay 50% of the sum between 3.19 EUR and the reference price/price agreement and everything exceeding the reference price/price agreement. The Health Insurance Fund shall pay 50% of the amount exceeding 3.19 EUR.

**A compensation rate of 90%** applies to medicinal products with a discount rate of 75% in case of the following patient groups:

- children aged 4 to 16 years;
- insured persons over 63 years of age, in addition, all persons who have been granted pension under the State Pension Insurance Act.

For children under 4 years old, compensation rate of 100% is applied on all medicinal products included in the EHIF list of medicinal products.

The out-of-pocket payment (OPP) system is rather intricate and combines fixed co-payments, percentage co-payments and deductibles. The fixed co-payments are, e.g., prescription fees of € 1.28 at the 100% and 75/90% reimbursement levels and € 3.20 at the 50% reimbursement level. These prescription fees have not been changed since the mid-1990s and there have been minor changes in the overall unavoidable percentage of OPP (90% reimbursement level divided into 75/90% in 2002).

## ■ LATVIA

The general principles of the reimbursement system of pharmaceuticals are set in the legislation. The reimbursement of pharmaceuticals shall be provided according to the character and severity of the disease. The following categories are applied:

**100% reimbursement** – for chronic, life threatening diseases or diseases causing irreversible disability, where the use of pharmaceuticals ensures and maintains the patient’s life functions,

**75% reimbursement** – for chronic diseases, for which the maintenance of the patient’s life functions are aggravated without the use of pharmaceuticals,

**50% reimbursement** – for diseases where pharmaceuticals maintain or improve the patient’s health and for vaccines.

All drugs for the same indication are reimbursed at the same rate. For the pharmaceuticals for which the reference price is calculated the reimbursement rate is applied to the reference price.

The pharmaceuticals eligible for the reimbursement are listed in the Positive List elaborated by the National Health Service (NHS) of Latvia.

The Positive List consists of three parts – List A, List B and List C according to the following basic principles:

- List A includes pharmaceuticals, which have several preparations of the same therapeutic effectiveness within the scope of the INN or the pharmaco-therapeutic group and medical devices of the same type.
- List B includes pharmaceuticals and medical devices, without an authorised alternative.
- List C includes pharmaceuticals, costs of which exceed 4270 € per patient per year and special medical restrictions cannot be applied to reduce the expenditure.

Reimbursable pharmaceuticals are prescribed by family doctors and certain specialists who have an agreement with the NHS of Latvia.

Reimbursement is provided through pharmacies on the basis of a special reimbursable prescription, patients have to pay the co-payment in the case of the 75% or 50% reimbursement levels or € 0.71 at the 100% reimbursement level.

A pharmaceutical to be included in the Positive List is to:

- be authorised by the national medicines agency or by the European Commission, or parallel imported according to the regulations;
- be classified as a “prescription only” (over-the-counter (OTC) products are not reimbursable);
- have an approved indication relevant to the diseases listed in Appendix of the Regulation of Cabinet of Ministers.

In Latvia, there is statutory pricing (after the negotiations) for reimbursable pharmaceuticals and free pricing for non-reimbursable pharmaceuticals at the manufacturer level. The process of pricing is incorporated into the procedure of

the reimbursement decision making. During the price negotiations both external and internal price referencing mechanisms are used. Prescription-only medicines that are not included in the Positive List, are reimbursed for children up to 24 months of age (reimbursement rate 50%) and for pregnant women and women within 42 days of postnatal period (reimbursement rate 25%).

### ■ LITHUANIA

The state health care system is intended to serve the entire population, and the Health Insurance Law requires all permanent residents to participate in the compulsory health insurance scheme without an option to opt-out. Compulsory health insurance covers almost all inhabitants. Compulsory health insurance provides a standard benefits package for all beneficiaries. There is no positive list of health services provided in the state-financed health care facilities. Emergency care is rendered free of charge to all permanent residents irrespective of their insurance status. Drugs prescribed by a physician are reimbursed according to the reimbursement lists. Expensive hospital medicines are centrally purchased by the National Health Insurance Fund.

There are two reimbursement lists, A and B.

**List A** covers pharmaceuticals for specific diseases in four reimbursement categories:

**100% reimbursement:** Covers the most serious and expensive diseases, including oncology, diabetes, haemophilia, schizophrenia, asthma etc.

**80% reimbursement:** Provides coverage for less serious diseases such conditions as cardiovascular diseases.

At **90% and 50% reimbursement** level are reimbursed only a few diseases.

Reimbursement from the disease-based list A accounts to approximately 95% of the country's total pharmaceutical reimbursement.

**List B** is a list of 75 active substances or combinations reimbursed for certain social groups, including children under 18 years old, the disabled and pensioners with two reimbursement rates:

- 100% is granted to children and the severely disabled,
- 50% is given for other disabled patients and pensioners.

## 4.2 Changes in the reimbursement systems (during the period of 2010–2012)

### ■ ESTONIA

There were no major changes in the reimbursement system during this period in Estonia. New active substances have been added to the list of reimbursed medicines on a regular basis according to the decisions of the Minister of Social Affairs.

Midwives obtained a right to prescribe a limited list of prescription medicines (including contraceptives) in 2010.

Since the same year wholesalers of medicinal products have to stock medicines which are priced cheaper than (or equal to) the reference price and pharmacists have an obligation to stock and offer to patient medicines with the smallest co-payment.

In 2012 the digital prescription IT tool was changed so that written justification is mandatory on digital prescription if the prescription is issued by the trade name.

The previously existing reimbursement ceiling of €12.79 per prescription in the 50% reimbursement category was removed in 2012.

### ■ LATVIA

In 2009 the reimbursement rates were reduced, the rate of 90% was abandoned.

From 2012 the doctor is obliged to prescribe by the INN for the newly diagnosed patients, but one can prescribe INN also for other patients. The pharmacist is obliged to dispense the cheapest drug in case the doctor has prescribed by the INN.

Managed entry agreements have been allowed by legislation.

From September 2012 reimbursement of prescription-only medicines that are not included in the Positive List, for children up to 24 months of age, pregnant women and women within 42 days of postnatal period has been introduced.

### ■ LITHUANIA

The onset of the financial crisis in 2008 has forced Lithuanian policy-makers to seek more efficiency in the pharmaceutical sector and to reduce the public expenditure on pharmaceuticals. Special plan was introduced in 2009 and as a result, while the number of prescriptions between 2008 and 2010 increased by 9%, the expenditure on pharmaceuticals and medical devices covered by the NHIF has decreased over the same period from 198 to 189 million Euros. This reduction has been achieved through the following measures (Garuoliene et al., 2011):

- Introduction of new requirements for generic pricing such that the first generic has to be priced 30% below the originator, while the second and third generics must be priced at least 10% below the first generic to be reimbursed;
- Trade-name based prescribing is only allowed for biological products, and all pharmacies are obliged to provide data on prices to the patients via computer screens and are obliged to have the cheapest product in store;
- Price-volume agreement schemes agreed and valid for a minimum of three years regarding all new pharmaceuticals that will increase the NHIF pharmaceutical budget compared with the current treatment approaches for the target population groups.

### 4.3 Reference price systems

#### ■ ESTONIA

Estonia established a reference price system in January 2003. The reference price is based on the internal price referencing, where the pharmaceuticals are grouped on the basis of active ingredients (Anatomic Therapeutic Chemical classification ATC-5 level), route of administration and pharmaceutical forms. Parallel traded pharmaceuticals have been incorporated into the reference price system as well.

The procedures for setting manufacturer prices differ depending on whether the pharmaceutical in questions is an innovative or a generic product. There are specific criteria for reimbursement of the parallelly traded pharmaceuticals: the price for these has to be 10% lower than the price of the primary authorised product on the market.

Statutory pricing – in combination with price negotiations – is applied to the innovative and in-patent reimbursable pharmaceuticals in Estonia. The statutory price levels are set according to the prices of the product in the reference countries (Latvia, Lithuania, Hungary, Portugal, France and the country of origin). If applicable, and similarity is proven, the prices of pharmaceuticals of similar effect are also compared.

The Ministry of Social Affairs is the main authority involved in the pricing decisions, receiving advice from the Pharmaceutical Committee.

If the price of the pharmaceutical is according to the opinion of the Pharmaceutical Committee set too high, price negotiations with the manufacturer are started. Negotiations are possible for the same pharmaceuticals and on the basis of the same legal framework/procedure as statutory pricing. This has been applied since 2003.

#### ■ LATVIA

The reference price system is used in Latvia. The products are grouped into clusters:

- within the INN or
- within the pharmacotherapeutic group if there are no clinically relevant differences in the effectiveness and side-effects for the same indication and drugs are intended for the same patient group.

Products are clustered according to the pharmaceutical form, dosage and pack size. Then the reference product for each cluster is identified (the cheapest pharmaceutical) and on the basis of the price of the reference product the reimbursement price for each pharmaceutical in the cluster is calculated.

#### ■ LITHUANIA

There have been a number of changes to the reference price system in Lithuania in the recent years. The system is based on both external and internal reference



pricing measures. Previously, maximum reimbursement prices, or reference prices, were set taking into account the lowest price on the Lithuanian market and ex-manufacturers' prices were negotiated taking into account prices in the neighbouring markets, including Latvia and Estonia. With effect from 2002, phased changes were introduced, to take into account the pricing of products relative to that in other EU states. In 2004, a temporary external reference pricing mechanism was based on a review of pricing in the then 15 EU member states (prior to the EU accession of Lithuania and other countries included in this report). This identified the lowest price in these states, to which 5% was added for Lithuanian pricing.

From 2005, six countries deemed to have similar per capita income to Lithuania: Latvia, Estonia, Poland, Czech Republic, Slovakia and Hungary are used to detect reference price level. Under the revised approach, the declared manufacturer price is compared with a level which is 95% of the average of that found in the reference countries. In cases where the product is not on the market in some of these countries, the average is taken from the markets in which it is present. In cases where the product is not on the market in any of the reference countries, the price of the product in the country of manufacture is used. From 2009 onwards, Romania and Bulgaria were added to the list of reference countries.

Both patent-protected and off-patent medicines are covered by the reference price system:

- **Patent-protected drugs:** the maximum reimbursement price (reference price) for each active ingredient is determined with a reference to the reference country/EU prices
- **Off-patent drugs:** the reference price is calculated taking into account the reference country/EU prices for the active ingredient, as well as the cheapest version of the drug available in Lithuania. In cases where the price of the cheapest version of the drug in Lithuania is above the level of 95% of the average seen in the reference countries, the price may be reduced to this level.

For the purposes of determining the reference price, products are grouped by the active ingredient, with separate clusters drawn up for the same route of administration and pharmaceutical form. Separate clusters are formed for modified release drugs and products for paediatric use. There are 445 clusters, corresponding to 1876 reimbursed pharmaceuticals, covered by the reference price system.

Given the nature of the system, patented products are at the moment protected from the impact of internal price referencing, which in effect results in reimbursement pricing at the level of the cheapest product in the group.

## 5. Materials and methods used for the Baltic Statistics on Medicines

### 5.1. Data collection in the Baltic states.

#### ■ ESTONIA

Estonian State Agency of Medicines (SAM) is collecting and analysing drug utilization data in Estonia.

According to the Medicinal Product Act and Decree of the Minister of Social Affairs all wholesalers of medicinal products have to report their sales data quarterly to SAM. The reports include the following data for each product: package ID, ATC code, active substance(s), trade name, pharmaceutical form, strength, package size and the manufacturer. The sales data are presented in monetary value and by unit of volume (number of packages).

From these reports only the sale to end-consumers (retail and hospital pharmacies, nursing homes etc) are used for calculating the medicines consumption.

Estonian SAM has been collecting and analysing the data since 1994. Statistics on medicines are annually published at the Agency's website ([www.ravimiamet.ee](http://www.ravimiamet.ee)).

#### ■ LATVIA

Statistical data regarding consumption of medicines in Latvia is collected and processed by the State Agency of Medicines (SAM). In accordance with the Pharmaceutical Law and Regulations of the Cabinet of Ministers all wholesalers of medicines submit their sales data (including data regarding parallel imported and parallel distributed medicines) for each month by uploading it to the Agency's database. The reports include the following data for each product: medicinal product identification code in accordance with medicinal product register; trade name; price per package; number of packages sold for the particular price and consumer group to which the product was sold.

Only data regarding sales of medicines to the final recipient (pharmacies, healthcare institutions, private practices) are used for calculating medicines consumption statistics. Latvian SAM has been collecting and analysing the data since 2001. The report on statistics on medicines consumption is annually published on the Agency's website ([www.zva.gov.lv](http://www.zva.gov.lv)).

#### ■ LITHUANIA

Lithuanian State Medicines Control Agency (SMCA) is responsible for collection and analysis of drug utilization data in Lithuania.

According to the Pharmaceutical Law and Order of the Head of State Medicines Control Agency all wholesalers of medicinal products have to report their sales data monthly to SMCA. The reports include the following data: a number of wholesaler's licence, package ID of medicinal product, and the number of packages sold. The sales data are presented in volume (number of packages).

From these reports only the sale to end-consumers are used to calculate the medicines consumption.

The Lithuanian SMCA has been collecting and analysing the data since 2009. Since 2010 statistics on medicines are annually published at the Agency's website ([www.vvkt.lt](http://www.vvkt.lt)).

## 5.2. ATC/DDD methodology and interpretation of drug sales statistics ([www.whocc.no](http://www.whocc.no))

The Anatomical Therapeutic Chemical (ATC) classification system and the Defined Daily Dose (DDD) as a measuring unit have become the gold standard for international drug utilization research.

The purpose of the ATC/DDD system is to serve as a tool for drug utilization research in order to improve quality of drug use. One component of this is the presentation and comparison of the drug consumption statistics at international and national levels.

In the Anatomical Therapeutic Chemical (ATC) classification system, the active substances are divided into different groups according to the organ or system on which they act and their therapeutic, pharmacological and chemical properties. Drugs are classified in groups at five different levels. The drugs are divided into fourteen main groups (1st level), with pharmacological/therapeutic subgroups (2nd level). The 3rd and 4th levels are chemical/pharmacological/therapeutic subgroups and the 5th level is the chemical substance. The 2nd, 3rd and 4th levels are often used to identify pharmacological subgroups when that is considered more appropriate than therapeutic or chemical subgroups. The complete classification of metformin illustrates the structure of the code:

A	Alimentary tract and metabolism (1st level, anatomical main group)
A10	Drugs used in diabetes (2nd level, therapeutic subgroup)
A10B	Blood glucose lowering drugs, excl. insulins (3rd level, pharmacological subgroup)
A10BA	Biguanides (4th level, chemical subgroup)
A10BA02	metformin (5th level, chemical substance)

Thus, in the ATC system all plain metformin preparations are given the code A10BA02.

Medicinal products are classified according to the main therapeutic use of their main active ingredient, on the basic principle of assigning only one ATC code for each pharmaceutical formulation (i.e. similar ingredients, strength and pharmaceutical form). A medicinal product can be given more than one ATC code if it is available in two or more strengths or formulations with clearly different therapeutic uses.

The Defined Daily Dose (DDD) is the assumed average maintenance dose per day for a drug used for its main indication in adults.

A DDD will only be assigned for drugs that already have an ATC code. DDDs are not established for topical products (e.g. dermatologicals), sera, vaccines, antineoplastic agents, allergen extracts, general and local anaesthetics and contrast media.

It should be emphasised that the defined daily dose is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose (PDD). Doses for individual patients and patient groups will often differ from the DDD and will necessarily have to be based on individual characteristics (e.g. age and weight) and pharmacokinetic considerations.

Drug consumption data presented in DDDs only give a rough estimate of consumption and not an exact picture of actual use. The DDD provide a fixed unit of measurement independent of price and dosage form (e.g. tablet strength) enabling the researcher to assess trends in drug consumption and to perform comparisons between population groups.

Drug consumption figures are usually presented as numbers of DDDs/1000 inhabitants/day. Sales data presented in DDD/1000 inhabitants/day provides a rough estimate of the proportion of the population within a defined area treated daily with certain drugs. For example, the figure 10 DDDs/1000 inhabitants/day indicates that 1% of the population on average gets a certain treatment daily.

The use of a drug expressed as DDD/1000 population/day is derived by calculating the overall amount of a drug being used over a specified period of time (e.g. a year) and dividing this by the DDD multiplied by the population and the number of days in the period.

$$\text{DDD/1000 population/day} = \frac{\text{Amount used in 1 year} * 1000}{\text{DDD} \times \text{population} \times 365(\text{days})}$$

Collecting and publishing drug utilization statistics are critical elements in the process of improving the prescription and dispensing of medicines. For drug utilization statistics to have the best possible impact on drug use, the statistics need to be used in a focused and active manner.

All figures presented in this publication are based on the ATC/DDD version valid from January 2013.

More detailed information can be found at [www.whocc.no](http://www.whocc.no).

### 5.3. Factors affecting the interpretation of drug utilization data

#### Classification of the medicinal products in the Baltic States

The classification of medicinal products may vary between countries. Consequently, data on drug use in different countries may not be directly comparable in all of the drug classes. For example some products may be classified as food supplements or natural remedies in one country and as a medicine in another country. For this reason the ATC groups A11 (vitamins) and A12 (mineral supplements) have been excluded from this publication.


## 6. Cost of drugs as a share of total health care expenditure in the Baltic countries

### 6.1. Medicinal products market

#### ■ ESTONIA

As shown below, the Estonian human medicines market plateaued during 2008–2010. In 2011 the human medicinal products market showed slight increase and in 2012 the market increased 8.5%, reaching 222 mln euros (excl. VAT).


**Estonian medicinal products market in 2008–2012**



#### ■ LATVIA


After a 6% decrease in 2009 the total turnover of medicines in Latvia has increased each year and in 2012 it reached 260 million euros (excl. VAT).

**Latvian medicinal products market in 2008–2012**



## ■ LITHUANIA


In 2009 the human medicinal products market decreased 6.5% and in 2010 reached the 2008 level. In 2012 market increased 6.3 %, reaching 473 mln euros (excl VAT).



### 6.2. Sale of drugs according to the ATC main groups (DDD/1000 inhabitants/day)

Comparing the consumption of the ATC main groups using ATC/DDD methodology the group of cardiovascular drugs stands out as the most widely used one in all Baltic countries. The second most used group is alimentary tract and metabolism drugs in Estonia and Latvia but nervous system drugs in Lithuania. On average the consumption of the main groups is quite similar in all the countries with differences around 10–15 % from median to minimum and maximum consumption. The biggest differences occur in the consumption of nervous system drugs, genitourinary system and sex hormones and systemic hormonal preparations with 40–60% differences in median consumption and maximum consumption.


**Consumption of medicinal products in the Baltic countries in 2012  
(defined daily doses 1000/inhabitants/day)**



### 6.3. Sale of drugs according to the ATC main groups (turnover)

#### ■ ESTONIA

In 2012, 2392 different medicinal preparations and 1197 active substances were used in Estonia. Based on ATC classification, the antineoplastic and immunomodulating drugs had the greatest market share (19%), the cardiovascular drugs followed with 15% and the alimentary tract and metabolism medicines with 12%. Also anti-infectives for systemic use (11%) and nervous system medicines (10%) had significant market share. The other ATC groups covered one third of medicinal products market. In 2012 the turnover increased in all ATC groups.






**LATVIA**

2964 different medicines containing 1146 different active substances were distributed in Latvia in 2012. By comparing the turnover of medicines (EUR) according to the main ATC groups, the medicines intended for treatment of cardiovascular system diseases make up the largest part (19%) of the market of medicines in Latvia, followed by the medicines for treatment of alimentary tract and metabolic diseases (13%), antineoplastic medicines and immunomodulating agents (12%), medicines for treatment of nervous system diseases (11%) and anti-infectives for systemic use (10%). The other ATC groups covered about one third of medicinal products market 35%.


**Latvian medicinal products market share between ATC groups in 2010–2012**



**LITHUANIA**

Lithuanian expenditure data is based on the NHIF database and depicts expenditure for medicines reimbursement and not wholesale turnover as the Estonian and Latvian data. OTC medicines and non-reimbursed medicines are not included on the figure.

**Lithuanian medicinal products market share between ATC groups in 2010–2012**




## 7. Sales statistics 2010-2012

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
<b>A</b>	<b>ALIMENTARY TRACT AND METABOLISM</b>				
	Estonia	90.93	96.06	107.31	12
	Latvia	95.84	102.91	107.81	5
	Lithuania	98.91	103.43	113.93	10
<b>A01</b>	<b>STOMATOLOGICAL PREPARATIONS</b>				
	Estonia	0.51	0.39	0.07	-82
	Latvia	7.32	7.80	6.50	-17
	Lithuania	-	-	-	
<b>A01A</b>	<b>STOMATOLOGICAL PREPARATIONS</b>				
	Estonia	0.51	0.39	0.07	-82
	Latvia	7.32	7.80	6.50	-17
	Lithuania	0.41	0.44	0.38	-14
<b>A01AA</b>	<b>Caries prophylactic agents</b>				
	Estonia	-	-	-	
	Latvia	7.10	7.58	6.33	-16
	Lithuania	-	-	-	
<b>A01AA01</b>	<b>sodium fluoride</b>				
	Estonia	-	-	-	
	Latvia	7.10	7.58	6.33	-16
	Lithuania	-	-	-	
<b>A01AB</b>	<b>Antiinfectives and antiseptics for local oral treatment</b>				
	Estonia	0.51	0.39	0.07	-82
	Latvia	0.23	0.23	0.17	-25
	Lithuania	0.32	0.07	0.07	
<b>A01AB03</b>	<b>chlorhexidine</b>				
	Estonia	0.44	0.31	-	
	Latvia	0.23	0.23	0.17	-25
	Lithuania	0.27	<0.01	-	
<b>A01AB09</b>	<b>miconazole</b>				
	Estonia	0.07	0.07	0.07	
	Latvia	-	-	-	
	Lithuania	0.06	0.06	0.07	17
<b>A02</b>	<b>DRUGS FOR ACID RELATED DISORDERS</b>				
	Estonia	24.53	27.16	31.43	16
	Latvia	25.02	26.47	29.02	10
	Lithuania	25.46	26.62	32.60	22
<b>A02A</b>	<b>ANTACIDS</b>				
	Estonia	0.87	0.87	0.95	9
	Latvia	0.71	0.73	0.77	5
	Lithuania	0.20	0.27	0.73	170
<b>A02AD</b>	<b>Combinations and complexes of aluminium, calcium and magnesium compounds</b>				
	Estonia	0.87	0.87	0.95	9
	Latvia	0.71	0.73	0.77	5
	Lithuania	0.20	0.26	0.72	177

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
A02AD01	<b>ordinary salt combinations</b>				
	Estonia	0.87	0.87	0.95	9
	Latvia	0.71	0.73	0.77	5
	Lithuania	0.20	0.26	0.72	177
A02B	<b>DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)</b>				
	Estonia	23.66	26.29	30.48	16
	Latvia	24.30	25.74	28.26	10
	Lithuania	25.26	26.35	31.87	21
A02BA	<b>H2-receptor antagonists</b>				
	Estonia	5.33	4.40	3.99	-9
	Latvia	4.24	4.06	3.58	-12
	Lithuania	9.46	9.09	10.16	12
A02BA02	<b>ranitidine</b>				
	Estonia	5.17	4.38	3.99	-9
	Latvia	4.12	3.96	3.50	-11
	Lithuania	9.28	8.90	9.97	12
A02BA03	<b>famotidine</b>				
	Estonia	0.16	0.02	-	
	Latvia	0.12	0.10	0.07	-27
	Lithuania	0.18	0.18	0.19	6
A02BC	<b>Proton pump inhibitors</b>				
	Estonia	18.32	21.89	26.49	21
	Latvia	19.87	21.59	24.57	14
	Lithuania	15.68	17.22	21.65	26
A02BC01	<b>omeprazole</b>				
	Estonia	14.32	16.35	18.73	15
	Latvia	16.47	17.62	18.76	6
	Lithuania	12.30	12.71	15.15	19
A02BC02	<b>pantoprazole</b>				
	Estonia	2.07	2.96	4.51	52
	Latvia	2.71	3.33	5.12	54
	Lithuania	1.82	3.18	5.04	58
A02BC03	<b>lansoprazole</b>				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	0.37	0.27	0.23	-17
	Lithuania	0.99	0.70	0.73	4
A02BC04	<b>rabeprazole</b>				
	Estonia	-	-	-	
	Latvia	-	-	-	
	Lithuania	0.02	0.02	0.03	50
A02BC05	<b>esomeprazole</b>				
	Estonia	1.93	2.58	3.26	26
	Latvia	0.31	0.36	0.47	28
	Lithuania	0.54	0.62	0.71	15

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
<b>A02BX</b>	<b>Other drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD)</b>				
	Estonia	-	-	-	
	Latvia	0.20	0.08	0.11	28
	Lithuania	0.12	0.04	0.06	50
<b>A02BX01</b>	<b>carbenoxolone</b>				
	Estonia	-	-	-	
	Latvia	-	-	-	
	Lithuania	0.12	0.04	0.06	50
<b>A02BX02</b>	<b>sucralfate</b>				
	Estonia	-	-	-	
	Latvia	0.18	0.07	0.09	31
	Lithuania	-	-	-	
<b>A02BX05</b>	<b>bismuth subcitrate</b>				
	Estonia	-	-	-	
	Latvia	0.02	0.02	0.02	19
	Lithuania	-	-	-	
<b>A03</b>	<b>DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS</b>				
	Estonia	4.56	4.73	5.22	10
	Latvia	10.46	10.05	10.06	
	Lithuania	6.96	7.18	7.70	7
<b>A03A</b>	<b>DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS</b>				
	Estonia	3.68	3.78	4.25	12
	Latvia	5.13	5.19	5.25	1
	Lithuania	5.35	5.46	5.88	8

### Consumption of drugs for acid related disorders (A02)



ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
<b>A03AA</b>	<b>Synthetic anticholinergics, esters with tertiary amino group</b>				
	Estonia	0.44	0.53	0.63	19
	Latvia	0.16	0.16	0.17	6
	Lithuania	0.24	0.26	0.29	12
<b>A03AA04</b>	<b>mebeverine</b>				
	Estonia	0.44	0.53	0.63	19
	Latvia	0.15	0.16	0.17	7
	Lithuania	0.24	0.26	0.29	12
<b>A03AA07</b>	<b>dicycloverine</b>				
	Estonia	-	-	-	
	Latvia	0.01	0.01	<0.01	
	Lithuania	-	-	-	
<b>A03AD</b>	<b>Papaverine and derivatives</b>				
	Estonia	3.23	3.25	3.61	11
	Latvia	4.34	4.33	4.41	2
	Lithuania	4.48	4.61	4.95	7
<b>A03AD02</b>	<b>drotaverine</b>				
	Estonia	3.23	3.25	3.61	11
	Latvia	4.34	4.33	4.41	2
	Lithuania	4.48	4.61	4.95	7
<b>A03AX</b>	<b>Other drugs for functional gastrointestinal disorders</b>				
	Estonia	-	-	-	
	Latvia	0.63	0.70	0.67	-4
	Lithuania	0.64	0.59	0.64	8
<b>A03AX13</b>	<b>silicones</b>				
	Estonia	-	-	-	
	Latvia	0.63	0.70	0.67	-4
	Lithuania	0.64	0.59	0.64	8
<b>A03B</b>	<b>BELLADONNA AND DERIVATIVES, PLAIN</b>				
	Estonia	0.12	0.12	0.11	-8
	Latvia	3.66	3.23	3.23	
	Lithuania	0.05	0.06	0.06	
<b>A03BA</b>	<b>Belladonna alkaloids, tertiary amines</b>				
	Estonia	0.10	0.10	0.09	-10
	Latvia	3.64	3.22	3.22	
	Lithuania	0.05	0.06	0.06	
<b>A03BA01</b>	<b>atropine</b>				
	Estonia	0.10	0.10	0.09	-10
	Latvia	0.05	0.06	0.05	-3
	Lithuania	0.05	0.06	0.06	
<b>A03BA04</b>	<b>belladonna total alkaloids</b>				
	Estonia	-	-	-	
	Latvia	3.59	3.16	3.16	
	Lithuania	-	-	-	

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
<b>A03BB</b>	<b>Belladonna alkaloids, semisynthetic, quaternary ammonium compounds</b>				
	Estonia	0.02	0.03	0.02	-33
	Latvia	0.01	0.02	0.02	
	Lithuania	-	-	-	
<b>A03BB01</b>	<b>butylscopolamine</b>				
	Estonia	0.02	0.03	0.02	-33
	Latvia	0.01	0.02	0.02	
	Lithuania	-	-	-	
<b>A03F</b>	<b>PROPULSIVES</b>				
	Estonia	0.76	0.83	0.87	5
	Latvia	1.67	1.62	1.57	-3
	Lithuania	1.57	1.67	1.77	6
<b>A03FA</b>	<b>Propulsives</b>				
	Estonia	0.76	0.83	0.87	5
	Latvia	1.67	1.62	1.57	-3
	Lithuania	1.57	1.67	1.77	6
<b>A03FA01</b>	<b>metoclopramide</b>				
	Estonia	0.75	0.81	0.84	4
	Latvia	1.41	1.33	1.22	-9
	Lithuania	1.29	1.26	1.33	6
<b>A03FA03</b>	<b>domperidone</b>				
	Estonia	0.01	0.01	0.02	100
	Latvia	0.26	0.29	0.36	23
	Lithuania	0.28	0.41	0.43	5
<b>A04</b>	<b>ANTIEMETICS AND ANTINAUSEANTS</b>				
	Estonia	0.12	0.10	0.11	10
	Latvia	0.03	0.04	0.05	16
	Lithuania	0.09	0.10	0.10	
<b>A04A</b>	<b>ANTIEMETICS AND ANTINAUSEANTS</b>				
	Estonia	0.12	0.10	0.11	10
	Latvia	0.03	0.04	0.05	16
	Lithuania	0.09	0.10	0.10	
<b>A04AA</b>	<b>Serotonin (5HT3) antagonists</b>				
	Estonia	0.11	0.09	0.10	11
	Latvia	0.03	0.04	0.05	17
	Lithuania	0.09	0.10	0.10	
<b>A04AA01</b>	<b>ondansetron</b>				
	Estonia	0.03	0.03	0.04	33
	Latvia	0.02	0.03	0.04	36
	Lithuania	0.09	0.10	0.10	
<b>A04AA02</b>	<b>granisetron</b>				
	Estonia	0.08	0.06	0.06	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	<0.01	<0.01	<0.01	

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
A04AA05	palonosetron				
	Estonia	-	-	-	
	Latvia	0.01	0.01	0.01	-11
	Lithuania	-	-	<0.01	
A04AD	Other antiemetics				
	Estonia	<0.01	0.01	0.01	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
A04AD12	aprepitant				
	Estonia	<0.01	0.01	0.01	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
A05	BILE AND LIVER THERAPY				
	Estonia	0.35	0.35	0.41	17
	Latvia	0.18	0.19	0.22	13
	Lithuania	0.15	0.19	0.19	
A05A	BILE THERAPY				
	Estonia	0.35	0.35	0.41	17
	Latvia	0.18	0.19	0.22	13
	Lithuania	0.15	0.19	0.19	
A05AA	Bile acid preparations				
	Estonia	0.35	0.35	0.41	17
	Latvia	0.18	0.19	0.22	13
	Lithuania	0.15	0.19	0.24	26
A05AA02	ursodeoxycholic acid				
	Estonia	0.35	0.35	0.41	17
	Latvia	0.18	0.19	0.22	13
	Lithuania	0.15	0.19	0.24	26
A06	DRUGS FOR CONSTIPATION				
	Estonia	10.82	11.38	12.44	9
	Latvia	7.91	8.14	8.34	2
	Lithuania	7.14	7.85	8.44	8
A06A	DRUGS FOR CONSTIPATION				
	Estonia	10.82	11.38	12.44	9
	Latvia	7.91	8.14	8.34	2
	Lithuania	7.14	7.85	8.44	8
A06AB	Contact laxatives				
	Estonia	6.01	6.09	6.33	4
	Latvia	6.22	6.25	6.51	4
	Lithuania	4.49	4.79	5.02	5
A06AB02	bisacodyl				
	Estonia	3.60	3.55	3.52	-1
	Latvia	2.78	2.78	2.72	-2
	Lithuania	2.61	2.71	2.78	3
A06AB05	castor oil				
	Estonia	0.02	0.01	0.01	
	Latvia	0.07	0.06	0.06	
	Lithuania	-	-	-	



ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
<b>A06AB06</b>	<b>senna glycosides</b>				
	Estonia	0.06	0.05	0.05	
	Latvia	1.56	1.47	1.74	19
	Lithuania	-	-	-	
<b>A06AB08</b>	<b>sodium picosulfate</b>				
	Estonia	2.33	2.48	2.75	11
	Latvia	1.81	1.93	1.99	3
	Lithuania	1.88	2.08	2.24	8
<b>A06AC</b>	<b>Bulk-forming laxatives</b>				
	Estonia	-	-	-	
	Latvia	0.02	0.03	0.05	66
	Lithuania	0.06	0.07	0.07	
<b>A06AC01</b>	<b>ispaghula (psylla seeds)</b>				
	Estonia	-	-	-	
	Latvia	0.02	0.03	0.05	66
	Lithuania	0.06	0.07	0.07	
<b>A06AD</b>	<b>Osmotically acting laxatives</b>				
	Estonia	4.45	4.86	5.55	14
	Latvia	1.67	1.86	1.78	-5
	Lithuania	2.35	2.71	3.01	11
<b>A06AD11</b>	<b>lactulose</b>				
	Estonia	4.37	4.77	5.44	14
	Latvia	1.58	1.75	1.64	-6
	Lithuania	1.91	2.15	2.42	13
<b>A06AD15</b>	<b>macrogol</b>				
	Estonia	0.08	0.08	0.11	38
	Latvia	0.09	0.12	0.14	19
	Lithuania	0.44	0.56	0.59	5
<b>A06AG</b>	<b>Enemas</b>				
	Estonia	0.35	0.43	0.56	30
	Latvia	-	-	-	
	Lithuania	0.24	0.28	0.35	25
<b>A06AG11</b>	<b>laurilsulfate, incl. combinations</b>				
	Estonia	0.35	0.43	0.56	30
	Latvia	-	-	-	
	Lithuania	0.24	0.28	0.35	25
<b>A07</b>	<b>ANTIIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS</b>				
	Estonia	2.91	2.98	3.26	9
	Latvia	2.17	2.43	3.03	24
	Lithuania	2.63	2.94	3.08	5
<b>A07A</b>	<b>INTESTINAL ANTIINFECTIVES</b>				
	Estonia	<0.01	<0.01	-	
	Latvia	-	-	-	
	Lithuania	0.12	0.12	0.12	

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
<b>A07AA</b>	<b>Antibiotics</b>				
	Estonia	<0.01	<0.01	-	
	Latvia	-	-	-	
	Lithuania	0.12	0.12	0.12	
<b>A07AA02</b>	<b>nystatin</b>				
	Estonia	<0.01	<0.01	-	
	Latvia	-	-	-	
	Lithuania	0.12	0.12	0.12	
<b>A07B</b>	<b>INTESTINAL ADSORBENTS</b>				
	Estonia	0.38	0.38	0.41	8
	Latvia	0.61	0.58	0.69	18
	Lithuania	0.97	1.08	1.05	-3
<b>A07BA</b>	<b>Charcoal preparations</b>				
	Estonia	-	-	-	
	Latvia	0.01	<0.01	<0.01	
	Lithuania	0.06	0.01	0.01	
<b>A07BA01</b>	<b>medicinal charcoal</b>				
	Estonia	-	-	-	
	Latvia	0.01	<0.01	<0.01	
	Lithuania	0.06	0.01	0.01	
<b>A07BC</b>	<b>Other intestinal adsorbents</b>				
	Estonia	0.38	0.38	0.41	8
	Latvia	0.60	0.58	0.69	18
	Lithuania	0.91	1.07	1.03	-4
<b>A07BC05</b>	<b>diosmectite</b>				
	Estonia	0.38	0.38	0.41	8
	Latvia	0.60	0.58	0.69	18
	Lithuania	0.91	1.07	1.03	-4
<b>A07D</b>	<b>ANTIPROPULSIVES</b>				
	Estonia	0.70	0.74	0.81	9
	Latvia	0.88	0.88	0.91	4
	Lithuania	0.85	0.96	0.98	2
<b>A07DA</b>	<b>Antipropulsives</b>				
	Estonia	0.70	0.74	0.81	9
	Latvia	0.88	0.88	0.91	4
	Lithuania	0.85	0.96	0.98	2
<b>A07DA03</b>	<b>loperamide</b>				
	Estonia	0.70	0.74	0.81	9
	Latvia	0.88	0.88	0.91	4
	Lithuania	0.85	0.96	0.98	2
<b>A07E</b>	<b>INTESTINAL ANTIINFLAMMATORY AGENTS</b>				
	Estonia	1.52	1.54	1.66	8
	Latvia	0.50	0.73	0.93	27
	Lithuania	0.61	0.67	0.79	18


ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
<b>A07EA</b>	<b>Corticosteroids acting locally</b>				
	Estonia	<0.01	-	-	
	Latvia	<0.01	<0.01	0.01	
	Lithuania	<0.01	<0.01	<0.01	
<b>A07EA06</b>	<b>budesonide</b>				
	Estonia	<0.01	-	-	
	Latvia	<0.01	<0.01	0.01	
	Lithuania	<0.01	<0.01	<0.01	
<b>A07EC</b>	<b>Aminosalicylic acid and similar agents</b>				
	Estonia	1.52	1.54	1.66	8
	Latvia	0.50	0.73	0.93	27
	Lithuania	0.60	0.67	0.78	16
<b>A07EC01</b>	<b>sulfasalazine</b>				
	Estonia	0.95	0.91	0.92	1
	Latvia	0.33	0.51	0.70	37
	Lithuania	0.25	0.26	0.28	8
<b>A07EC02</b>	<b>mesalazine</b>				
	Estonia	0.57	0.63	0.74	17
	Latvia	0.17	0.22	0.23	5
	Lithuania	0.36	0.41	0.50	22
<b>A07F</b>	<b>ANTIDIARRHEAL MICROORGANISMS</b>				
	Estonia	0.31	0.32	0.38	19
	Latvia	0.17	0.24	0.49	105
	Lithuania	0.09	0.11	0.15	36
<b>A07FA</b>	<b>Antidiarrheal microorganisms</b>				
	Estonia	0.31	0.32	0.38	19
	Latvia	0.17	0.24	0.49	105
	Lithuania	0.09	0.11	0.15	36
<b>A07FA02</b>	<b>saccharomyces boulardii</b>				
	Estonia	0.31	0.32	0.38	19
	Latvia	0.17	0.19	0.22	18
	Lithuania	0.09	0.11	0.15	36
<b>A07FA07</b>	<b>lactic acid producing organisms</b>				
	Estonia	-	-	-	
	Latvia	-	-	-	
	Lithuania	-	-	-	
<b>A08</b>	<b>ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS</b>				
	Estonia	0.22	0.11	0.04	-64
	Latvia	0.08	0.04	0.04	10
	Lithuania	0.08	0.02	0.01	-50
<b>A08A</b>	<b>ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS</b>				
	Estonia	0.22	0.11	0.04	-64
	Latvia	0.08	0.04	0.04	10
	Lithuania	0.08	0.02	0.01	-50

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
<b>A08AA</b>	<b>Centrally acting antiobesity products</b>				
	Estonia	<0.01	-	-	
	Latvia	0.02	<0.01	<0.01	
	Lithuania	0.03	-	-	
<b>A08AA10</b>	<b>sibutramine</b>				
	Estonia	<0.01	-	-	
	Latvia	0.02	<0.01	<0.01	
	Lithuania	0.03	-	-	
<b>A08AB</b>	<b>Peripherally acting antiobesity products</b>				
	Estonia	0.22	0.11	0.04	-64
	Latvia	0.06	0.04	0.04	10
	Lithuania	0.05	0.02	0.01	-50
<b>A08AB01</b>	<b>orlistat</b>				
	Estonia	0.22	0.11	0.04	-64
	Latvia	0.06	0.04	0.04	10
	Lithuania	0.05	0.02	0.01	-50
<b>A09</b>	<b>DIGESTIVES, INCL. ENZYMES</b>				
	Estonia	1.27	1.27	1.31	3
	Latvia	3.80	4.45	4.44	
	Lithuania	-	-	-	
<b>A09A</b>	<b>DIGESTIVES, INCL. ENZYMES</b>				
	Estonia	1.27	1.27	1.31	3
	Latvia	3.80	4.45	4.44	
	Lithuania	-	-	-	
<b>A09AA</b>	<b>Enzyme preparations</b>				
	Estonia	1.27	1.27	1.31	3
	Latvia	3.80	4.45	4.44	
	Lithuania	-	-	-	
<b>A09AA02</b>	<b>multienzymes (lipase, protease etc.)</b>				
	Estonia	1.27	1.27	1.31	3
	Latvia	3.80	4.45	4.44	
	Lithuania	-	-	-	
<b>A10</b>	<b>DRUGS USED IN DIABETES</b>				
	Estonia	45.23	47.15	52.57	11
	Latvia	36.21	40.37	42.91	6
	Lithuania	30.11	32.37	36.96	14
<b>A10A</b>	<b>INSULINS AND ANALOGUES</b>				
	Estonia	13.81	13.89	15.12	9
	Latvia	10.34	10.49	11.05	5
	Lithuania	9.75	10.05	11.38	13
<b>A10AB</b>	<b>Insulins and analogues for injection, fast-acting</b>				
	Estonia	4.93	5.13	5.67	11
	Latvia	4.07	4.14	4.33	4
	Lithuania	2.67	2.33	2.84	22

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
<b>A10AB01</b>	<b>insulin (human)</b>				
	Estonia	0.08	0.07	0.06	-14
	Latvia	0.15	0.13	0.12	-7
	Lithuania	0.08	0.07	0.07	
<b>A10AB04</b>	<b>insulin lispro</b>				
	Estonia	1.19	1.22	1.26	3
	Latvia	0.85	0.83	0.90	8
	Lithuania	1.09	0.68	0.72	6
<b>A10AB05</b>	<b>insulin aspart</b>				
	Estonia	3.16	3.28	3.73	14
	Latvia	2.05	2.13	2.26	6
	Lithuania	1.04	1.03	1.37	33
<b>A10AB06</b>	<b>insulin glulisine</b>				
	Estonia	0.50	0.56	0.62	11
	Latvia	1.02	1.05	1.05	
	Lithuania	0.46	0.55	0.68	24
<b>A10AC</b>	<b>Insulins and analogues for injection, intermediate-acting</b>				
	Estonia	0.62	0.27	0.24	-11
	Latvia	1.52	1.55	1.77	14
	Lithuania	0.56	0.45	0.52	16
<b>A10AC01</b>	<b>insulin (human)</b>				
	Estonia	0.62	0.27	0.24	-11
	Latvia	1.52	1.55	1.77	14
	Lithuania	0.28	0.13	0.10	-23
<b>A10AC04</b>	<b>insulin lispro</b>				
	Estonia	-	-	-	
	Latvia	-	-	-	
	Lithuania	0.28	0.32	0.42	31
<b>A10AD</b>	<b>Insulins and analogues for injection, intermediate-acting combined with fast-acting</b>				
	Estonia	2.27	2.07	2.04	-1
	Latvia	2.44	2.39	2.51	5
	Lithuania	4.95	5.42	5.76	6
<b>A10AD04</b>	<b>insulin lispro</b>				
	Estonia	0.78	0.72	0.72	
	Latvia	0.91	0.93	1.07	15
	Lithuania	1.68	2.03	2.23	10
<b>A10AD05</b>	<b>insulin aspart</b>				
	Estonia	1.49	1.35	1.32	-2
	Latvia	1.52	1.46	1.44	-1
	Lithuania	3.28	3.39	3.53	4
<b>A10AE</b>	<b>Insulins and analogues for injection, long-acting</b>				
	Estonia	5.99	6.43	7.17	12
	Latvia	2.32	2.41	2.45	2
	Lithuania	1.57	1.85	2.25	22

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
<b>A10AE04</b>	<b>insulin glargine</b>				
	Estonia	3.35	3.37	3.79	12
	Latvia	1.31	1.39	1.40	1
	Lithuania	0.91	1.12	1.38	23
<b>A10AE05</b>	<b>insulin detemir</b>				
	Estonia	2.63	3.05	3.38	11
	Latvia	1.00	1.02	1.05	3
	Lithuania	0.65	0.73	0.87	19
<b>A10B</b>	<b>BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS</b>				
	Estonia	31.43	33.25	37.44	13
	Latvia	25.87	29.87	31.86	7
	Lithuania	20.36	22.32	25.58	15
<b>A10BA</b>	<b>Biguanides</b>				
	Estonia	15.06	15.75	17.57	12
	Latvia	11.49	12.43	13.22	6
	Lithuania	9.16	10.50	12.51	19
<b>A10BA02</b>	<b>metformin</b>				
	Estonia	15.06	15.75	17.57	12
	Latvia	11.49	12.43	13.22	6
	Lithuania	9.16	10.50	12.51	19
<b>A10BB</b>	<b>Sulfonamides, urea derivatives</b>				
	Estonia	14.79	15.46	16.90	9
	Latvia	11.82	13.94	14.39	3
	Lithuania	10.50	11.09	12.35	11
<b>A10BB07</b>	<b>glipizide</b>				
	Estonia	0.69	0.59	0.51	-14
	Latvia	0.77	0.71	0.65	-8
	Lithuania	0.74	0.80	0.87	9

Consumption of insulins (A10A)




ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
<b>A10BB08</b>	<b>gliquidone</b>				
	Estonia	-	-	-	
	Latvia	0.21	0.24	0.26	10
	Lithuania	0.09	0.08	0.09	13
<b>A10BB09</b>	<b>gliclazide</b>				
	Estonia	8.59	8.37	9.33	11
	Latvia	4.97	7.17	7.72	8
	Lithuania	5.99	6.72	7.91	18
<b>A10BB12</b>	<b>glimepiride</b>				
	Estonia	5.51	6.50	7.07	9
	Latvia	5.87	5.82	5.76	-1
	Lithuania	3.68	3.49	3.49	
<b>A10BD</b>	<b>Combinations of oral blood glucose lowering drugs</b>				
	Estonia	0.20	0.55	1.02	85
	Latvia	1.79	2.31	2.79	21
	Lithuania	-	-	0.21	
<b>A10BD03</b>	<b>metformin and rosiglitazone</b>				
	Estonia	0.12	-	-	
	Latvia	0.88	<0.01	<0.01	
	Lithuania	-	-	-	
<b>A10BD04</b>	<b>glimepiride and rosiglitazone</b>				
	Estonia	-	-	-	
	Latvia	0.02	<0.01	<0.01	
	Lithuania	-	-	-	
<b>A10BD05</b>	<b>metformin and pioglitazone</b>				
	Estonia	-	-	-	
	Latvia	0.89	1.56	1.32	-16
	Lithuania	-	-	0.17	
<b>A10BD07</b>	<b>metformin and sitagliptin</b>				
	Estonia	0.07	0.55	1.02	85
	Latvia	<0.01	0.75	1.33	77
	Lithuania	-	-	0.04	
<b>A10BD08</b>	<b>metformin and vildagliptin</b>				
	Estonia	-	-	-	
	Latvia	<0.01	<0.01	0.15	
	Lithuania	-	-	-	
<b>A10BG</b>	<b>Thiazolidinediones</b>				
	Estonia	0.34	0.28	0.24	-14
	Latvia	0.57	0.60	0.51	-14
	Lithuania	0.61	0.48	0.38	-21
<b>A10BG02</b>	<b>rosiglitazone</b>				
	Estonia	0.05	-	-	
	Latvia	0.04	<0.01	<0.01	
	Lithuania	0.09	-	-	

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
<b>A10BG03</b>	<b>pioglitazone</b>				
	Estonia	0.29	0.28	0.24	-14
	Latvia	0.53	0.60	0.51	-14
	Lithuania	0.52	0.48	0.38	-21
<b>A10BH</b>	<b>Dipeptidyl peptidase 4 (DPP-4) inhibitors</b>				
	Estonia	1.04	1.21	1.54	27
	Latvia	0.01	0.39	0.75	94
	Lithuania	-	-	0.72	
<b>A10BH01</b>	<b>sitagliptin</b>				
	Estonia	1.04	1.21	1.48	22
	Latvia	0.01	0.30	0.49	61
	Lithuania	-	-	0.72	
<b>A10BH03</b>	<b>saxagliptin</b>				
	Estonia	-	-	-	
	Latvia	<0.01	0.08	0.15	81
	Lithuania	-	-	-	
<b>A10BH05</b>	<b>linagliptin</b>				
	Estonia	-	-	0.06	
	Latvia	<0.01	<0.01	0.11	
	Lithuania	-	-	-	
<b>A10BX</b>	<b>Other blood glucose lowering drugs, excl. insulins</b>				
	Estonia	0.01	<0.01	0.18	
	Latvia	0.20	0.21	0.19	-8
	Lithuania	0.09	0.26	0.34	31
<b>A10BX02</b>	<b>repaglinide</b>				
	Estonia	0.01	<0.01	-	
	Latvia	0.20	0.21	0.19	-9
	Lithuania	0.08	0.06	0.05	-17
<b>A10BX04</b>	<b>exenatide</b>				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	0.02	0.20	0.29	45
<b>A10BX07</b>	<b>liraglutide</b>				
	Estonia	-	-	0.18	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
<b>A14</b>	<b>ANABOLIC AGENTS FOR SYSTEMIC USE</b>				
	Estonia	0.02	0.01	0.01	
	Latvia	0.13	0.13	0.12	-12
	Lithuania	0.09	0.09	0.09	
<b>A14A</b>	<b>ANABOLIC STEROIDS</b>				
	Estonia	0.02	0.01	0.01	
	Latvia	0.13	0.13	0.12	-12
	Lithuania	0.09	0.09	0.09	



## Consumption of blood glucose lowering drugs excl. insulins (A10B)



ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
<b>A14AB</b>	<b>Estren derivatives</b>				
	Estonia	0.02	0.01	0.01	
	Latvia	0.13	0.13	0.12	-12
	Lithuania	0.09	0.09	0.09	
<b>A14AB01</b>	<b>nandrolone</b>				
	Estonia	0.02	0.01	0.01	
	Latvia	0.13	0.13	0.12	-12
	Lithuania	0.09	0.09	0.09	
<b>A16</b>	<b>OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS</b>				
	Estonia	0.39	0.43	0.45	5
	Latvia	2.53	2.80	3.09	10
	Lithuania	0.30	0.33	0.38	15
<b>A16A</b>	<b>OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS</b>				
	Estonia	0.39	0.43	0.45	5
	Latvia	2.53	2.80	3.09	10
	Lithuania	0.30	0.33	0.38	15
<b>A16AA</b>	<b>Amino acids and derivatives</b>				
	Estonia	-	-	-	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
<b>A16AA01</b>	<b>levocarnitine</b>				
	Estonia	-	-	-	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
<b>A16AA06</b>	<b>betaine</b>				
	Estonia	-	-	-	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	


ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
<b>A16AB</b>	<b>Enzymes</b>				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	<0.01	<0.01	0.03	
	Lithuania	-	-	-	
<b>A16AB05</b>	<b>laronidase</b>				
	Estonia	-	-	-	
	Latvia	<0.01	<0.01	0.03	
	Lithuania	-	-	-	
<b>A16AX</b>	<b>Various alimentary tract and metabolism products</b>				
	Estonia	0.38	0.42	0.45	7
	Latvia	2.53	2.80	3.06	9
	Lithuania	0.30	0.33	0.37	12
<b>A16AX01</b>	<b>thioctic acid</b>				
	Estonia	0.38	0.42	0.44	5
	Latvia	2.53	2.80	3.06	9
	Lithuania	0.30	0.33	0.37	12
<b>A16AX05</b>	<b>zinc acetate</b>				
	Estonia	<0.01	0.01	0.01	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	<0.01	<0.01	<0.01	

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
<b>B</b>	<b>BLOOD AND BLOOD FORMING ORGANS</b>				
	Estonia	67.53	74.52	90.43	21
	Latvia	66.34	78.47	82.91	6
	Lithuania	53.81	59.06	69.13	17
<b>B01</b>	<b>ANTITHROMBOTIC AGENTS</b>				
	Estonia	59.09	64.88	78.83	22
	Latvia	59.40	70.52	74.04	5
	Lithuania	48.96	53.57	63.49	19
<b>B01A</b>	<b>ANTITHROMBOTIC AGENTS</b>				
	Estonia	59.09	64.88	78.83	22
	Latvia	59.40	70.52	74.04	5
	Lithuania	48.96	53.57	63.49	19
<b>B01AA</b>	<b>Vitamin K antagonists</b>				
	Estonia	5.36	5.94	7.15	20
	Latvia	3.12	3.49	4.00	15
	Lithuania	6.23	6.91	8.11	17
<b>B01AA03</b>	<b>warfarin</b>				
	Estonia	5.36	5.94	7.15	20
	Latvia	3.12	3.49	4.00	15
	Lithuania	6.20	6.87	8.09	18
<b>B01AA07</b>	<b>acenocoumarol</b>				
	Estonia	-	-	-	
	Latvia	-	-	-	
	Lithuania	0.03	0.04	0.02	-50
<b>B01AB</b>	<b>Heparin group</b>				
	Estonia	2.04	1.78	2.03	14
	Latvia	1.41	1.29	1.56	21
	Lithuania	3.73	2.05	1.69	-18
<b>B01AB01</b>	<b>heparin</b>				
	Estonia	0.12	0.10	0.09	-10
	Latvia	0.39	0.23	0.23	
	Lithuania	2.63	0.38	0.34	-11
<b>B01AB04</b>	<b>dalteparin</b>				
	Estonia	0.04	0.05	0.07	40
	Latvia	0.19	0.24	0.46	94
	Lithuania	0.48	0.76	0.38	-50
<b>B01AB05</b>	<b>enoxaparin</b>				
	Estonia	1.63	1.38	1.58	14
	Latvia	0.50	0.46	0.45	-2
	Lithuania	0.18	0.35	0.28	-20
<b>B01AB06</b>	<b>nadroparin</b>				
	Estonia	0.11	0.06	0.07	17
	Latvia	0.29	0.33	0.39	21
	Lithuania	0.32	0.36	0.47	31

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
<b>B01AB12</b>	<b>bemiparin</b>				
	Estonia	0.14	0.19	0.23	21
	Latvia	0.04	0.04	0.04	-2
	Lithuania	0.12	0.19	0.22	16
<b>B01AC</b>	<b>Platelet aggregation inhibitors excl. heparin</b>				
	Estonia	51.61	56.96	69.16	21
	Latvia	54.82	65.69	68.36	4
	Lithuania	38.96	44.51	53.59	20
<b>B01AC04</b>	<b>clopidogrel</b>				
	Estonia	2.04	3.01	3.95	31
	Latvia	2.24	2.91	2.96	2
	Lithuania	3.72	4.52	6.04	34
<b>B01AC06</b>	<b>acetylsalicylic acid</b>				
	Estonia	9.91	11.53	13.87	20
	Latvia	52.57	62.52	64.61	3
	Lithuania	35.24	39.98	47.53	19
<b>B01AC22</b>	<b>prasugrel</b>				
	Estonia	<0.01	<0.01	-	
	Latvia	0.01	<0.01	<0.01	
	Lithuania	-	-	-	
<b>B01AC24</b>	<b>ticagrelor</b>				
	Estonia	-	0.01	0.26	
	Latvia	<0.01	<0.01	0.02	
	Lithuania	-	0.01	0.03	200
<b>B01AC30</b>	<b>combinations</b>				
	Estonia	39.66	42.41	53.39	
	Latvia	<0.01	0.25	0.77	201
	Lithuania	-	-	-	
<b>B01AE</b>	<b>Direct thrombin inhibitors</b>				
	Estonia	0.06	0.13	0.27	108
	Latvia	0.03	0.04	0.10	142
	Lithuania	0.01	0.01	0.04	300
<b>B01AE07</b>	<b>dabigatran etexilate</b>				
	Estonia	0.06	0.13	0.27	108
	Latvia	0.03	0.04	0.10	142
	Lithuania	0.01	0.01	0.04	300
<b>B01AF</b>	<b>Direct factor Xa inhibitors</b>				
	Estonia	<0.01	0.04	0.18	350
	Latvia	-	-	-	
	Lithuania	-	-	0.05	
<b>B01AF01</b>	<b>rivaroxaban</b>				
	Estonia	<0.01	0.04	0.18	350
	Latvia	-	-	-	
	Lithuania	-	-	0.05	

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
<b>B01AX</b>	<b>Other antithrombotic agents</b>				
	Estonia	0.03	0.03	0.03	
	Latvia	0.02	0.02	0.01	-13
	Lithuania	<0.01	<0.01	<0.01	
<b>B01AX05</b>	<b>fondaparinux</b>				
	Estonia	0.03	0.03	0.03	
	Latvia	0.02	0.02	0.01	-13
	Lithuania	<0.01	<0.01	<0.01	
<b>B02</b>	<b>ANTIHEMORRHAGICS</b>				
	Estonia	0.17	0.17	0.19	12
	Latvia	0.03	0.04	0.03	-29
	Lithuania	0.04	0.05	0.07	40
<b>B02A</b>	<b>ANTIFIBRINOLYTICS</b>				
	Estonia	0.07	0.08	0.09	13
	Latvia	0.01	0.01	0.01	24
	Lithuania	-	-	-	
<b>B02AA</b>	<b>Amino acids</b>				
	Estonia	0.07	0.08	0.09	13
	Latvia	0.01	0.01	0.01	24
	Lithuania	-	-	-	
<b>B02AA01</b>	<b>aminocaproic acid</b>				
	Estonia	0.01	0.01	0.01	
	Latvia	-	-	-	
	Lithuania	-	-	-	
<b>B02AA02</b>	<b>tranexamic acid</b>				
	Estonia	0.07	0.08	0.09	13
	Latvia	0.01	0.01	0.01	24
	Lithuania	-	-	-	

### Consumption of antithrombotic agents (B01A)



ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
<b>B02B</b>	<b>VITAMIN K AND OTHER HEMOSTATICS</b>				
	Estonia	0.10	0.08	0.10	25
	Latvia	0.02	0.03	0.02	-48
	Lithuania	0.04	0.05	0.07	40
<b>B02BA</b>	<b>Vitamin K</b>				
	Estonia	0.10	0.07	0.07	
	Latvia	0.01	0.01	0.01	
	Lithuania	0.03	0.03	0.03	
<b>B02BA01</b>	<b>phytomenadione</b>				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	0.01	0.01	0.01	
	Lithuania	0.03	0.03	0.03	
<b>B02BA02</b>	<b>menadione</b>				
	Estonia	0.09	0.07	0.07	
	Latvia	-	-	-	
	Lithuania	-	-	-	
<b>B02BD</b>	<b>Blood coagulation factors</b>				
	Estonia	0.01	0.01	0.02	100
	Latvia	0.02	0.02	0.01	-67
	Lithuania	0.01	0.01	0.03	200
<b>B02BD02</b>	<b>coagulation factor VIII</b>				
	Estonia	0.01	0.01	0.02	100
	Latvia	<0.01	<0.01	0.01	
	Lithuania	<0.01	0.01	0.03	200
<b>B02BD03</b>	<b>factor VIII inhibitor bypassing activity</b>				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	0.01	0.02	<0.01	
	Lithuania	-	-	-	
<b>B02BD04</b>	<b>coagulation factor IX</b>				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	<0.01	0.01	0.01	
<b>B03</b>	<b>ANTI-ANEMIC PREPARATIONS</b>				
	Estonia	8.26	9.47	11.42	21
	Latvia	6.90	7.91	8.84	12
	Lithuania	4.81	5.44	5.53	2
<b>B03A</b>	<b>IRON PREPARATIONS</b>				
	Estonia	1.97	2.11	2.40	14
	Latvia	4.06	4.67	5.57	19
	Lithuania	2.64	2.84	3.23	14
<b>B03AA</b>	<b>Iron bivalent, oral preparations</b>				
	Estonia	1.97	2.03	2.23	10
	Latvia	0.32	0.04	<0.01	
	Lithuania	1.28	1.44	1.63	13

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
<b>B03AA05</b>	<b>ferrous chloride</b>				
	Estonia	-	-	-	
	Latvia	-	-	-	
	Lithuania	0.03	0.03	0.03	
<b>B03AA07</b>	<b>ferrous sulfate</b>				
	Estonia	1.97	2.03	2.23	10
	Latvia	0.32	0.04	<0.01	
	Lithuania	1.25	1.42	1.61	13
<b>B03AB</b>	<b>Iron trivalent, oral preparations</b>				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	1.67	2.01	2.38	18
	Lithuania	0.36	0.34	0.36	6
<b>B03AB05</b>	<b>ferric oxide polymaltose complexes</b>				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	1.67	2.01	2.38	18
	Lithuania	0.36	0.34	0.36	6
<b>B03AC</b>	<b>Iron trivalent, parenteral preparations</b>				
	Estonia	-	-	-	
	Latvia	0.06	0.07	0.08	10
	Lithuania	-	-	-	
<b>B03AC02</b>	<b>saccharated iron oxide</b>				
	Estonia	-	-	-	
	Latvia	0.02	0.01	0.02	132
	Lithuania	-	-	-	
<b>B03AC06</b>	<b>ferric oxide dextran complexes</b>				
	Estonia	-	-	-	
	Latvia	0.04	0.06	0.05	-11
	Lithuania	-	-	-	
<b>B03AD</b>	<b>Iron in combination with folic acid</b>				
	Estonia	-	0.07	0.18	157
	Latvia	2.01	2.55	3.11	22
	Lithuania	0.15	0.18	0.18	
<b>B03AD02</b>	<b>ferrous fumarate</b>				
	Estonia	-	0.07	0.18	157
	Latvia	2.01	2.55	3.11	22
	Lithuania	0.15	0.18	0.18	
<b>B03B</b>	<b>VITAMIN B12 AND FOLIC ACID</b>				
	Estonia	5.79	6.84	8.51	24
	Latvia	2.09	2.40	2.37	-1
	Lithuania	1.65	1.91	1.50	-21
<b>B03BA</b>	<b>Vitamin B12 (cyanocobalamin and analogues)</b>				
	Estonia	4.07	3.95	4.82	22
	Latvia	2.09	2.40	2.37	-1
	Lithuania	1.65	1.91	1.50	-21

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
<b>B03BA01</b>	<b>cyanocobalamin</b>				
	Estonia	4.07	3.94	4.81	22
	Latvia	2.09	2.40	2.37	-1
	Lithuania	1.65	1.91	1.50	-21
<b>B03BA03</b>	<b>hydroxocobalamin</b>				
	Estonia	0.01	0.01	0.01	
	Latvia	-	-	-	
	Lithuania	-	-	-	
<b>B03BB</b>	<b>Folic acid and derivatives</b>				
	Estonia	1.72	2.89	3.69	28
	Latvia	-	-	-	
	Lithuania	-	-	-	
<b>B03BB01</b>	<b>folic acid</b>				
	Estonia	1.72	2.89	3.69	28
	Latvia	-	-	-	
	Lithuania	-	-	-	
<b>B03X</b>	<b>OTHER ANTIANEMIC PREPARATIONS</b>				
	Estonia	0.50	0.52	0.50	-4
	Latvia	0.75	0.83	0.90	8
	Lithuania	0.52	0.70	0.80	14
<b>B03XA</b>	<b>Other antianemic preparations</b>				
	Estonia	0.50	0.52	0.50	-4
	Latvia	0.75	0.83	0.90	8
	Lithuania	0.52	0.70	0.80	14
<b>B03XA01</b>	<b>erythropoietin</b>				
	Estonia	0.14	0.10	0.09	-10
	Latvia	0.08	0.09	0.10	8
	Lithuania	0.16	0.16	0.20	25
<b>B03XA02</b>	<b>darbepoetin alfa</b>				
	Estonia	0.21	0.26	0.31	19
	Latvia	0.36	0.45	0.59	32
	Lithuania	0.36	0.54	0.60	11
<b>B03XA03</b>	<b>methoxy polyethylene glycol-epoetin beta</b>				
	Estonia	0.15	0.16	0.09	-44
	Latvia	0.31	0.30	0.22	-27
	Lithuania	-	-	-	




ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
<b>C</b>	<b>CARDIOVASCULAR SYSTEM</b>				
	Estonia	349.60	355.75	394.88	11
	Latvia	285.27	313.37	349.10	11
	Lithuania	357.62	373.14	425.45	14
<b>C01</b>	<b>CARDIAC THERAPY</b>				
	Estonia	33.73	33.01	34.27	4
	Latvia	24.63	25.44	27.06	6
	Lithuania	40.10	40.30	49.82	24
<b>C01A</b>	<b>CARDIAC GLYCOSIDES</b>				
	Estonia	6.04	5.35	5.20	-3
	Latvia	4.91	4.68	4.61	-2
	Lithuania	4.15	3.90	4.20	8
<b>C01AA</b>	<b>Digitalis glycosides</b>				
	Estonia	6.04	5.35	5.20	-3
	Latvia	4.91	4.68	4.61	-2
	Lithuania	4.15	3.90	4.20	8
<b>C01AA05</b>	<b>digoxin</b>				
	Estonia	6.04	5.35	5.20	-3
	Latvia	4.91	4.68	4.61	-2
	Lithuania	4.15	3.90	4.20	8
<b>C01B</b>	<b>ANTIARRHYTHMICS, CLASS I AND III</b>				
	Estonia	4.56	4.92	5.61	14
	Latvia	2.33	2.35	2.38	1
	Lithuania	5.55	2.80	6.29	125
<b>C01BC</b>	<b>Antiarrhythmics, class Ic</b>				
	Estonia	1.95	2.28	2.80	23
	Latvia	0.29	0.38	0.43	12
	Lithuania	1.41	1.63	1.95	20
<b>C01BC03</b>	<b>propafenone</b>				
	Estonia	1.93	2.26	2.77	23
	Latvia	0.29	0.38	0.43	12
	Lithuania	1.41	1.63	1.95	20
<b>C01BC04</b>	<b>flecainide</b>				
	Estonia	0.03	0.02	0.03	50
	Latvia	-	-	-	
	Lithuania	-	-	-	
<b>C01BD</b>	<b>Antiarrhythmics, class III</b>				
	Estonia	2.60	2.64	2.81	6
	Latvia	2.04	1.97	1.95	-1
	Lithuania	4.15	1.20	4.36	263
<b>C01BD01</b>	<b>amiodarone</b>				
	Estonia	2.59	2.62	2.78	6
	Latvia	2.04	1.97	1.95	-1
	Lithuania	4.14	1.18	4.34	268

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
<b>C01BD07</b>	<b>dronedarone</b>				
	Estonia	0.01	0.02	0.03	50
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	<0.01	0.02	0.02	
<b>C01C</b>	<b>CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES</b>				
	Estonia	0.86	0.85	0.82	-4
	Latvia	0.34	0.35	0.32	-10
	Lithuania	0.74	0.80	0.86	8
<b>C01CA</b>	<b>Adrenergic and dopaminergic agents</b>				
	Estonia	0.86	0.85	0.82	-4
	Latvia	0.34	0.35	0.32	-10
	Lithuania	0.74	0.8	0.85	6
<b>C01CA03</b>	<b>norepinephrine</b>				
	Estonia	0.10	0.12	0.11	-8
	Latvia	-	-	-	
	Lithuania	-	-	-	
<b>C01CA04</b>	<b>dopamine</b>				
	Estonia	0.02	0.02	0.02	
	Latvia	0.01	0.01	<0.01	
	Lithuania	0.02	0.02	0.03	50
<b>C01CA06</b>	<b>phenylephrine</b>				
	Estonia	0.14	0.13	0.13	
	Latvia	-	-	-	
	Lithuania	-	-	-	
<b>C01CA07</b>	<b>dobutamine</b>				
	Estonia	0.01	<0.01	0.01	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
<b>C01CA24</b>	<b>epinephrine</b>				
	Estonia	0.57	0.55	0.53	-4
	Latvia	0.32	0.34	0.32	-8
	Lithuania	0.72	0.78	0.83	6
<b>C01CA26</b>	<b>ephedrine</b>				
	Estonia	0.03	0.03	0.03	
	Latvia	-	-	-	
	Lithuania	-	-	-	
<b>C01D</b>	<b>VASODILATORS USED IN CARDIAC DISEASES</b>				
	Estonia	12.58	11.30	11.23	-1
	Latvia	10.51	10.07	9.33	-7
	Lithuania	12.69	12.79	13.26	4
<b>C01DA</b>	<b>Organic nitrates</b>				
	Estonia	12.58	11.30	11.23	-1
	Latvia	10.51	10.07	9.33	-7
	Lithuania	12.69	12.79	13.26	4

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
<b>C01DA02</b>	<b>glyceryl trinitrate</b>				
	Estonia	0.63	0.61	0.61	
	Latvia	0.82	0.95	0.87	-8
	Lithuania	3.95	3.97	3.73	-6
<b>C01DA08</b>	<b>isosorbide dinitrate</b>				
	Estonia	0.82	0.68	0.67	-1
	Latvia	1.15	0.81	0.51	-37
	Lithuania	1.49	1.42	1.47	4
<b>C01DA14</b>	<b>isosorbide mononitrate</b>				
	Estonia	11.12	10.01	9.95	-1
	Latvia	8.54	8.31	7.95	-4
	Lithuania	7.24	7.40	8.05	9
<b>C01E</b>	<b>OTHER CARDIAC PREPARATIONS</b>				
	Estonia	9.69	10.58	11.41	8
	Latvia	6.54	7.98	10.43	31
	Lithuania	16.97	20.01	25.23	26
<b>C01EA</b>	<b>Prostaglandins</b>				
	Estonia	-	-	-	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
<b>C01EA01</b>	<b>alprostadil</b>				
	Estonia	-	-	-	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
<b>C01EB</b>	<b>Other cardiac preparations</b>				
	Estonia	9.69	10.58	11.41	8
	Latvia	6.54	7.98	10.43	31
	Lithuania	16.97	20.01	25.23	26
<b>C01EB10</b>	<b>adenosine</b>				
	Estonia	0.01	0.01	0.01	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	<0.01	<0.01	<0.01	
<b>C01EB15</b>	<b>trimetazidine</b>				
	Estonia	9.64	10.53	11.33	8
	Latvia	6.22	7.38	9.49	29
	Lithuania	16.44	19.23	22.92	19
<b>C01EB17</b>	<b>ivabradine</b>				
	Estonia	0.05	0.04	0.05	25
	Latvia	0.32	0.60	0.94	57
	Lithuania	0.54	0.79	2.30	191
<b>C01EB18</b>	<b>ranolazine</b>				
	Estonia	-	<0.01	0.01	
	Latvia	<0.01	<0.01	0.01	
	Lithuania	-	<0.01	0.01	

## Consumption of drugs for cardiac therapy (C01)



ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
<b>C02</b>	<b>ANTIHYPERTENSIVES</b>				
	Estonia	3.42	3.43	3.77	10
	Latvia	6.12	6.91	7.73	12
	Lithuania	20.17	21.92	25.65	17
<b>C02A</b>	<b>ANTIADRENERGIC AGENTS, CENTRALLY ACTING</b>				
	Estonia	1.83	1.88	2.16	15
	Latvia	3.76	4.61	5.49	19
	Lithuania	12.97	14.21	17.25	21
<b>C02AB</b>	<b>Methyldopa</b>				
	Estonia	-	-	-	
	Latvia	0.06	0.06	0.07	23
	Lithuania	0.06	0.06	0.07	17
<b>C02AB01</b>	<b>methyldopa (levorotatory)</b>				
	Estonia	-	-	-	
	Latvia	0.06	0.06	0.07	23
	Lithuania	0.06	0.06	0.07	17
<b>C02AC</b>	<b>Imidazoline receptor agonists</b>				
	Estonia	1.83	1.88	2.16	15
	Latvia	3.71	4.55	5.42	19
	Lithuania	12.91	14.15	17.18	21
<b>C02AC01</b>	<b>clonidine</b>				
	Estonia	0.09	0.08	0.07	-13
	Latvia	1.11	1.16	1.23	6
	Lithuania	-	-	-	
<b>C02AC05</b>	<b>moxonidine</b>				
	Estonia	1.74	1.80	2.09	16
	Latvia	2.59	3.38	4.19	24
	Lithuania	12.91	14.15	17.18	21

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
<b>C02C</b>	<b>ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING</b>				
	Estonia	1.58	1.55	1.60	3
	Latvia	2.36	2.30	2.24	-3
	Lithuania	7.20	7.70	8.40	9
<b>C02CA</b>	<b>Alpha-adrenoreceptor antagonists</b>				
	Estonia	1.58	1.55	1.60	3
	Latvia	2.36	2.30	2.24	-3
	Lithuania	7.20	7.70	8.40	9
<b>C02CA04</b>	<b>doxazosin</b>				
	Estonia	1.58	1.55	1.60	3
	Latvia	2.36	2.30	2.24	-3
	Lithuania	7.20	7.70	8.40	9
<b>C02D</b>	<b>ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON</b>				
	Estonia	-	-	-	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
<b>C02DD</b>	<b>Nitroferricyanide derivatives</b>				
	Estonia	-	-	-	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
<b>C02DD01</b>	<b>nitroprusside</b>				
	Estonia	-	-	-	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
<b>C02K</b>	<b>OTHER ANTIHYPERTENSIVES</b>				
	Estonia	0.01	0.01	0.01	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	<0.01	0.01	0.01	
<b>C02KX</b>	<b>Other antihypertensives</b>				
	Estonia	0.01	0.01	0.01	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	<0.01	0.01	0.01	
<b>C02KX01</b>	<b>bosentan</b>				
	Estonia	0.01	0.01	0.01	
	Latvia	-	-	-	
	Lithuania	<0.01	<0.01	<0.01	
<b>C03</b>	<b>DIURETICS</b>				
	Estonia	21.68	21.15	22.67	7
	Latvia	18.22	17.91	18.63	4
	Lithuania	18.26	17.68	19.83	12
<b>C03A</b>	<b>LOW-CEILING DIURETICS, THIAZIDES</b>				
	Estonia	5.50	4.41	4.17	-5
	Latvia	0.84	0.78	0.72	-8
	Lithuania	0.12	0.13	0.13	

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
<b>C03AA</b>	<b>Thiazides, plain</b>				
	Estonia	5.50	4.41	4.17	-5
	Latvia	0.84	0.78	0.72	-8
	Lithuania	0.12	0.13	0.13	
<b>C03AA03</b>	<b>hydrochlorothiazide</b>				
	Estonia	5.50	4.41	4.17	-5
	Latvia	0.84	0.78	0.72	-8
	Lithuania	0.12	0.13	0.13	
<b>C03B</b>	<b>LOW-CEILING DIURETICS, EXCL. THIAZIDES</b>				
	Estonia	1.67	1.91	2.25	18
	Latvia	5.44	5.23	5.07	-3
	Lithuania	6.58	5.52	5.48	-1
<b>C03BA</b>	<b>Sulfonamides, plain</b>				
	Estonia	1.67	1.91	2.25	18
	Latvia	5.44	5.23	5.07	-3
	Lithuania	6.58	5.52	5.48	-1
<b>C03BA11</b>	<b>indapamide</b>				
	Estonia	1.67	1.91	2.25	18
	Latvia	5.44	5.23	5.07	-3
	Lithuania	6.58	5.52	5.48	-1
<b>C03C</b>	<b>HIGH-CEILING DIURETICS</b>				
	Estonia	11.33	11.83	13.21	12
	Latvia	7.03	7.11	7.82	10
	Lithuania	8.39	8.78	10.28	17
<b>C03CA</b>	<b>Sulfonamides, plain</b>				
	Estonia	11.33	11.83	13.21	12
	Latvia	7.03	7.11	7.82	10
	Lithuania	8.39	8.78	10.28	17
<b>C03CA01</b>	<b>furosemide</b>				
	Estonia	5.77	5.38	5.30	-1
	Latvia	3.42	3.12	3.23	4
	Lithuania	2.80	2.74	2.90	6
<b>C03CA04</b>	<b>torasemide</b>				
	Estonia	5.57	6.45	7.90	22
	Latvia	3.60	3.99	4.58	15
	Lithuania	5.59	6.05	7.38	22
<b>C03D</b>	<b>POTASSIUM-SPARING AGENTS</b>				
	Estonia	3.05	2.96	3.02	2
	Latvia	4.92	4.79	5.03	5
	Lithuania	3.17	3.24	3.94	22
<b>C03DA</b>	<b>Aldosterone antagonists</b>				
	Estonia	3.05	2.96	3.02	2
	Latvia	4.92	4.79	5.03	5
	Lithuania	3.17	3.24	3.94	22

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
<b>C03DA01</b>	<b>spironolactone</b>				
	Estonia	3.05	2.96	3.02	2
	Latvia	4.92	4.79	5.02	5
	Lithuania	3.16	3.23	3.93	22
<b>C03DA04</b>	<b>eplerenone</b>				
	Estonia	-	-	-	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	0.01	0.01	0.01	
<b>C03E</b>	<b>DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION</b>				
	Estonia	0.12	0.04	0.02	-50
	Latvia	-	-	-	
	Lithuania	-	-	-	
<b>C03EA</b>	<b>Low-ceiling diuretics and potassium-sparing agents</b>				
	Estonia	0.12	0.04	0.02	-50
	Latvia	-	-	-	
	Lithuania	-	-	-	
<b>C03EA01</b>	<b>hydrochlorothiazide and potassium-sparing agents</b>				
	Estonia	0.12	0.04	0.02	-50
	Latvia	-	-	-	
	Lithuania	-	-	-	
<b>C04</b>	<b>PERIPHERAL VASODILATORS</b>				
	Estonia	2.52	2.57	2.72	6
	Latvia	2.96	3.00	3.22	7
	Lithuania	4.42	4.53	4.89	8
<b>C04A</b>	<b>PERIPHERAL VASODILATORS</b>				
	Estonia	2.52	2.57	2.72	6
	Latvia	2.96	3.00	3.22	7
	Lithuania	4.42	4.53	4.89	8
<b>C04AD</b>	<b>Purine derivatives</b>				
	Estonia	2.31	2.33	2.45	5
	Latvia	1.46	1.40	1.44	2
	Lithuania	4.42	4.53	4.89	8
<b>C04AD02</b>	<b>xantinol nicotinate</b>				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	-	-	-	
	Lithuania	0.04	0.04	0.04	
<b>C04AD03</b>	<b>pentoxifylline</b>				
	Estonia	2.31	2.32	2.44	5
	Latvia	1.46	1.40	1.44	2
	Lithuania	4.38	4.49	4.85	8
<b>C04AX</b>	<b>Other peripheral vasodilators</b>				
	Estonia	0.21	0.24	0.27	13
	Latvia	1.50	1.60	1.79	12
	Lithuania	-	-	-	

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
<b>C04AX21</b>	<b>naftidrofuryl</b>				
	Estonia	0.21	0.24	0.27	13
	Latvia	1.50	1.60	1.79	12
	Lithuania	-	-	-	
<b>C07</b>	<b>BETA BLOCKING AGENTS</b>				
	Estonia	33.53	35.52	40.38	14
	Latvia	32.62	36.64	40.12	10
	Lithuania	46.12	51.35	60.19	17
<b>C07A</b>	<b>BETA BLOCKING AGENTS</b>				
	Estonia	33.53	35.52	40.38	14
	Latvia	32.62	36.64	40.12	10
	Lithuania	46.12	50.56	57.95	15
<b>C07AA</b>	<b>Beta blocking agents, non-selective</b>				
	Estonia	2.20	2.16	2.28	6
	Latvia	0.48	0.50	0.54	9
	Lithuania	0.06	0.09	0.13	44
<b>C07AA05</b>	<b>propranolol</b>				
	Estonia	0.39	0.40	0.44	10
	Latvia	0.37	0.36	0.37	4
	Lithuania	0.06	0.09	0.13	44
<b>C07AA07</b>	<b>sotalol</b>				
	Estonia	1.81	1.76	1.84	5
	Latvia	0.12	0.14	0.17	22
	Lithuania	-	-	-	
<b>C07AB</b>	<b>Beta blocking agents, selective</b>				
	Estonia	30.61	32.67	37.33	14
	Latvia	31.49	35.54	39.02	10
	Lithuania	43.82	47.95	55.00	15
<b>C07AB02</b>	<b>metoprolol</b>				
	Estonia	21.97	21.05	22.31	6
	Latvia	12.57	13.10	13.52	3
	Lithuania	15.20	16.30	18.34	13
<b>C07AB03</b>	<b>atenolol</b>				
	Estonia	1.56	1.32	1.23	-7
	Latvia	0.84	0.77	0.72	-7
	Lithuania	0.88	0.85	0.90	6
<b>C07AB05</b>	<b>betaxolol</b>				
	Estonia	-	-	-	
	Latvia	1.62	1.89	2.15	14
	Lithuania	4.75	4.86	5.44	12
<b>C07AB07</b>	<b>bisoprolol</b>				
	Estonia	0.36	0.40	0.51	28
	Latvia	14.09	15.56	17.12	10
	Lithuania	0.03	0.05	0.06	20



ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
<b>C07AB12</b>	<b>nebivolol</b>				
	Estonia	6.71	9.89	13.28	34
	Latvia	2.38	4.21	5.52	31
	Lithuania	22.95	25.89	30.26	17
<b>C07AG</b>	<b>Alpha and beta blocking agents</b>				
	Estonia	0.71	0.70	0.77	10
	Latvia	0.65	0.60	0.56	-7
	Lithuania	2.24	2.52	2.82	12
<b>C07AG01</b>	<b>labetalol</b>				
	Estonia	0.05	0.06	0.06	
	Latvia	-	-	-	
	Lithuania	-	-	-	
<b>C07AG02</b>	<b>carvedilol</b>				
	Estonia	0.66	0.64	0.71	11
	Latvia	0.65	0.60	0.56	-7
	Lithuania	2.24	2.52	2.82	12
<b>C07B</b>	<b>BETA BLOCKING AGENTS AND THIAZIDES</b>				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	-	-	-	
	Lithuania	-	0.79	2.24	184
<b>C07BB</b>	<b>Beta blocking agents, selective, and thiazides</b>				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	-	-	-	
	Lithuania	-	0.79	2.24	184
<b>C07BB12</b>	<b>nebivolol and thiazides</b>				
	Estonia	-	-	-	
	Latvia	-	-	-	
	Lithuania	-	0.79	2.24	184
<b>C08</b>	<b>CALCIUM CHANNEL BLOCKERS</b>				
	Estonia	66.03	64.18	68.13	6
	Latvia	34.05	36.46	37.50	3
	Lithuania	36.23	36.37	37.88	4
<b>C08C</b>	<b>SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS</b>				
	Estonia	63.58	61.85	65.60	6
	Latvia	33.17	35.66	36.73	3
	Lithuania	32.26	32.38	33.70	4
<b>C08CA</b>	<b>Dihydropyridine derivatives</b>				
	Estonia	63.58	61.85	65.60	6
	Latvia	33.17	35.66	36.73	3
	Lithuania	32.26	32.38	33.70	4
<b>C08CA01</b>	<b>amlodipine</b>				
	Estonia	37.68	35.87	37.05	3
	Latvia	19.93	20.36	20.28	
	Lithuania	11.92	10.84	10.83	

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
<b>C08CA02</b>	<b>felodipine</b>				
	Estonia	7.59	6.72	6.62	-1
	Latvia	1.80	1.58	1.50	-5
	Lithuania	0.71	0.60	0.53	-12
<b>C08CA05</b>	<b>nifedipine</b>				
	Estonia	3.38	2.80	2.64	-6
	Latvia	1.69	1.50	1.52	1
	Lithuania	0.19	0.19	0.19	
<b>C08CA06</b>	<b>nimodipine</b>				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	0.01	0.01	0.01	2
	Lithuania	-	-	-	
<b>C08CA08</b>	<b>nitrendipine</b>				
	Estonia	6.50	6.22	6.64	7
	Latvia	3.19	3.12	3.26	5
	Lithuania	0.60	0.50	0.47	-6
<b>C08CA09</b>	<b>lacidipine</b>				
	Estonia	7.77	7.00	6.96	-1
	Latvia	4.34	4.22	4.20	-1
	Lithuania	7.01	6.52	6.26	-4
<b>C08CA13</b>	<b>lercanidipine</b>				
	Estonia	0.66	3.23	5.69	76
	Latvia	2.21	4.87	5.97	23
	Lithuania	11.84	13.74	15.42	12
<b>C08D</b>	<b>SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS</b>				
	Estonia	2.45	2.33	2.53	9
	Latvia	0.89	0.80	0.77	-4
	Lithuania	3.97	4.00	4.18	5
<b>C08DA</b>	<b>Phenylalkylamine derivatives</b>				
	Estonia	2.33	2.22	2.43	9
	Latvia	0.44	0.41	0.41	-2
	Lithuania	1.53	1.62	1.83	13
<b>C08DA01</b>	<b>verapamil</b>				
	Estonia	2.33	2.22	2.43	9
	Latvia	0.44	0.41	0.41	-2
	Lithuania	1.53	1.62	1.83	13
<b>C08DB</b>	<b>Benzothiazepine derivatives</b>				
	Estonia	0.12	0.11	0.09	-18
	Latvia	0.45	0.39	0.36	-7
	Lithuania	2.45	2.38	2.36	-1
<b>C08DB01</b>	<b>diltiazem</b>				
	Estonia	0.12	0.11	0.09	-18
	Latvia	0.45	0.39	0.36	-7
	Lithuania	2.45	2.38	2.36	-1

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
<b>C09</b>	<b>AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM</b>				
	Estonia	162.35	164.13	183.36	12
	Latvia	140.47	154.55	173.02	12
	Lithuania	184.33	191.10	214.04	12
<b>C09A</b>	<b>ACE INHIBITORS, PLAIN</b>				
	Estonia	93.98	90.23	95.73	6
	Latvia	65.30	66.05	69.13	5
	Lithuania	113.68	105.66	111.79	6
<b>C09AA</b>	<b>ACE inhibitors, plain</b>				
	Estonia	93.98	90.23	95.73	6
	Latvia	65.30	66.05	69.13	5
	Lithuania	113.68	105.66	111.79	6
<b>C09AA01</b>	<b>captopril</b>				
	Estonia	0.22	0.17	0.15	-12
	Latvia	1.02	1.01	0.99	-3
	Lithuania	8.72	8.90	10.57	19
<b>C09AA02</b>	<b>enalapril</b>				
	Estonia	19.83	17.76	18.91	6
	Latvia	25.43	23.89	22.92	-4
	Lithuania	14.83	12.81	11.75	-8
<b>C09AA03</b>	<b>lisinopril</b>				
	Estonia	0.17	0.14	<0.01	
	Latvia	1.09	0.97	0.96	-1
	Lithuania	3.95	3.35	3.29	-2
<b>C09AA04</b>	<b>perindopril</b>				
	Estonia	0.91	0.82	0.87	6
	Latvia	19.76	20.36	21.00	3
	Lithuania	19.65	19.25	21.32	11
<b>C09AA05</b>	<b>ramipril</b>				
	Estonia	58.18	58.21	62.86	8
	Latvia	13.51	15.78	19.47	23
	Lithuania	38.96	36.57	38.90	6
<b>C09AA06</b>	<b>quinapril</b>				
	Estonia	0.09	0.06	0.06	
	Latvia	1.79	1.64	1.54	-6
	Lithuania	11.03	9.31	9.18	-1
<b>C09AA09</b>	<b>fosinopril</b>				
	Estonia	14.51	13.01	12.81	-2
	Latvia	2.59	2.32	2.16	-7
	Lithuania	7.24	6.11	6.00	-2
<b>C09AA10</b>	<b>trandolapril</b>				
	Estonia	0.04	0.06	0.08	33
	Latvia	0.06	0.05	0.07	46
	Lithuania	1.54	1.89	2.05	8


ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
<b>C09AA11</b>	<b>spirapril</b>				
	Estonia	<0.01	-	-	
	Latvia	0.01	<0.01	<0.01	
	Lithuania	0.56	0.46	0.30	-35
<b>C09AA15</b>	<b>zofenopril</b>				
	Estonia	0.02	<0.01	<0.01	
	Latvia	0.03	0.02	0.02	
	Lithuania	7.20	7.02	8.43	20
<b>C09B</b>	<b>ACE INHIBITORS, COMBINATIONS</b>				
	Estonia	27.21	26.26	29.35	12
	Latvia	62.11	72.51	84.88	17
	Lithuania	32.39	37.36	44.18	18
<b>C09BA</b>	<b>ACE inhibitors and diuretics</b>				
	Estonia	26.21	23.95	25.54	7
	Latvia	50.98	56.12	62.84	12
	Lithuania	25.74	26.30	28.19	7
<b>C09BA02</b>	<b>enalapril and diuretics</b>				
	Estonia	17.06	15.07	14.82	-2
	Latvia	14.61	13.80	13.27	-4
	Lithuania	1.11	0.82	0.68	-17
<b>C09BA03</b>	<b>lisinopril and diuretics</b>				
	Estonia	-	-	-	
	Latvia	0.03	<0.01	<0.01	
	Lithuania	-	-	-	
<b>C09BA04</b>	<b>perindopril and diuretics</b>				
	Estonia	2.19	2.47	4.14	68
	Latvia	20.96	26.13	33.16	27
	Lithuania	15.40	17.05	19.64	15
<b>C09BA05</b>	<b>ramipril and diuretics</b>				
	Estonia	4.09	3.75	3.86	3
	Latvia	0.92	1.72	2.38	39
	Lithuania	1.07	1.54	1.46	-5
<b>C09BA06</b>	<b>quinapril and diuretics</b>				
	Estonia	0.24	0.18	0.17	-6
	Latvia	11.37	11.57	11.30	-2
	Lithuania	6.05	5.19	4.79	-8
<b>C09BA09</b>	<b>fosinopril and diuretics</b>				
	Estonia	2.63	2.47	2.56	4
	Latvia	3.09	2.90	2.73	-6
	Lithuania	2.11	1.70	1.62	-5
<b>C09BB</b>	<b>ACE inhibitors and calcium channel blockers</b>				
	Estonia	1.00	2.32	3.81	64
	Latvia	11.13	16.40	22.04	34
	Lithuania	6.65	11.06	15.99	45

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
<b>C09BB03</b>	<b>lisinopril and amlodipine</b>				
	Estonia	0.45	1.48	2.12	43
	Latvia	0.86	1.84	2.45	33
	Lithuania	0.17	1.08	1.66	54
<b>C09BB04</b>	<b>perindopril and amlodipine</b>				
	Estonia	-	-	0.53	
	Latvia	10.26	14.55	19.59	35
	Lithuania	4.47	7.62	11.41	50
<b>C09BB07</b>	<b>ramipril and amlodipine</b>				
	Estonia	-	-	0.10	
	Latvia	-	-	-	
	Lithuania	-	-	-	
<b>C09BB10</b>	<b>trandolapril and verapamil</b>				
	Estonia	0.56	0.83	1.06	28
	Latvia	-	-	-	
	Lithuania	2.01	2.36	2.92	24
<b>C09C</b>	<b>ANGIOTENSIN II ANTAGONISTS, PLAIN</b>				
	Estonia	29.53	32.97	38.46	17
	Latvia	8.19	9.64	10.17	6
	Lithuania	31.95	38.59	44.24	15
<b>C09CA</b>	<b>Angiotensin II antagonists, plain</b>				
	Estonia	29.53	32.97	38.46	17
	Latvia	8.19	9.64	10.17	6
	Lithuania	31.95	38.59	44.24	15
<b>C09CA01</b>	<b>losartan</b>				
	Estonia	8.64	7.74	7.32	-5
	Latvia	0.73	1.50	1.84	23
	Lithuania	16.79	13.10	10.95	-16
<b>C09CA02</b>	<b>eprosartan</b>				
	Estonia	0.06	0.04	0.03	-25
	Latvia	0.02	0.01	0.01	-32
	Lithuania	0.10	0.07	0.05	-29
<b>C09CA03</b>	<b>valsartan</b>				
	Estonia	4.56	5.12	6.04	18
	Latvia	0.22	0.09	0.16	65
	Lithuania	12.49	15.02	19.45	29
<b>C09CA04</b>	<b>irbesartan</b>				
	Estonia	0.06	0.03	<0.01	
	Latvia	0.43	0.34	0.29	-13
	Lithuania	0.41	0.33	0.29	-12
<b>C09CA06</b>	<b>candesartan</b>				
	Estonia	6.61	5.84	6.18	6
	Latvia	3.43	2.14	1.92	-11
	Lithuania	0.20	0.16	0.14	-13

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
<b>C09CA07</b>	<b>telmisartan</b>				
	Estonia	8.39	12.47	16.72	34
	Latvia	2.37	4.01	4.43	11
	Lithuania	1.12	9.11	12.50	37
<b>C09CA08</b>	<b>olmesartan medoxomil</b>				
	Estonia	1.22	1.73	2.16	25
	Latvia	0.98	1.54	1.53	-1
	Lithuania	0.85	0.80	0.85	6
<b>C09D</b>	<b>ANGIOTENSIN II ANTAGONISTS, COMBINATIONS</b>				
	Estonia	11.62	14.66	19.83	35
	Latvia	4.87	6.35	8.85	39
	Lithuania	6.31	9.48	13.83	46
<b>C09DA</b>	<b>Angiotensin II antagonists and diuretics</b>				
	Estonia	11.62	13.36	16.10	21
	Latvia	4.66	5.55	7.14	29
	Lithuania	6.30	9.07	12.24	35
<b>C09DA01</b>	<b>losartan and diuretics</b>				
	Estonia	4.57	3.86	3.96	3
	Latvia	0.19	1.15	1.50	30
	Lithuania	3.68	3.53	2.87	-19
<b>C09DA03</b>	<b>valsartan and diuretics</b>				
	Estonia	0.51	1.19	1.81	52
	Latvia	0.14	0.10	0.44	346
	Lithuania	2.29	4.91	7.79	59
<b>C09DA04</b>	<b>irbesartan and diuretics</b>				
	Estonia	-	-	-	
	Latvia	0.16	0.14	0.12	-19
	Lithuania	-	-	-	
<b>C09DA06</b>	<b>candesartan and diuretics</b>				
	Estonia	1.63	1.44	1.48	3
	Latvia	-	0.01	0.21	
	Lithuania	-	-	-	
<b>C09DA07</b>	<b>telmisartan and diuretics</b>				
	Estonia	4.52	6.57	8.66	32
	Latvia	3.29	3.49	4.12	18
	Lithuania	0.07	0.29	1.12	286
<b>C09DA08</b>	<b>olmesartan medoxomil and diuretics</b>				
	Estonia	0.39	0.30	0.19	-37
	Latvia	0.87	0.66	0.75	13
	Lithuania	0.26	0.34	0.45	32
<b>C09DB</b>	<b>Angiotensin II antagonists and calcium channel blockers</b>				
	Estonia	<0.01	1.30	3.72	186
	Latvia	0.21	0.76	1.50	97
	Lithuania	0.01	0.41	1.60	290

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
<b>C09DB01</b>	<b>valsartan and amlodipine</b>				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	0.14	0.27	0.27	
	Lithuania	0.01	0.22	0.85	286
<b>C09DB02</b>	<b>olmesartan medoxomil and amlodipine</b>				
	Estonia	-	-	-	
	Latvia	0.07	0.34	0.73	117
	Lithuania	-	0.19	0.75	295
<b>C09DB04</b>	<b>telmisartan and amlodipine</b>				
	Estonia	-	1.30	3.72	186
	Latvia	-	0.15	0.49	234
	Lithuania	-	-	-	
<b>C09DX</b>	<b>Angiotensin II antagonists, other combinations</b>				
	Estonia	-	-	-	
	Latvia	-	0.03	0.20	481
	Lithuania	-	-	-	
<b>C09DX01</b>	<b>valsartan, amlodipine and hydrochlorothiazide</b>				
	Estonia	-	-	-	
	Latvia	-	0.03	0.20	481
	Lithuania	-	-	-	
<b>C10</b>	<b>LIPID MODIFYING AGENTS</b>				
	Estonia	26.34	31.76	39.57	25
	Latvia	26.20	32.47	41.82	29
	Lithuania	7.99	9.89	13.15	33
<b>C10A</b>	<b>LIPID MODIFYING AGENTS, PLAIN</b>				
	Estonia	26.34	31.74	39.18	23
	Latvia	26.11	32.40	41.68	29
	Lithuania	7.96	9.80	13.08	33


### Consumption of antihypertensive drugs (C02–C09)



ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
<b>C10AA</b>	<b>HMG CoA reductase inhibitors</b>				
	Estonia	26.13	31.48	38.85	23
	Latvia	25.59	31.84	40.97	29
	Lithuania	7.85	9.68	12.86	33
<b>C10AA01</b>	<b>simvastatin</b>				
	Estonia	7.05	6.92	7.48	8
	Latvia	0.78	0.79	0.70	-11
	Lithuania	0.27	0.19	0.24	26
<b>C10AA02</b>	<b>lovastatin</b>				
	Estonia	-	-	-	
	Latvia	0.01	<0.01	<0.01	
	Lithuania	-	-	-	
<b>C10AA03</b>	<b>pravastatin</b>				
	Estonia	0.72	0.59	0.58	-2
	Latvia	-	-	-	
	Lithuania	-	-	-	
<b>C10AA04</b>	<b>fluvastatin</b>				
	Estonia	1.05	1.05	1.03	-2
	Latvia	0.06	0.07	0.07	8
	Lithuania	0.24	0.17	0.12	-29
<b>C10AA05</b>	<b>atorvastatin</b>				
	Estonia	6.68	8.27	10.33	25
	Latvia	22.31	24.91	30.31	22
	Lithuania	6.42	8.29	10.83	31
<b>C10AA07</b>	<b>rosuvastatin</b>				
	Estonia	10.64	14.64	19.42	33
	Latvia	2.43	6.07	9.89	63
	Lithuania	0.92	1.04	1.68	62
<b>C10AB</b>	<b>Fibrates</b>				
	Estonia	0.10	0.12	0.17	42
	Latvia	0.32	0.35	0.50	42
	Lithuania	0.10	0.12	0.21	75
<b>C10AB05</b>	<b>fenofibrate</b>				
	Estonia	0.06	0.08	0.12	50
	Latvia	0.32	0.35	0.50	42
	Lithuania	0.10	0.12	0.21	75
<b>C10AB08</b>	<b>ciprofibrate</b>				
	Estonia	0.04	0.04	0.05	25
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	0.01	<0.01	-	
<b>C10AX</b>	<b>Other lipid modifying agents</b>				
	Estonia	0.10	0.14	0.17	21
	Latvia	0.20	0.21	0.21	-4
	Lithuania	<0.01	<0.01	<0.01	



## Consumption of statins (C10AA)



ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
C10AX09	ezetimibe				
	Estonia	0.10	0.14	0.17	21
	Latvia	0.20	0.21	0.21	-4
	Lithuania	<0.01	<0.01	<0.01	
C10B	LIPID MODIFYING AGENTS, COMBINATIONS				
	Estonia	-	0.01	0.39	
	Latvia	0.09	0.06	0.14	113
	Lithuania	0.03	0.09	0.07	-22
C10BA	HMG CoA reductase inhibitors in combination with other lipid modifying agents				
	Estonia	-	-	-	
	Latvia	0.09	0.06	0.14	113
	Lithuania	-	-	-	
C10BA02	simvastatin and ezetimibe				
	Estonia	-	-	-	
	Latvia	0.09	0.06	0.14	113
	Lithuania	-	-	-	
C10BX	HMG CoA reductase inhibitors, other combinations				
	Estonia	-	0.01	0.39	
	Latvia	-	-	-	
	Lithuania	0.03	0.09	0.07	-22
C10BX03	atorvastatin and amlodipine				
	Estonia	-	0.01	0.39	
	Latvia	-	-	-	
	Lithuania	0.03	0.09	0.07	-22

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
<b>D</b>	<b>DERMATOLOGICALS</b>				
	Estonia	1.37	1.51	1.62	7
	Latvia	0.28	0.33	0.37	13
	Lithuania	0.39	0.48	0.54	13
<b>D01</b>	<b>ANTIFUNGALS FOR DERMATOLOGICAL USE</b>				
	Estonia	0.93	1.02	1.07	5
	Latvia	0.23	0.28	0.32	14
	Lithuania	0.33	0.41	0.43	5
<b>D01B</b>	<b>ANTIFUNGALS FOR SYSTEMIC USE</b>				
	Estonia	0.93	1.02	1.07	5
	Latvia	0.23	0.28	0.32	14
	Lithuania	0.33	0.41	0.43	5
<b>D01BA</b>	<b>Antifungals for systemic use</b>				
	Estonia	0.93	1.01	1.07	6
	Latvia	0.23	0.28	0.32	14
	Lithuania	0.33	0.41	0.43	5
<b>D01BA02</b>	<b>terbinafine</b>				
	Estonia	0.93	1.01	1.07	6
	Latvia	0.23	0.28	0.32	14
	Lithuania	0.33	0.41	0.43	5
<b>D05</b>	<b>ANTIPSORIATICS</b>				
	Estonia	0.02	0.02	0.03	50
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	<0.01	<0.01	0.01	
<b>D05B</b>	<b>ANTIPSORIATICS FOR SYSTEMIC USE</b>				
	Estonia	0.02	0.02	0.03	50
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	<0.01	<0.01	0.01	
<b>D05BB</b>	<b>Retinoids for treatment of psoriasis</b>				
	Estonia	0.02	0.02	0.03	50
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	<0.01	<0.01	0.01	
<b>D05BB02</b>	<b>acitretin</b>				
	Estonia	0.02	0.02	0.03	50
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	<0.01	<0.01	0.01	
<b>D10</b>	<b>ANTI-ACNE PREPARATIONS</b>				
	Estonia	0.37	0.42	0.47	12
	Latvia	0.04	0.05	0.05	12
	Lithuania	0.06	0.07	0.10	43
<b>D10B</b>	<b>ANTI-ACNE PREPARATIONS FOR SYSTEMIC USE</b>				
	Estonia	0.37	0.42	0.47	12
	Latvia	0.04	0.05	0.05	12
	Lithuania	0.06	0.07	0.10	43

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
<b>D10BA</b>	<b>Retinoids for treatment of acne</b>				
	Estonia	0.37	0.42	0.47	12
	Latvia	0.04	0.05	0.05	12
	Lithuania	0.06	0.07	0.10	43
<b>D10BA01</b>	<b>isotretinoin</b>				
	Estonia	0.37	0.42	0.47	12
	Latvia	0.04	0.05	0.05	12
	Lithuania	0.06	0.07	0.10	43
<b>D11</b>	<b>OTHER DERMATOLOGICAL PREPARATIONS</b>				
	Estonia	0.06	0.05	0.05	
	Latvia	-	-	-	
	Lithuania	-	-	-	
<b>D11A</b>	<b>OTHER DERMATOLOGICAL PREPARATIONS</b>				
	Estonia	0.06	0.05	0.05	
	Latvia	-	-	-	
	Lithuania	-	-	-	
<b>D11AX</b>	<b>Other dermatologicals</b>				
	Estonia	0.06	0.05	0.05	
	Latvia	-	-	-	
	Lithuania	-	-	-	
<b>D11AX10</b>	<b>finasteride</b>				
	Estonia	0.06	0.05	0.05	
	Latvia	-	-	-	
	Lithuania	-	-	-	

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
<b>G</b>	<b>GENITO URINARY SYSTEM AND SEX HORMONES</b>				
	Estonia	50.16	51.85	54.42	5
	Latvia	31.84	33.29	32.82	-1
	Lithuania	28.79	27.37	30.07	10
<b>G01</b>	<b>GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS</b>				
	Estonia	1.09	0.83	0.77	-7
	Latvia	0.67	0.71	0.68	-3
	Lithuania	2.26	2.32	2.61	13
<b>G01A</b>	<b>ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS</b>				
	Estonia	1.09	0.83	0.77	-7
	Latvia	0.67	0.71	0.68	-3
	Lithuania	1.64	1.69	1.89	12
<b>G01AA</b>	<b>Antibiotics</b>				
	Estonia	0.11	0.11	0.10	-9
	Latvia	0.03	0.04	0.04	4
	Lithuania	0.89	0.94	1.06	13
<b>G01AA10</b>	<b>clindamycin</b>				
	Estonia	0.11	0.11	0.10	-9
	Latvia	0.03	0.04	0.04	4
	Lithuania	0.28	0.32	0.36	13
<b>G01AA51</b>	<b>nystatin, combinations</b>				
	Estonia	-	-	-	
	Latvia	-	-	-	
	Lithuania	0.61	0.62	0.70	13
<b>G01AD</b>	<b>Organic acids</b>				
	Estonia	-	-	-	
	Latvia	-	-	-	
	Lithuania	0.02	<0.01	<0.01	
<b>G01AD01</b>	<b>lactic acid</b>				
	Estonia	-	-	-	
	Latvia	-	-	-	
	Lithuania	0.02	<0.01	<0.01	
<b>G01AF</b>	<b>Imidazole derivatives</b>				
	Estonia	0.98	0.72	0.66	-8
	Latvia	0.56	0.58	0.57	-1
	Lithuania	0.51	0.57	0.60	5
<b>G01AF01</b>	<b>metronidazole</b>				
	Estonia	0.17	0.13	0.10	-23
	Latvia	0.04	0.04	0.04	-4
	Lithuania	0.02	0.03	0.03	
<b>G01AF02</b>	<b>clotrimazole</b>				
	Estonia	0.68	0.45	0.42	-7
	Latvia	0.33	0.36	0.37	1
	Lithuania	0.15	0.16	0.17	6

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
<b>G01AF05</b>	<b>econazole</b>				
	Estonia	0.13	0.15	0.15	
	Latvia	0.09	0.09	0.08	-5
	Lithuania	0.03	0.03	0.03	
<b>G01AF12</b>	<b>fenticonazole</b>				
	Estonia	-	-	-	
	Latvia	0.09	0.07	0.07	-7
	Lithuania	0.31	0.35	0.37	6
<b>G01AF15</b>	<b>butoconazole</b>				
	Estonia	-	-	-	
	Latvia	0.01	0.01	0.01	7
	Lithuania	-	-	-	
<b>G01AX</b>	<b>Other antiinfectives and antiseptics</b>				
	Estonia	-	<0.01	0.01	
	Latvia	0.08	0.08	0.07	-20
	Lithuania	0.11	0.07	0.12	71
<b>G01AX03</b>	<b>policresulen</b>				
	Estonia	-	<0.01	0.01	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
<b>G01AX05</b>	<b>nifuratel</b>				
	Estonia	-	-	-	
	Latvia	-	-	-	
	Lithuania	0.07	0.03	0.09	200
<b>G01AX11</b>	<b>povidone-iodine</b>				
	Estonia	-	-	-	
	Latvia	0.08	0.08	0.07	-20
	Lithuania	0.04	0.04	0.04	
<b>G02</b>	<b>OTHER GYNECOLOGICALS</b>				
	Estonia	4.32	4.58	4.74	3
	Latvia	1.03	1.20	1.24	3
	Lithuania	1.17	1.13	1.13	
<b>G02A</b>	<b>OXYTOCICS</b>				
	Estonia	0.02	0.02	0.01	-50
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
<b>G02AB</b>	<b>Ergot alkaloids</b>				
	Estonia	0.01	0.01	0.01	
	Latvia	-	-	-	
	Lithuania	-	-	-	
<b>G02AB01</b>	<b>methylergometrine</b>				
	Estonia	0.01	0.01	0.01	
	Latvia	-	-	-	
	Lithuania	-	-	-	


ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
<b>G02AD</b>	<b>Prostaglandins</b>				
	Estonia	0.01	0.01	<0.01	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
<b>G02AD02</b>	<b>dinoprostone</b>				
	Estonia	0.01	0.01	<0.01	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
<b>G02B</b>	<b>CONTRACEPTIVES FOR TOPICAL USE</b>				
	Estonia	3.24	3.44	3.49	1
	Latvia	1.03	1.19	1.23	3
	Lithuania	1.01	0.97	0.98	1
<b>G02BA</b>	<b>Intrauterine contraceptives</b>				
	Estonia	0.01	0.01	0.01	
	Latvia	-	-	-	
	Lithuania	-	-	-	
<b>G02BA03</b>	<b>plastic IUD with progestogen</b>				
	Estonia	0.01	0.01	0.01	
	Latvia	-	-	-	
	Lithuania	-	-	-	
<b>G02BB</b>	<b>Intravaginal contraceptives</b>				
	Estonia	3.24	3.43	3.48	1
	Latvia	1.03	1.19	1.23	3
	Lithuania	1.01	0.97	0.98	1
<b>G02BB01</b>	<b>vaginal ring with progestogen and estrogen</b>				
	Estonia	3.24	3.43	3.48	1
	Latvia	1.03	1.19	1.23	3
	Lithuania	1.01	0.97	0.98	1
<b>G02C</b>	<b>OTHER GYNECOLOGICALS</b>				
	Estonia	1.06	1.13	1.24	10
	Latvia	0.01	0.01	0.01	45
	Lithuania	0.16	0.16	0.16	
<b>G02CB</b>	<b>Prolactine inhibitors</b>				
	Estonia	0.15	0.15	0.17	13
	Latvia	0.01	0.01	0.01	45
	Lithuania	0.16	0.16	0.16	
<b>G02CB01</b>	<b>bromocriptine</b>				
	Estonia	0.15	0.14	0.16	14
	Latvia	-	-	-	
	Lithuania	0.16	0.16	0.16	
<b>G02CB03</b>	<b>cabergoline</b>				
	Estonia	0.01	0.01	0.01	
	Latvia	0.01	0.01	0.01	45
	Lithuania	-	<0.01	-	

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
<b>G02CX</b>	<b>Other gynecologicals</b>				
	Estonia	0.91	0.98	1.07	9
	Latvia	-	-	-	
	Lithuania	-	-	-	
<b>G02CX03</b>	<b>Agni casti fructus</b>				
	Estonia	0.42	0.44	0.53	20
	Latvia	-	-	-	
	Lithuania	-	-	-	
<b>G02CX04</b>	<b>Cimicifugae rhizoma</b>				
	Estonia	0.48	0.54	0.54	
	Latvia	-	-	-	
	Lithuania	-	-	-	
<b>G03</b>	<b>SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM</b>				
	Estonia	36.18	36.73	37.75	3
	Latvia	22.10	23.08	22.17	-4
	Lithuania	17.88	16.06	16.33	2
<b>G03A</b>	<b>HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE</b>				
	Estonia	25.71	26.48	27.40	3
	Latvia	11.99	12.35	12.54	2
	Lithuania	13.25	12.71	13.04	3
<b>G03AA</b>	<b>Progestogens and estrogens, fixed combinations</b>				
	Estonia	22.62	23.48	24.46	4
	Latvia	10.59	10.85	10.82	
	Lithuania	11.45	11.33	11.39	1
<b>G03AA07</b>	<b>levonorgestrel and ethinylestradiol</b>				
	Estonia	-	-	-	
	Latvia	0.66	0.59	0.58	-3
	Lithuania	0.67	0.39	0.34	-13
<b>G03AA09</b>	<b>desogestrel and ethinylestradiol</b>				
	Estonia	2.96	2.96	2.84	-4
	Latvia	1.97	1.96	1.72	-12
	Lithuania	2.93	2.64	2.37	-10
<b>G03AA10</b>	<b>gestodene and ethinylestradiol</b>				
	Estonia	7.14	7.30	8.01	10
	Latvia	3.67	3.75	3.62	-4
	Lithuania	4.12	4.27	4.06	-5
<b>G03AA11</b>	<b>norgestimate and ethinylestradiol</b>				
	Estonia	0.23	0.19	0.17	-11
	Latvia	0.35	0.29	0.26	-11
	Lithuania	0.52	0.43	0.34	-21
<b>G03AA12</b>	<b>drospirenone and ethinylestradiol</b>				
	Estonia	9.29	10.20	10.59	4
	Latvia	3.48	3.92	4.07	4
	Lithuania	2.67	3.12	3.79	21

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
<b>G03AA13</b>	<b>norelgestromin and ethinylestradiol</b>				
	Estonia	2.37	2.28	2.26	-1
	Latvia	0.34	0.31	0.25	-20
	Lithuania	0.55	0.50	0.49	-2
<b>G03AA14</b>	<b>nomegestrol and estradiol</b>				
	Estonia	-	-	0.06	
	Latvia	-	-	0.13	
	Lithuania	-	-	-	
<b>G03AA15</b>	<b>chlormadinone and ethinylestradiol</b>				
	Estonia	0.64	0.56	0.54	-4
	Latvia	0.13	0.03	0.20	571
	Lithuania	-	-	-	
<b>G03AB</b>	<b>Progestogens and estrogens, sequential preparations</b>				
	Estonia	0.97	0.85	0.79	-7
	Latvia	0.84	0.85	1.04	23
	Lithuania	1.44	1.09	1.28	17
<b>G03AB03</b>	<b>levonorgestrel and ethinylestradiol</b>				
	Estonia	0.80	0.67	0.62	-7
	Latvia	0.49	0.42	0.37	-12
	Lithuania	0.66	0.62	0.60	-3
<b>G03AB05</b>	<b>desogestrel and ethinylestradiol</b>				
	Estonia	0.08	0.08	0.07	-13
	Latvia	0.12	0.12	0.10	-11
	Lithuania	0.19	0.16	0.15	-6
<b>G03AB07</b>	<b>chlormadinone and ethinylestradiol</b>				
	Estonia	-	-	-	
	Latvia	-	-	-	
	Lithuania	0.29	0.01	0.12	
<b>G03AB08</b>	<b>dienogest and estradiol</b>				
	Estonia	0.09	0.10	0.11	10
	Latvia	0.23	0.31	0.56	83
	Lithuania	0.29	0.30	0.42	40
<b>G03AC</b>	<b>Progestogens</b>				
	Estonia	2.05	2.08	2.08	
	Latvia	0.33	0.43	0.45	5
	Lithuania	0.22	0.29	0.32	10
<b>G03AC09</b>	<b>desogestrel</b>				
	Estonia	2.05	2.08	2.08	
	Latvia	0.33	0.43	0.45	5
	Lithuania	0.22	0.29	0.32	10
<b>G03AD</b>	<b>Emergency contraceptives</b>				
	Estonia	0.06	0.07	0.07	
	Latvia	0.23	0.23	0.23	2
	Lithuania	0.14	0.01	0.05	400



## Consumption of hormonal contraceptives (G02BB and G03A)



ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
G03AD01	levonorgestrel				
	Estonia	0.06	0.07	0.07	
	Latvia	0.23	0.23	0.23	2
	Lithuania	0.14	<0.01	0.05	
G03B	ANDROGENS				
	Estonia	0.14	0.19	0.21	11
	Latvia	0.16	0.22	0.26	20
	Lithuania	0.06	0.08	0.07	-13
G03BA	3-oxoandrostens (4) derivatives				
	Estonia	0.14	0.19	0.21	11
	Latvia	0.16	0.22	0.26	20
	Lithuania	0.06	0.08	0.07	-13
G03BA03	testosterone				
	Estonia	0.14	0.19	0.21	11
	Latvia	0.16	0.22	0.26	20
	Lithuania	0.06	0.08	0.07	-13
G03C	ESTROGENS				
	Estonia	1.64	1.74	1.75	1
	Latvia	3.06	3.38	3.36	
	Lithuania	0.74	0.73	0.73	
G03CA	Natural and semisynthetic estrogens, plain				
	Estonia	1.51	1.59	1.59	
	Latvia	3.01	3.32	3.30	
	Lithuania	0.68	0.67	0.66	-1
G03CA03	estradiol				
	Estonia	1.12	1.08	1.13	5
	Latvia	2.85	3.12	3.10	-1
	Lithuania	0.45	0.45	0.42	-7

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
<b>G03CA04</b>	<b>estriol</b>				
	Estonia	0.38	0.51	0.46	-10
	Latvia	0.16	0.20	0.21	1
	Lithuania	0.23	0.23	0.24	4
<b>G03CX</b>	<b>Other estrogens</b>				
	Estonia	0.14	0.15	0.16	7
	Latvia	0.05	0.06	0.06	-3
	Lithuania	0.06	0.06	0.07	17
<b>G03CX01</b>	<b>tibolone</b>				
	Estonia	0.14	0.15	0.16	7
	Latvia	0.05	0.06	0.06	-3
	Lithuania	0.06	0.06	0.07	17
<b>G03D</b>	<b>PROGESTOGENS</b>				
	Estonia	1.93	1.86	1.98	6
	Latvia	1.06	1.02	0.96	-6
	Lithuania	0.92	0.90	0.94	4
<b>G03DA</b>	<b>Pregnen (4) derivatives</b>				
	Estonia	0.99	0.97	1.04	7
	Latvia	0.26	0.23	0.20	-10
	Lithuania	0.21	0.22	0.23	5
<b>G03DA02</b>	<b>medroxyprogesterone</b>				
	Estonia	0.59	0.53	0.53	
	Latvia	0.26	0.23	0.20	-10
	Lithuania	0.21	0.22	0.23	5
<b>G03DA04</b>	<b>progesterone</b>				
	Estonia	0.40	0.44	0.52	18
	Latvia	-	-	-	
	Lithuania	-	-	-	
<b>G03DB</b>	<b>Pregnadien derivatives</b>				
	Estonia	0.94	0.89	0.94	6
	Latvia	0.80	0.79	0.76	-5
	Lithuania	0.72	0.68	0.71	4
<b>G03DB01</b>	<b>dydrogesterone</b>				
	Estonia	0.94	0.88	0.90	2
	Latvia	0.80	0.79	0.76	-5
	Lithuania	0.72	0.67	0.70	4
<b>G03DB08</b>	<b>dienogest</b>				
	Estonia	-	0.01	0.03	200
	Latvia	-	-	-	
	Lithuania	-	<0.01	0.01	
<b>G03F</b>	<b>PROGESTOGENS AND ESTROGENS IN COMBINATION</b>				
	Estonia	4.88	4.65	4.66	
	Latvia	1.45	1.50	1.51	
	Lithuania	1.30	1.32	1.33	1

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
<b>G03FA</b>	<b>Progestogens and estrogens, fixed combinations</b>				
	Estonia	4.25	4.07	4.06	
	Latvia	1.37	1.40	1.38	-2
	Lithuania	1.03	1.03	1.05	2
<b>G03FA01</b>	<b>norethisterone and estrogen</b>				
	Estonia	1.40	1.30	1.31	1
	Latvia	0.62	0.64	0.62	-3
	Lithuania	0.28	0.29	0.29	
<b>G03FA14</b>	<b>dydrogesterone and estrogen</b>				
	Estonia	-	-	-	
	Latvia	-	-	-	
	Lithuania	0.01	0.02	0.06	200
<b>G03FA15</b>	<b>dienogest and estrogen</b>				
	Estonia	2.62	2.52	2.50	-1
	Latvia	0.57	0.55	0.52	-6
	Lithuania	0.69	0.67	0.65	-3
<b>G03FA17</b>	<b>drospirenone and estrogen</b>				
	Estonia	0.23	0.24	0.25	4
	Latvia	0.19	0.21	0.24	14
	Lithuania	0.05	0.06	0.06	
<b>G03FB</b>	<b>Progestogens and estrogens, sequential preparations</b>				
	Estonia	0.63	0.58	0.60	3
	Latvia	0.08	0.10	0.13	29
	Lithuania	0.27	0.29	0.28	-3
<b>G03FB05</b>	<b>norethisterone and estrogen</b>				
	Estonia	0.54	0.48	0.46	-4
	Latvia	-	-	-	
	Lithuania	0.18	0.19	0.19	
<b>G03FB06</b>	<b>medroxyprogesterone and estrogen</b>				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	0.01	<0.01	<0.01	
	Lithuania	-	-	-	
<b>G03FB08</b>	<b>dydrogesterone and estrogen</b>				
	Estonia	0.09	0.10	0.13	30
	Latvia	0.08	0.10	0.13	29
	Lithuania	0.01	0.02	-	
<b>G03FB09</b>	<b>levonorgestrel and estrogen</b>				
	Estonia	-	-	-	
	Latvia	-	-	-	
	Lithuania	0.08	0.09	0.09	
<b>G03G</b>	<b>GONADOTROPINS AND OTHER OVULATION STIMULANTS</b>				
	Estonia	0.42	0.46	0.41	-11
	Latvia	3.32	3.53	2.50	-29
	Lithuania	0.19	0.18	0.17	-6

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
<b>G03GA</b>	<b>Gonadotropins</b>				
	Estonia	0.11	0.15	0.12	-20
	Latvia	3.21	3.41	2.37	-31
	Lithuania	0.07	0.06	0.06	
<b>G03GA01</b>	<b>chorionic gonadotrophin</b>				
	Estonia	0.03	0.03	0.02	-33
	Latvia	0.12	0.06	0.01	-84
	Lithuania	0.06	0.05	0.06	20
<b>G03GA02</b>	<b>human menopausal gonadotrophin</b>				
	Estonia	-	0.03	-	
	Latvia	-	-	-	
	Lithuania	-	-	-	
<b>G03GA05</b>	<b>follitropin alfa</b>				
	Estonia	0.06	0.07	0.07	
	Latvia	0.01	<0.01	<0.01	
	Lithuania	0.01	<0.01	<0.01	
<b>G03GA06</b>	<b>follitropin beta</b>				
	Estonia	0.01	0.02	0.02	
	Latvia	<0.01	0.01	0.01	-15
	Lithuania	<0.01	<0.01	<0.01	
<b>G03GA08</b>	<b>choriogonadotropin alfa</b>				
	Estonia	0.01	0.01	0.01	
	Latvia	3.08	3.34	2.35	-30
	Lithuania	<0.01	<0.01	-	
<b>G03GB</b>	<b>Ovulation stimulants, synthetic</b>				
	Estonia	0.31	0.31	0.29	-6
	Latvia	0.11	0.12	0.14	12
	Lithuania	0.13	0.12	0.11	-8
<b>G03GB02</b>	<b>clomifene</b>				
	Estonia	0.31	0.31	0.29	-6
	Latvia	0.11	0.12	0.14	12
	Lithuania	0.13	0.12	0.11	-8
<b>G03H</b>	<b>ANTIANDROGENS</b>				
	Estonia	1.47	1.36	1.33	-2
	Latvia	1.04	1.08	1.04	-3
	Lithuania	1.42	0.14	0.06	-57
<b>G03HA</b>	<b>Antiandrogens, plain</b>				
	Estonia	0.50	0.43	0.36	-16
	Latvia	0.21	0.16	0.12	-22
	Lithuania	0.19	0.14	0.06	-57
<b>G03HA01</b>	<b>cyproterone</b>				
	Estonia	0.50	0.43	0.36	-16
	Latvia	0.21	0.16	0.12	-22
	Lithuania	0.19	0.14	0.06	-57

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
<b>G03HB</b>	<b>Antiandrogens and estrogens</b>				
	Estonia	0.97	0.93	0.97	4
	Latvia	0.84	0.92	0.92	
	Lithuania	1.23	1.16	1.20	3
<b>G03HB01</b>	<b>cyproterone and estrogen</b>				
	Estonia	0.97	0.93	0.97	4
	Latvia	0.84	0.92	0.92	
	Lithuania	1.23	1.16	1.20	3
<b>G03X</b>	<b>OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM</b>				
	Estonia	-	-	-	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
<b>G03XB</b>	<b>Antiprogestogens</b>				
	Estonia	-	-	-	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
<b>G03XB01</b>	<b>mifepristone</b>				
	Estonia	-	-	-	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
<b>G04</b>	<b>UROLOGICALS</b>				
	Estonia	8.56	9.69	11.16	15
	Latvia	8.04	8.31	8.72	5
	Lithuania	7.48	7.86	9.99	27
<b>G04B</b>	<b>UROLOGICALS</b>				
	Estonia	1.18	1.34	1.58	18
	Latvia	0.62	0.74	0.79	6
	Lithuania	1.22	1.65	2.06	25
<b>G04BD</b>	<b>Drugs for urinary frequency and incontinence</b>				
	Estonia	0.73	0.78	0.89	14
	Latvia	0.32	0.40	0.43	8
	Lithuania	0.86	1.14	1.41	24
<b>G04BD02</b>	<b>flavoxate</b>				
	Estonia	-	-	-	
	Latvia	-	-	-	
	Lithuania	-	0.04	0.05	25
<b>G04BD04</b>	<b>oxybutynin</b>				
	Estonia	0.55	0.58	0.65	12
	Latvia	0.26	0.28	0.31	9
	Lithuania	0.34	0.34	0.36	6
<b>G04BD07</b>	<b>tolterodine</b>				
	Estonia	0.07	0.08	0.10	25
	Latvia	0.05	0.09	0.08	-6
	Lithuania	0.51	0.76	1.00	32

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
<b>G04BD08</b>	<b>solifenacin</b>				
	Estonia	<0.01	<0.01	-	
	Latvia	0.01	0.01	0.04	265
	Lithuania	<0.01	<0.01	0.01	
<b>G04BD09</b>	<b>trospium</b>				
	Estonia	0.10	0.11	0.15	36
	Latvia	<0.01	0.02	<0.01	
	Lithuania	<0.01	<0.01	-	
<b>G04BE</b>	<b>Drugs used in erectile dysfunction</b>				
	Estonia	0.45	0.56	0.69	23
	Latvia	0.30	0.34	0.36	5
	Lithuania	0.36	0.51	0.65	27
<b>G04BE01</b>	<b>alprostadil</b>				
	Estonia	0.01	0.01	0.01	
	Latvia	<0.01	<0.01	0.01	
	Lithuania	<0.01	<0.01	<0.01	
<b>G04BE03</b>	<b>sildenafil</b>				
	Estonia	0.30	0.42	0.56	33
	Latvia	0.20	0.24	0.25	6
	Lithuania	0.26	0.42	0.55	31
<b>G04BE08</b>	<b>tadalafil</b>				
	Estonia	0.10	0.09	0.09	
	Latvia	0.04	0.04	0.04	8
	Lithuania	0.08	0.07	0.07	
<b>G04BE09</b>	<b>vardenafil</b>				
	Estonia	0.04	0.04	0.04	
	Latvia	0.06	0.06	0.06	-5
	Lithuania	0.02	0.02	0.03	50
<b>G04C</b>	<b>DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY</b>				
	Estonia	7.38	8.35	9.58	15
	Latvia	7.42	7.57	7.93	5
	Lithuania	6.26	6.21	7.93	28
<b>G04CA</b>	<b>Alpha-adrenoreceptor antagonists</b>				
	Estonia	4.24	5.54	6.84	23
	Latvia	3.22	4.11	4.75	16
	Lithuania	3.53	4.09	5.06	24
<b>G04CA01</b>	<b>alfuzosin</b>				
	Estonia	1.28	1.33	1.58	19
	Latvia	0.19	0.16	0.15	-4
	Lithuania	0.10	0.11	0.11	
<b>G04CA02</b>	<b>tamsulosin</b>				
	Estonia	2.94	3.41	3.98	17
	Latvia	2.82	2.77	2.84	2
	Lithuania	3.43	3.59	3.99	11

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
<b>G04CA52</b>	<b>tamsulosin and dutasteride</b>				
	Estonia	0.02	0.79	1.28	62
	Latvia	0.21	1.18	1.76	50
	Lithuania	0.01	0.39	0.96	146
<b>G04CB</b>	<b>Testosterone-5-alpha reductase inhibitors</b>				
	Estonia	0.78	0.53	0.45	-15
	Latvia	1.84	1.53	1.48	-3
	Lithuania	2.73	2.12	2.88	36
<b>G04CB01</b>	<b>finasteride</b>				
	Estonia	0.23	0.19	0.16	-16
	Latvia	0.93	0.83	0.83	
	Lithuania	1.51	0.84	1.74	107
<b>G04CB02</b>	<b>dutasteride</b>				
	Estonia	0.55	0.34	0.29	-15
	Latvia	0.91	0.70	0.65	-7
	Lithuania	1.21	1.28	1.14	-11
<b>G04CX</b>	<b>Other drugs used in benign prostatic hypertrophy</b>				
	Estonia	2.36	2.29	2.29	
	Latvia	2.37	1.93	1.70	-12
	Lithuania	-	-	-	
<b>G04CX01</b>	<b>Prunus africanae cortex</b>				
	Estonia	-	-	-	
	Latvia	0.02	<0.01	<0.01	
	Lithuania	-	-	-	
<b>G04CX02</b>	<b>Sabalıs serrulatae fructus</b>				
	Estonia	2.36	2.29	2.29	
	Latvia	2.35	1.91	1.70	-11
	Lithuania	-	-	-	
<b>G04CX03</b>	<b>mepartricin</b>				
	Estonia	-	-	-	
	Latvia	<0.01	0.02	<0.01	
	Lithuania	-	-	-	

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
<b>H</b>	<b>SYSTEMIC HORMONAL PREPARATIONS, EXCL.</b>				
	Estonia	19.24	19.66	21.88	11
	Latvia	18.11	19.32	20.76	7
	Lithuania	27.70	30.45	34.60	14
<b>H01</b>	<b>PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES</b>				
	Estonia	0.34	0.34	0.35	3
	Latvia	0.38	0.43	0.46	8
	Lithuania	0.25	0.27	0.29	7
<b>H01A</b>	<b>ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES</b>				
	Estonia	0.08	0.08	0.08	
	Latvia	0.15	0.19	0.22	12
	Lithuania	0.10	0.11	0.13	18
<b>H01AC</b>	<b>Somatropin and somatropin agonists</b>				
	Estonia	0.08	0.08	0.08	
	Latvia	0.15	0.19	0.22	12
	Lithuania	0.10	0.11	0.13	18
<b>H01AC01</b>	<b>somatropin</b>				
	Estonia	0.08	0.08	0.08	
	Latvia	0.15	0.19	0.22	12
	Lithuania	0.10	0.11	0.13	18
<b>H01B</b>	<b>POSTERIOR PITUITARY LOBE HORMONES</b>				
	Estonia	0.22	0.21	0.21	
	Latvia	0.20	0.19	0.19	2
	Lithuania	0.14	0.14	0.15	7
<b>H01BA</b>	<b>Vasopressin and analogues</b>				
	Estonia	0.08	0.09	0.10	11
	Latvia	0.06	0.06	0.06	-3
	Lithuania	0.10	0.10	0.10	
<b>H01BA02</b>	<b>desmopressin</b>				
	Estonia	0.08	0.09	0.10	11
	Latvia	0.06	0.06	0.06	-3
	Lithuania	0.10	0.10	0.10	
<b>H01BB</b>	<b>Oxytocin and analogues</b>				
	Estonia	0.14	0.12	0.11	-8
	Latvia	0.14	0.12	0.13	5
	Lithuania	0.04	0.04	0.04	
<b>H01BB01</b>	<b>demoxycocin</b>				
	Estonia	0.11	0.10	0.09	-10
	Latvia	0.09	0.08	0.09	3
	Lithuania	-	-	-	
<b>H01BB02</b>	<b>oxytocin</b>				
	Estonia	0.03	0.03	0.03	
	Latvia	0.05	0.04	0.04	8
	Lithuania	0.04	0.04	0.04	



ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
<b>H01C</b>	<b>HYPOTHALAMIC HORMONES</b>				
	Estonia	0.04	0.05	0.05	
	Latvia	0.04	0.05	0.05	11
	Lithuania	0.01	0.02	0.01	-50
<b>H01CB</b>	<b>Somatostatin and analogues</b>				
	Estonia	0.03	0.04	0.04	
	Latvia	0.03	0.04	0.05	10
	Lithuania	0.01	0.02	0.01	-50
<b>H01CB02</b>	<b>octreotide</b>				
	Estonia	0.03	0.03	0.03	
	Latvia	0.01	0.02	0.02	28
	Lithuania	0.01	0.02	0.01	-50
<b>H01CB03</b>	<b>lanreotide</b>				
	Estonia	<0.01	<0.01	0.01	
	Latvia	0.02	0.02	0.02	-5
	Lithuania	0.01	<0.01	-	
<b>H01CC</b>	<b>Anti-gonadotropin-releasing hormones</b>				
	Estonia	0.01	0.01	0.01	
	Latvia	<0.01	<0.01	0.01	
	Lithuania	<0.01	<0.01	<0.01	
<b>H01CC01</b>	<b>ganirelix</b>				
	Estonia	0.01	0.01	0.01	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
<b>H01CC02</b>	<b>cetrorelix</b>				
	Estonia	<0.01	0.01	<0.01	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	<0.01	<0.01	<0.01	
<b>H02</b>	<b>CORTICOSTEROIDS FOR SYSTEMIC USE</b>				
	Estonia	6.28	6.52	6.97	7
	Latvia	7.46	7.69	7.91	3
	Lithuania	17.08	18.75	21.24	13
<b>H02A</b>	<b>CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN</b>				
	Estonia	6.28	6.52	6.97	7
	Latvia	7.46	7.69	7.91	3
	Lithuania	6.74	7.39	8.22	11
<b>H02AA</b>	<b>Mineralocorticoids</b>				
	Estonia	0.09	0.10	0.12	20
	Latvia	0.05	0.04	0.05	24
	Lithuania	0.05	0.06	0.06	
<b>H02AA02</b>	<b>fludrocortisone</b>				
	Estonia	0.09	0.10	0.12	20
	Latvia	0.05	0.04	0.05	24
	Lithuania	0.05	0.06	0.06	

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
<b>H02AB</b>	<b>Glucocorticoids</b>				
	Estonia	6.19	6.42	6.85	7
	Latvia	7.41	7.65	7.86	3
	Lithuania	6.69	7.34	8.16	11
<b>H02AB01</b>	<b>betamethasone</b>				
	Estonia	0.03	0.02	0.02	
	Latvia	-	-	-	
	Lithuania	-	-	-	
<b>H02AB02</b>	<b>dexamethasone</b>				
	Estonia	0.95	1.03	1.11	8
	Latvia	3.10	3.34	3.22	-4
	Lithuania	2.97	3.36	3.95	18
<b>H02AB04</b>	<b>methylprednisolone</b>				
	Estonia	1.90	2.00	2.22	11
	Latvia	1.98	2.07	2.28	10
	Lithuania	1.92	2.14	2.24	5
<b>H02AB06</b>	<b>prednisolone</b>				
	Estonia	2.75	2.87	2.92	2
	Latvia	1.70	1.69	1.77	4
	Lithuania	1.56	1.60	1.69	6
<b>H02AB07</b>	<b>prednisone</b>				
	Estonia	0.03	0.02	-	
	Latvia	-	-	-	
	Lithuania	-	-	-	
<b>H02AB08</b>	<b>triamcinolone</b>				
	Estonia	0.38	0.29	0.36	24
	Latvia	0.40	0.29	0.34	16
	Lithuania	0.18	0.17	0.21	24
<b>H02AB09</b>	<b>hydrocortisone</b>				
	Estonia	0.16	0.19	0.22	16
	Latvia	0.21	0.26	0.27	3
	Lithuania	0.06	0.06	0.07	17
<b>H03</b>	<b>THYROID THERAPY</b>				
	Estonia	12.62	12.77	14.53	14
	Latvia	10.24	11.16	12.35	11
	Lithuania	10.34	11.35	13.03	15
<b>H03A</b>	<b>THYROID PREPARATIONS</b>				
	Estonia	11.47	11.60	13.32	15
	Latvia	8.75	9.56	10.59	11
	Lithuania	8.98	9.95	11.58	16
<b>H03AA</b>	<b>Thyroid hormones</b>				
	Estonia	11.47	11.60	13.32	15
	Latvia	8.75	9.56	10.59	11
	Lithuania	8.98	9.95	11.58	16

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
<b>H03AA01</b>	<b>levothyroxine sodium</b>				
	Estonia	11.47	11.60	13.32	15
	Latvia	8.75	9.56	10.59	11
	Lithuania	8.98	9.95	11.58	16
<b>H03B</b>	<b>ANTITHYROID PREPARATIONS</b>				
	Estonia	1.14	1.16	1.21	4
	Latvia	1.49	1.61	1.76	9
	Lithuania	1.36	1.41	1.45	3
<b>H03BA</b>	<b>Thiouracils</b>				
	Estonia	0.78	0.71	0.64	-10
	Latvia	-	-	-	
	Lithuania	-	-	-	
<b>H03BA02</b>	<b>propylthiouracil</b>				
	Estonia	0.78	0.71	0.64	-10
	Latvia	-	-	-	
	Lithuania	-	-	-	
<b>H03BB</b>	<b>Sulfur-containing imidazole derivatives</b>				
	Estonia	0.36	0.45	0.57	27
	Latvia	1.49	1.61	1.76	9
	Lithuania	1.36	1.41	1.45	3
<b>H03BB02</b>	<b>thiamazole</b>				
	Estonia	0.36	0.45	0.57	27
	Latvia	1.49	1.61	1.76	9
	Lithuania	1.36	1.41	1.45	3
<b>H04</b>	<b>PANCREATIC HORMONES</b>				
	Estonia	-	-	-	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
<b>H04A</b>	<b>GLYCOGENOLYTIC HORMONES</b>				
	Estonia	-	-	-	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
<b>H04AA</b>	<b>Glycogenolytic hormones</b>				
	Estonia	-	-	-	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
<b>H04AA01</b>	<b>glucagon</b>				
	Estonia	-	-	-	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
<b>H05</b>	<b>CALCIUM HOMEOSTASIS</b>				
	Estonia	0.01	0.03	0.02	-33
	Latvia	0.02	0.03	0.03	7
	Lithuania	0.03	0.08	0.04	-50
<b>H05A</b>	<b>PARATHYROID HORMONES AND ANALOGUES</b>				
	Estonia	-	0.01	-	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	0.03	0.07	0.02	-71
<b>H05AA</b>	<b>Parathyroid hormones and analogues</b>				
	Estonia	-	0.01	-	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	0.03	0.07	0.02	-71
<b>H05AA02</b>	<b>teriparatide</b>				
	Estonia	-	0.01	-	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	0.02	0.07	0.01	-86
<b>H05AA03</b>	<b>parathyroid hormone</b>				
	Estonia	-	-	-	
	Latvia	-	-	-	
	Lithuania	0.01	-	<0.01	
<b>H05B</b>	<b>ANTI-PARATHYROID AGENTS</b>				
	Estonia	0.01	0.02	0.02	
	Latvia	0.02	0.03	0.03	11
	Lithuania	<0.01	0.01	0.03	200
<b>H05BX</b>	<b>Other anti-parathyroid agents</b>				
	Estonia	0.01	0.02	0.02	
	Latvia	0.02	0.03	0.03	11
	Lithuania	<0.01	0.01	0.03	200
<b>H05BX01</b>	<b>cinacalcet</b>				
	Estonia	0.01	0.02	0.02	
	Latvia	0.02	0.02	0.02	-15
	Lithuania	<0.01	0.01	0.03	200
<b>H05BX02</b>	<b>paricalcitol</b>				
	Estonia	<0.01	0.01	<0.01	
	Latvia	<0.01	0.01	0.02	61
	Lithuania	-	<0.01	-	

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
<b>J</b>	<b>ANTIINFECTIVES FOR SYSTEMIC USE</b>				
	Estonia	16.34	18.08	17.99	
	Latvia	15.24	17.06	17.39	2
	Lithuania	19.83	21.04	20.26	-4
<b>J01</b>	<b>ANTIBACTERIALS FOR SYSTEMIC USE</b>				
	Estonia	13.07	14.12	13.84	-2
	Latvia	13.74	15.42	16.03	4
	Lithuania	18.57	19.52	19.01	-3
<b>J01A</b>	<b>TETRACYCLINES</b>				
	Estonia	1.99	2.18	1.88	-14
	Latvia	2.48	2.67	2.70	1
	Lithuania	1.72	1.67	1.61	-4
<b>J01AA</b>	<b>Tetracyclines</b>				
	Estonia	1.99	2.18	1.88	-14
	Latvia	2.48	2.67	2.70	1
	Lithuania	1.72	1.67	1.61	-4
<b>J01AA02</b>	<b>doxycycline</b>				
	Estonia	1.91	2.10	1.80	-14
	Latvia	2.48	2.67	2.70	1
	Lithuania	1.72	1.67	1.61	-4
<b>J01AA07</b>	<b>tetracycline</b>				
	Estonia	0.08	0.08	0.08	
	Latvia	-	-	-	
	Lithuania	-	-	-	
<b>J01C</b>	<b>BETA-LACTAM ANTIBACTERIALS, PENICILLINS</b>				
	Estonia	4.86	5.22	5.11	-2
	Latvia	6.14	6.76	6.84	1
	Lithuania	10.09	10.76	10.32	-4
<b>J01CA</b>	<b>Penicillins with extended spectrum</b>				
	Estonia	2.86	2.97	2.77	-7
	Latvia	4.37	4.89	4.83	-1
	Lithuania	7.71	8.37	7.89	-6
<b>J01CA01</b>	<b>ampicillin</b>				
	Estonia	0.08	0.07	0.05	-29
	Latvia	0.39	0.24	0.21	-13
	Lithuania	1.08	0.89	0.37	-58
<b>J01CA04</b>	<b>amoxicillin</b>				
	Estonia	2.78	2.90	2.73	-6
	Latvia	3.98	4.65	4.62	-1
	Lithuania	6.63	7.48	7.52	1
<b>J01CE</b>	<b>Beta-lactamase sensitive penicillins</b>				
	Estonia	0.29	0.27	0.25	-7
	Latvia	0.08	0.02	0.02	-16
	Lithuania	0.54	0.45	0.43	-4

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
<b>J01CE01</b>	<b>benzylpenicillin</b>				
	Estonia	0.03	0.03	0.03	
	Latvia	0.03	0.02	0.02	-16
	Lithuania	0.36	0.28	0.25	-11
<b>J01CE02</b>	<b>phenoxymethylpenicillin</b>				
	Estonia	0.25	0.24	0.22	-8
	Latvia	0.05	<0.01	<0.01	
	Lithuania	0.18	0.16	0.18	13
<b>J01CF</b>	<b>Beta-lactamase resistant penicillins</b>				
	Estonia	0.14	0.13	0.15	15
	Latvia	0.02	<0.01	<0.01	
	Lithuania	0.03	-	-	
<b>J01CF04</b>	<b>oxacillin</b>				
	Estonia	0.14	0.13	0.15	15
	Latvia	0.02	<0.01	<0.01	
	Lithuania	0.03	-	-	
<b>J01CR</b>	<b>Combinations of penicillins, incl. beta-lactamase inhibitors</b>				
	Estonia	1.57	1.85	1.94	5
	Latvia	1.67	1.85	2.00	8
	Lithuania	1.82	1.95	2.00	3
<b>J01CR01</b>	<b>ampicillin and enzyme inhibitor</b>				
	Estonia	0.16	0.17	0.17	
	Latvia	0.05	0.07	0.05	-26
	Lithuania	0.01	-	-	
<b>J01CR02</b>	<b>amoxicillin and enzyme inhibitor</b>				
	Estonia	1.29	1.56	1.66	6
	Latvia	1.61	1.77	1.93	9
	Lithuania	1.69	1.80	1.87	4
<b>J01CR04</b>	<b>sultamicillin</b>				
	Estonia	0.10	0.10	0.10	
	Latvia	-	-	-	
	Lithuania	0.12	0.14	0.12	-14
<b>J01CR05</b>	<b>piperacillin and enzyme inhibitor</b>				
	Estonia	0.02	0.02	0.02	
	Latvia	0.01	0.01	0.01	14
	Lithuania	<0.01	0.01	0.01	
<b>J01D</b>	<b>OTHER BETA-LACTAM ANTIBACTERIALS</b>				
	Estonia	1.36	1.50	1.52	1
	Latvia	1.12	1.08	1.10	2
	Lithuania	1.12	1.34	1.48	10
<b>J01DB</b>	<b>First-generation cephalosporins</b>				
	Estonia	0.30	0.31	0.31	
	Latvia	0.52	0.43	0.38	-12
	Lithuania	0.40	0.44	0.44	

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
<b>J01DB01</b>	<b>cefalexin</b>				
	Estonia	-	-	-	
	Latvia	0.10	0.08	<0.01	
	Lithuania	-	-	-	
<b>J01DB04</b>	<b>cefazolin</b>				
	Estonia	0.07	0.07	0.07	
	Latvia	0.27	0.17	0.20	16
	Lithuania	0.18	0.23	0.25	9
<b>J01DB05</b>	<b>cefadroxil</b>				
	Estonia	0.22	0.24	0.24	
	Latvia	0.15	0.18	0.18	
	Lithuania	0.22	0.21	0.19	-10
<b>J01DC</b>	<b>Second-generation cephalosporins</b>				
	Estonia	0.97	1.08	1.10	2
	Latvia	0.22	0.24	0.28	20
	Lithuania	0.62	0.77	0.88	14
<b>J01DC02</b>	<b>cefuroxime</b>				
	Estonia	0.86	0.96	1.00	4
	Latvia	0.21	0.23	0.28	20
	Lithuania	0.62	0.77	0.88	14
<b>J01DC10</b>	<b>cefprozil</b>				
	Estonia	0.11	0.11	0.09	-18
	Latvia	0.01	<0.01	<0.01	
	Lithuania	<0.01	<0.01	-	
<b>J01DD</b>	<b>Third-generation cephalosporins</b>				
	Estonia	0.05	0.05	0.06	20
	Latvia	0.34	0.39	0.43	10
	Lithuania	0.08	0.11	0.14	27
<b>J01DD01</b>	<b>cefotaxime</b>				
	Estonia	0.02	0.02	0.03	50
	Latvia	0.01	0.01	0.01	-54
	Lithuania	0.01	0.01	0.01	
<b>J01DD02</b>	<b>ceftazidime</b>				
	Estonia	0.02	0.02	0.02	
	Latvia	0.01	0.01	0.01	-33
	Lithuania	0.01	0.01	0.01	
<b>J01DD04</b>	<b>ceftriaxone</b>				
	Estonia	0.01	0.01	0.01	
	Latvia	0.32	0.36	0.41	13
	Lithuania	0.07	0.09	0.13	44
<b>J01DE</b>	<b>Fourth-generation cephalosporins</b>				
	Estonia	0.02	0.02	0.02	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	<0.01	<0.01	<0.01	

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
<b>J01DE01</b>	<b>cefepime</b>				
	Estonia	0.02	0.02	0.02	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	<0.01	<0.01	<0.01	
<b>J01DH</b>	<b>Carbapenems</b>				
	Estonia	0.03	0.03	0.04	33
	Latvia	0.04	0.03	0.01	-61
	Lithuania	0.02	0.02	0.02	
<b>J01DH02</b>	<b>meropenem</b>				
	Estonia	<0.01	<0.01	0.01	
	Latvia	0.04	0.02	0.01	-59
	Lithuania	0.01	0.01	0.01	
<b>J01DH03</b>	<b>ertapenem</b>				
	Estonia	0.01	0.02	0.02	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	<0.01	<0.01	<0.01	
<b>J01DH51</b>	<b>imipenem and enzyme inhibitor</b>				
	Estonia	0.01	0.01	0.01	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	0.01	0.01	0.01	
<b>J01E</b>	<b>SULFONAMIDES AND TRIMETHOPRIM</b>				
	Estonia	0.49	0.54	0.52	-4
	Latvia	0.98	1.09	1.04	-5
	Lithuania	0.40	0.39	0.38	-3
<b>J01EA</b>	<b>Trimethoprim and derivatives</b>				
	Estonia	0.02	0.02	0.03	50
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	0.01	0.01	0.01	
<b>J01EA01</b>	<b>trimethoprim</b>				
	Estonia	0.02	0.02	0.03	50
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	0.01	0.01	0.01	
<b>J01EE</b>	<b>Combinations of sulfonamides and trimethoprim, incl. derivatives</b>				
	Estonia	0.47	0.52	0.49	-6
	Latvia	0.98	1.09	1.03	-5
	Lithuania	0.39	0.39	0.37	-5
<b>J01EE01</b>	<b>sulfamethoxazole and trimethoprim</b>				
	Estonia	0.40	0.52	0.49	-6
	Latvia	0.91	0.99	0.98	-1
	Lithuania	0.39	0.39	0.37	-5
<b>J01EE03</b>	<b>sulfametrole and trimethoprim</b>				
	Estonia	0.07	<0.01	-	
	Latvia	0.07	0.10	0.05	-47
	Lithuania	-	-	-	




ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
<b>J01F</b>	<b>MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS</b>				
	Estonia	2.35	2.66	2.65	
	Latvia	1.20	1.47	1.65	12
	Lithuania	1.91	2.12	2.21	4
<b>J01FA</b>	<b>Macrolides</b>				
	Estonia	2.22	2.51	2.47	-2
	Latvia	1.09	1.35	1.51	12
	Lithuania	1.88	2.09	2.18	4
<b>J01FA01</b>	<b>erythromycin</b>				
	Estonia	<0.01	-	<0.01	
	Latvia	0.09	0.08	0.06	-17
	Lithuania	0.07	0.07	0.05	-29
<b>J01FA02</b>	<b>spiramycin</b>				
	Estonia	0.01	0.01	0.01	
	Latvia	0.05	0.04	0.04	-7
	Lithuania	0.04	0.03	0.03	
<b>J01FA09</b>	<b>clarithromycin</b>				
	Estonia	1.84	2.02	1.88	-7
	Latvia	0.70	0.89	1.02	14
	Lithuania	1.43	1.53	1.56	2
<b>J01FA10</b>	<b>azithromycin</b>				
	Estonia	0.36	0.48	0.58	21
	Latvia	0.26	0.34	0.39	15
	Lithuania	0.34	0.45	0.55	22
<b>J01FF</b>	<b>Lincosamides</b>				
	Estonia	0.13	0.15	0.18	20
	Latvia	0.11	0.12	0.14	8
	Lithuania	0.03	0.03	0.03	
<b>J01FF01</b>	<b>clindamycin</b>				
	Estonia	0.13	0.15	0.18	20
	Latvia	0.10	0.11	0.12	9
	Lithuania	-	-	<0.01	
<b>J01FF02</b>	<b>lincomycin</b>				
	Estonia	-	-	-	
	Latvia	0.01	0.01	0.01	3
	Lithuania	0.03	0.03	0.03	
<b>J01G</b>	<b>AMINOGLYCOSIDE ANTIBACTERIALS</b>				
	Estonia	0.14	0.06	0.07	17
	Latvia	0.16	0.63	0.92	45
	Lithuania	0.30	0.31	0.32	3
<b>J01GA</b>	<b>Streptomycins</b>				
	Estonia	0.05	-	-	
	Latvia	0.01	<0.01	<0.01	
	Lithuania	0.01	<0.01	-	

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
<b>J01GA01</b>	<b>streptomycin</b>				
	Estonia	0.05	-	-	
	Latvia	0.01	<0.01	<0.01	
	Lithuania	0.01	<0.01	-	
<b>J01GB</b>	<b>Other aminoglycosides</b>				
	Estonia	0.09	0.06	0.07	17
	Latvia	0.15	0.63	0.91	45
	Lithuania	0.29	0.31	0.32	3
<b>J01GB01</b>	<b>tobramycin</b>				
	Estonia	0.01	<0.01	0.02	
	Latvia	-	-	-	
	Lithuania	-	-	-	
<b>J01GB03</b>	<b>gentamicin</b>				
	Estonia	0.07	0.05	0.04	-20
	Latvia	0.13	0.09	0.09	-3
	Lithuania	0.27	0.27	0.24	-11
<b>J01GB04</b>	<b>kanamycin</b>				
	Estonia	<0.01	-	-	
	Latvia	0.01	0.53	0.82	54
	Lithuania	<0.01	0.01	0.05	400
<b>J01GB06</b>	<b>amikacin</b>				
	Estonia	0.01	0.01	0.01	
	Latvia	0.01	<0.01	<0.01	
	Lithuania	0.02	0.03	0.03	
<b>J01M</b>	<b>QUINOLONE ANTIBACTERIALS</b>				
	Estonia	1.02	1.07	1.16	8
	Latvia	1.28	1.31	1.36	4
	Lithuania	1.14	1.24	1.42	15
<b>J01MA</b>	<b>Fluoroquinolones</b>				
	Estonia	1.02	1.07	1.16	8
	Latvia	1.24	1.26	1.32	4
	Lithuania	1.06	1.17	1.36	16
<b>J01MA01</b>	<b>ofloxacin</b>				
	Estonia	0.09	0.09	0.06	-33
	Latvia	0.23	0.18	0.18	
	Lithuania	0.25	0.31	0.27	-13
<b>J01MA02</b>	<b>ciprofloxacin</b>				
	Estonia	0.63	0.68	0.70	3
	Latvia	0.78	0.85	0.89	6
	Lithuania	0.58	0.61	0.66	8
<b>J01MA06</b>	<b>norfloxacin</b>				
	Estonia	0.28	0.26	0.26	
	Latvia	0.20	0.20	0.19	-3
	Lithuania	0.23	0.23	0.23	

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
<b>J01MA12</b>	<b>levofloxacin</b>				
	Estonia	0.01	0.01	0.11	
	Latvia	-	-	-	
	Lithuania	-	-	0.20	
<b>J01MA14</b>	<b>moxifloxacin</b>				
	Estonia	0.01	0.03	0.03	
	Latvia	0.03	0.04	0.05	24
	Lithuania	0.01	0.02	0.01	-50
<b>J01MB</b>	<b>Other quinolones</b>				
	Estonia	-	-	-	
	Latvia	0.05	0.04	0.04	-6
	Lithuania	0.08	0.07	0.05	-29
<b>J01MB04</b>	<b>pipemidic acid</b>				
	Estonia	-	-	-	
	Latvia	0.05	0.04	0.04	-6
	Lithuania	0.08	0.07	0.05	-29
<b>J01X</b>	<b>OTHER ANTIBACTERIALS</b>				
	Estonia	0.86	0.89	0.91	2
	Latvia	0.37	0.40	0.43	9
	Lithuania	2.28	2.09	1.64	-22
<b>J01XA</b>	<b>Glycopeptide antibacterials</b>				
	Estonia	0.01	0.01	0.01	
	Latvia	0.02	0.02	0.02	-4
	Lithuania	0.01	0.01	0.02	100
<b>J01XA01</b>	<b>vancomycin</b>				
	Estonia	0.01	0.01	0.01	
	Latvia	0.02	0.02	0.02	-4
	Lithuania	0.01	0.01	0.02	100
<b>J01XD</b>	<b>Imidazole derivatives</b>				
	Estonia	0.35	0.36	0.35	-3
	Latvia	0.09	0.12	0.16	25
	Lithuania	1.03	0.82	0.22	-73
<b>J01XD01</b>	<b>metronidazole</b>				
	Estonia	0.35	0.36	0.35	-3
	Latvia	0.07	0.10	0.14	42
	Lithuania	1.03	0.82	0.22	-73
<b>J01XD02</b>	<b>tinidazole</b>				
	Estonia	-	-	-	
	Latvia	0.02	0.03	0.02	-39
	Lithuania	-	-	-	
<b>J01XE</b>	<b>Nitrofuran derivatives</b>				
	Estonia	0.49	0.51	0.54	6
	Latvia	0.21	0.20	0.21	5
	Lithuania	1.19	1.20	1.36	13

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
<b>J01XE01</b>	<b>nitrofurantoin</b>				
	Estonia	0.49	0.51	0.54	6
	Latvia	0.21	0.20	0.21	5
	Lithuania	1.19	1.20	1.36	13
<b>J01XX</b>	<b>Other antibacterials</b>				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	0.06	0.05	0.05	-8
	Lithuania	0.05	0.05	0.04	-20
<b>J01XX07</b>	<b>nitroxoline</b>				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	0.05	0.05	0.04	-11
	Lithuania	0.04	0.04	0.04	
<b>J01XX08</b>	<b>linezolid</b>				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	0.01	0.01	<0.01	
<b>J02</b>	<b>ANTIMYCOTICS FOR SYSTEMIC USE</b>				
	Estonia	0.35	0.39	0.38	-3
	Latvia	0.31	0.31	0.33	9
	Lithuania	0.21	0.25	0.26	4
<b>J02A</b>	<b>ANTIMYCOTICS FOR SYSTEMIC USE</b>				
	Estonia	0.34	0.39	0.37	-5
	Latvia	0.31	0.31	0.33	9
	Lithuania	0.21	0.25	0.26	4
<b>J02AA</b>	<b>Antibiotics</b>				
	Estonia	-	-	-	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	

Consumption of antibiotics for systemic use (J01)



ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
<b>J02AA01</b>	<b>amphotericin B</b>				
	Estonia	-	-	-	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
<b>J02AB</b>	<b>Imidazole derivatives</b>				
	Estonia	0.12	0.13	0.11	-15
	Latvia	0.10	0.09	0.08	-7
	Lithuania	0.07	0.08	0.08	
<b>J02AB02</b>	<b>ketoconazole</b>				
	Estonia	0.12	0.13	0.11	-15
	Latvia	0.10	0.09	0.08	-7
	Lithuania	0.07	0.08	0.08	
<b>J02AC</b>	<b>Triazole derivatives</b>				
	Estonia	0.23	0.26	0.26	
	Latvia	0.21	0.22	0.25	16
	Lithuania	0.14	0.17	0.18	6
<b>J02AC01</b>	<b>fluconazole</b>				
	Estonia	0.13	0.14	0.13	-7
	Latvia	0.14	0.13	0.14	6
	Lithuania	0.11	0.12	0.13	8
<b>J02AC02</b>	<b>itraconazole</b>				
	Estonia	0.09	0.11	0.12	9
	Latvia	0.06	0.08	0.11	32
	Lithuania	0.03	0.04	0.05	25
<b>J02AC03</b>	<b>voriconazole</b>				
	Estonia	<0.01	0.01	<0.01	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	<0.01	<0.01	<0.01	
<b>J02AX</b>	<b>Other antimycotics for systemic use</b>				
	Estonia	-	-	-	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
<b>J02AX04</b>	<b>casprofungin</b>				
	Estonia	-	-	-	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
<b>J04</b>	<b>ANTIMYCOBACTERIALS</b>				
	Estonia	0.32	0.37	0.37	
	Latvia	0.46	0.50	0.11	-79
	Lithuania	0.79	0.80	0.79	-1
<b>J04A</b>	<b>DRUGS FOR TREATMENT OF TUBERCULOSIS</b>				
	Estonia	0.30	0.36	0.35	-3
	Latvia	0.46	0.50	0.11	-79
	Lithuania	0.79	0.80	0.79	-1

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
<b>J04AA</b>	<b>Aminosalicilic acid and derivatives</b>				
	Estonia	0.01	0.03	0.01	-67
	Latvia	0.06	0.03	<0.01	
	Lithuania	-	-	-	
<b>J04AA01</b>	<b>4-aminosalicylic acid</b>				
	Estonia	0.01	0.01	0.01	
	Latvia	-	-	-	
	Lithuania	-	-	-	
<b>J04AA02</b>	<b>sodium aminosalicylate</b>				
	Estonia	<0.01	0.01	0.01	
	Latvia	0.06	0.03	<0.01	
	Lithuania	-	-	-	
<b>J04AB</b>	<b>Antibiotics</b>				
	Estonia	0.06	0.04	0.08	100
	Latvia	0.16	0.13	0.11	-18
	Lithuania	0.33	0.32	0.26	-19
<b>J04AB01</b>	<b>cycloserine</b>				
	Estonia	0.04	0.02	0.03	50
	Latvia	-	-	-	
	Lithuania	-	-	-	
<b>J04AB02</b>	<b>rifampicin</b>				
	Estonia	<0.01	0.02	0.03	50
	Latvia	0.16	0.13	0.11	-18
	Lithuania	0.33	0.32	0.26	-19
<b>J04AB30</b>	<b>capreomycin</b>				
	Estonia	0.02	-	0.03	
	Latvia	-	-	-	
	Lithuania	-	-	-	
<b>J04AC</b>	<b>Hydrazides</b>				
	Estonia	0.06	<0.01	0.08	
	Latvia	-	-	-	
	Lithuania	-	-	-	
<b>J04AC01</b>	<b>isoniazid</b>				
	Estonia	0.01	<0.01	0.08	
	Latvia	-	-	-	
	Lithuania	-	-	-	
<b>J04AC51</b>	<b>isoniazid, combinations</b>				
	Estonia	0.05	-	-	
	Latvia	-	-	-	
	Lithuania	-	-	-	
<b>J04AD</b>	<b>Thiocarbamide derivatives</b>				
	Estonia	0.04	0.02	0.04	100
	Latvia	0.04	0.05	<0.01	
	Lithuania	0.05	0.07	0.07	

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
<b>J04AD01</b>	<b>protonamide</b>				
	Estonia	0.04	0.02	0.04	100
	Latvia	0.04	0.05	<0.01	
	Lithuania	0.05	0.07	0.07	
<b>J04AK</b>	<b>Other drugs for treatment of tuberculosis</b>				
	Estonia	0.13	0.24	0.06	-75
	Latvia	0.21	0.29	<0.01	
	Lithuania	0.42	0.41	0.45	10
<b>J04AK01</b>	<b>pyrazinamide</b>				
	Estonia	0.04	0.08	0.06	-25
	Latvia	0.09	0.11	<0.01	
	Lithuania	0.19	0.18	0.22	22
<b>J04AK02</b>	<b>ethambutol</b>				
	Estonia	0.09	0.15	-	
	Latvia	0.12	0.18	<0.01	
	Lithuania	0.23	0.23	0.23	
<b>J04AM</b>	<b>Combinations of drugs for treatment of tuberculosis</b>				
	Estonia	0.01	0.04	0.07	75
	Latvia	-	-	-	
	Lithuania	-	0.01	0.03	200
<b>J04AM02</b>	<b>rifampicin and isoniazid</b>				
	Estonia	0.01	0.04	0.07	75
	Latvia	-	-	-	
	Lithuania	-	0.01	0.03	200
<b>J04B</b>	<b>DRUGS FOR TREATMENT OF LEPRA</b>				
	Estonia	0.01	0.01	0.02	100
	Latvia	-	-	-	
	Lithuania	-	-	-	
<b>J04BA</b>	<b>Drugs for treatment of lepra</b>				
	Estonia	0.01	0.01	0.02	100
	Latvia	-	-	-	
	Lithuania	-	-	-	
<b>J04BA02</b>	<b>dapsone</b>				
	Estonia	0.01	0.01	0.02	100
	Latvia	-	-	-	
	Lithuania	-	-	-	
<b>J05</b>	<b>ANTIVIRALS FOR SYSTEMIC USE</b>				
	Estonia	2.61	3.19	3.40	7
	Latvia	0.73	0.83	0.92	11
	Lithuania	0.25	0.47	0.20	-57
<b>J05A</b>	<b>DIRECT ACTING ANTIVIRALS</b>				
	Estonia	2.61	3.19	3.40	7
	Latvia	0.73	0.83	0.92	11
	Lithuania	0.25	0.47	0.20	-57

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
<b>J05AB</b>	<b>Nucleosides and nucleotides excl. reverse transcriptase inhibitors</b>				
	Estonia	0.24	0.25	0.32	28
	Latvia	0.26	0.27	0.26	-7
	Lithuania	0.17	0.13	0.13	
<b>J05AB01</b>	<b>aciclovir</b>				
	Estonia	0.04	0.04	0.05	25
	Latvia	0.04	0.05	0.05	18
	Lithuania	0.04	0.05	0.06	20
<b>J05AB04</b>	<b>ribavirin</b>				
	Estonia	0.13	0.13	0.18	38
	Latvia	0.21	0.22	0.19	-12
	Lithuania	0.12	0.07	0.06	-14
<b>J05AB11</b>	<b>valaciclovir</b>				
	Estonia	0.06	0.07	0.09	29
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	0.01	0.01	0.02	100
<b>J05AB14</b>	<b>valganciclovir</b>				
	Estonia	<0.01	0.01	0.01	
	Latvia	<0.01	0.01	0.01	-8
	Lithuania	-	-	-	
<b>J05AE</b>	<b>Protease inhibitors</b>				
	Estonia	0.15	0.37	0.37	
	Latvia	0.05	0.09	0.11	17
	Lithuania	0.03	0.06	<0.01	
<b>J05AE01</b>	<b>saquinavir</b>				
	Estonia	-	-	-	
	Latvia	0.03	0.02	0.01	-23
	Lithuania	<0.01	<0.01	-	
<b>J05AE03</b>	<b>ritonavir</b>				
	Estonia	0.02	0.13	0.04	-69
	Latvia	0.01	0.04	0.05	22
	Lithuania	<0.01	<0.01	-	
<b>J05AE04</b>	<b>nelfinavir</b>				
	Estonia	0.02	0.04	0.01	-75
	Latvia	-	-	-	
	Lithuania	-	-	-	
<b>J05AE06</b>	<b>lopinavir</b>				
	Estonia	-	-	-	
	Latvia	-	-	-	
	Lithuania	0.03	0.05	-	
<b>J05AE07</b>	<b>fosamprenavir</b>				
	Estonia	0.10	0.14	0.19	36
	Latvia	<0.01	0.01	0.02	30
	Lithuania	<0.01	<0.01	-	



ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
<b>J05AE08</b>	<b>atazanavir</b>				
	Estonia	0.02	0.02	0.04	100
	Latvia	0.01	0.01	0.02	53
	Lithuania	-	<0.01	-	
<b>J05AE10</b>	<b>darunavir</b>				
	Estonia	0.01	0.04	0.09	125
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	<0.01	<0.01	<0.01	
<b>J05AE12</b>	<b>boceprevir</b>				
	Estonia	-	0.01	0.01	
	Latvia	-	-	-	
	Lithuania	-	-	-	
<b>J05AF</b>	<b>Nucleoside and nucleotide reverse transcriptase inhibitors</b>				
	Estonia	0.52	0.35	0.20	-43
	Latvia	0.09	0.07	0.11	44
	Lithuania	0.01	0.01	0.02	100
<b>J05AF01</b>	<b>zidovudine</b>				
	Estonia	0.04	0.02	0.01	-50
	Latvia	0.01	0.01	0.03	85
	Lithuania	-	-	-	
<b>J05AF02</b>	<b>didanosine</b>				
	Estonia	0.24	0.17	0.09	-47
	Latvia	0.01	0.01	0.01	-13
	Lithuania	-	-	-	
<b>J05AF04</b>	<b>stavudine</b>				
	Estonia	-	-	-	
	Latvia	0.01	<0.01	<0.01	
	Lithuania	-	-	-	
<b>J05AF05</b>	<b>lamivudine</b>				
	Estonia	0.24	0.15	0.09	-40
	Latvia	0.03	0.02	0.03	17
	Lithuania	-	-	-	
<b>J05AF06</b>	<b>abacavir</b>				
	Estonia	<0.01	0.01	0.01	
	Latvia	0.02	0.01	0.02	37
	Lithuania	-	-	-	
<b>J05AF07</b>	<b>tenofovir disoproxil</b>				
	Estonia	-	-	-	
	Latvia	0.01	0.01	0.02	148
	Lithuania	<0.01	0.01	0.01	
<b>J05AF10</b>	<b>entecavir</b>				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	0.01	0.01	0.01	

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
<b>J05AG</b>	<b>Non-nucleoside reverse transcriptase inhibitors</b>				
	Estonia	0.51	0.63	0.58	-8
	Latvia	0.15	0.17	0.19	8
	Lithuania	<0.01	-	0.01	
<b>J05AG01</b>	<b>nevirapine</b>				
	Estonia	0.02	0.04	0.04	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
<b>J05AG03</b>	<b>efavirenz</b>				
	Estonia	0.49	0.59	0.54	-8
	Latvia	0.14	0.17	0.19	9
	Lithuania	<0.01	-	0.01	
<b>J05AH</b>	<b>Neuraminidase inhibitors</b>				
	Estonia	0.06	0.02	0.01	-50
	Latvia	<0.01	0.07	0.01	-84
	Lithuania	0.01	0.24	0.01	-96
<b>J05AH01</b>	<b>zanamivir</b>				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	<0.01	0.10	<0.01	
<b>J05AH02</b>	<b>oseltamivir</b>				
	Estonia	0.06	0.02	0.01	-50
	Latvia	<0.01	0.07	0.01	-84
	Lithuania	0.01	0.13	<0.01	
<b>J05AR</b>	<b>Antivirals for treatment of HIV infections, combinations</b>				
	Estonia	1.13	1.56	1.89	21
	Latvia	0.18	0.15	0.25	67
	Lithuania	-	-	0.01	
<b>J05AR01</b>	<b>zidovudine and lamivudine</b>				
	Estonia	0.59	0.62	0.48	-23
	Latvia	0.13	0.10	0.14	45
	Lithuania	-	-	-	
<b>J05AR02</b>	<b>lamivudine and abacavir</b>				
	Estonia	0.14	0.44	0.75	70
	Latvia	0.04	0.03	0.07	109
	Lithuania	-	-	-	
<b>J05AR03</b>	<b>tenofovir disoproxil and emtricitabine</b>				
	Estonia	0.02	0.06	0.21	250
	Latvia	<0.01	0.01	0.01	90
	Lithuania	-	-	-	
<b>J05AR04</b>	<b>zidovudine, lamivudine and abacavir</b>				
	Estonia	-	-	-	
	Latvia	0.01	0.01	0.03	114
	Lithuania	-	-	-	

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
<b>J05AR10</b>	<b>lopinavir and ritonavir</b>				
	Estonia	0.38	0.44	0.45	2
	Latvia	-	-	-	
	Lithuania	-	-	0.01	
<b>J05AX</b>	<b>Other antivirals</b>				
	Estonia	<0.01	0.01	0.03	200
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
<b>J05AX08</b>	<b>raltegravir</b>				
	Estonia	<0.01	0.01	0.03	200
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
<b>L</b>	<b>ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS</b>				
	Estonia	6.88	7.74	8.60	11
	Latvia	4.35	4.39	4.79	9
	Lithuania	4.85	5.35	5.56	4
<b>L02</b>	<b>ENDOCRINE THERAPY</b>				
	Estonia	3.18	3.54	3.80	7
	Latvia	2.85	2.79	3.12	12
	Lithuania	3.32	3.57	3.60	1
<b>L02A</b>	<b>HORMONES AND RELATED AGENTS</b>				
	Estonia	0.14	0.13	0.14	8
	Latvia	1.38	1.17	1.49	27
	Lithuania	1.61	1.67	1.71	2
<b>L02AB</b>	<b>Progestogens</b>				
	Estonia	0.02	0.01	0.01	
	Latvia	0.04	0.04	0.02	-41
	Lithuania	0.41	0.38	0.43	13
<b>L02AB01</b>	<b>megestrol</b>				
	Estonia	-	-	-	
	Latvia	0.04	0.04	0.02	-41
	Lithuania	0.41	0.38	0.43	13
<b>L02AB02</b>	<b>medroxyprogesterone</b>				
	Estonia	0.02	0.01	0.01	
	Latvia	-	-	-	
	Lithuania	-	-	-	
<b>L02AE</b>	<b>Gonadotropin releasing hormone analogues</b>				
	Estonia	0.12	0.11	0.12	9
	Latvia	1.35	1.14	1.47	29
	Lithuania	1.20	1.30	1.28	-2
<b>L02AE01</b>	<b>buserelin</b>				
	Estonia	0.01	0.01	0.01	
	Latvia	-	-	-	
	Lithuania	-	-	-	
<b>L02AE02</b>	<b>leuprorelin</b>				
	Estonia	<0.01	<0.01	-	
	Latvia	0.57	0.18	0.69	291
	Lithuania	0.04	0.02	0.04	100
<b>L02AE03</b>	<b>goserelin</b>				
	Estonia	0.08	0.06	0.06	
	Latvia	0.30	0.27	0.13	-53
	Lithuania	0.28	0.35	0.28	-20
<b>L02AE04</b>	<b>triptorelin</b>				
	Estonia	0.04	0.04	0.04	
	Latvia	0.48	0.69	0.65	-6
	Lithuania	0.87	0.93	0.94	1

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
L02AE05	histrelin				
	Estonia	-	<0.01	0.01	
	Latvia	-	-	-	
	Lithuania	-	-	0.02	
L02B	HORMONE ANTAGONISTS AND RELATED AGENTS				
	Estonia	3.05	3.41	3.67	8
	Latvia	1.47	1.62	1.63	1
	Lithuania	1.71	1.89	1.90	1
L02BA	Anti-estrogens				
	Estonia	0.41	0.45	0.51	13
	Latvia	0.81	0.90	0.96	6
	Lithuania	0.89	0.93	1.08	16
L02BA01	tamoxifen				
	Estonia	0.40	0.39	0.46	18
	Latvia	0.81	0.90	0.95	6
	Lithuania	0.89	0.92	1.06	15
L02BA03	fulvestrant				
	Estonia	0.01	0.05	0.06	20
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	<0.01	0.01	
L02BB	Anti-androgens				
	Estonia	1.49	1.80	1.93	7
	Latvia	0.29	0.27	0.23	-16
	Lithuania	0.36	0.45	0.30	-33
L02BB01	flutamide				
	Estonia	-	-	-	
	Latvia	0.09	0.07	0.06	-14
	Lithuania	<0.01	<0.01	-	
L02BB03	bicalutamide				
	Estonia	1.49	1.80	1.93	7
	Latvia	0.20	0.20	0.17	-17
	Lithuania	0.36	0.45	0.30	-33
L02BG	Aromatase inhibitors				
	Estonia	1.14	1.17	1.21	3
	Latvia	0.36	0.45	0.44	-1
	Lithuania	0.46	0.52	0.52	
L02BG03	anastrozole				
	Estonia	0.55	0.52	0.48	-8
	Latvia	0.24	0.33	0.35	6
	Lithuania	0.26	0.29	0.26	-10
L02BG04	letrozole				
	Estonia	0.52	0.56	0.64	14
	Latvia	0.08	0.08	0.06	-28
	Lithuania	0.09	0.11	0.13	18

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
<b>L02BG06</b>	<b>exemestane</b>				
	Estonia	0.08	0.09	0.09	
	Latvia	0.05	0.04	0.04	-6
	Lithuania	0.11	0.13	0.14	8
<b>L02BX</b>	<b>Other hormone antagonists and related agents</b>				
	Estonia	-	-	0.01	
	Latvia	-	-	-	
	Lithuania	-	-	-	
<b>L02BX03</b>	<b>abiraterone</b>				
	Estonia	-	-	0.01	
	Latvia	-	-	-	
	Lithuania	-	-	-	
<b>L03</b>	<b>IMMUNOSTIMULANTS</b>				
	Estonia	0.67	0.83	0.88	6
	Latvia	0.90	0.93	0.94	2
	Lithuania	0.74	0.79	0.88	11
<b>L03A</b>	<b>IMMUNOSTIMULANTS</b>				
	Estonia	0.67	0.83	0.88	6
	Latvia	0.90	0.93	0.94	2
	Lithuania	0.74	0.79	0.88	11
<b>L03AA</b>	<b>Colony stimulating factors</b>				
	Estonia	0.01	0.02	0.04	100
	Latvia	0.05	0.08	0.09	15
	Lithuania	0.03	0.04	0.06	50
<b>L03AA02</b>	<b>filgrastim</b>				
	Estonia	0.01	0.02	0.02	
	Latvia	0.01	0.02	0.02	28
	Lithuania	0.03	0.04	0.05	25
<b>L03AA13</b>	<b>pegfilgrastim</b>				
	Estonia	-	0.01	0.02	100
	Latvia	0.04	0.06	0.07	12
	Lithuania	-	-	0.01	
<b>L03AB</b>	<b>Interferons</b>				
	Estonia	0.59	0.71	0.75	6
	Latvia	0.77	0.76	0.78	3
	Lithuania	0.64	0.68	0.73	7
<b>L03AB04</b>	<b>interferon alfa-2a</b>				
	Estonia	0.03	0.03	0.04	33
	Latvia	0.05	0.06	0.06	11
	Lithuania	-	-	-	
<b>L03AB05</b>	<b>interferon alfa-2b</b>				
	Estonia	-	-	-	
	Latvia	0.01	0.01	0.01	-4
	Lithuania	0.12	0.12	0.09	-25

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
<b>L03AB07</b>	<b>interferon beta-1a</b>				
	Estonia	0.33	0.41	0.42	2
	Latvia	0.37	0.34	0.37	8
	Lithuania	0.31	0.33	0.36	9
<b>L03AB08</b>	<b>interferon beta-1b</b>				
	Estonia	0.06	0.08	0.10	25
	Latvia	0.10	0.09	0.10	3
	Lithuania	0.04	0.04	0.05	25
<b>L03AB10</b>	<b>peginterferon alfa-2b</b>				
	Estonia	0.08	0.12	0.10	-17
	Latvia	0.06	0.12	0.13	11
	Lithuania	0.12	0.15	0.17	13
<b>L03AB11</b>	<b>peginterferon alfa-2a</b>				
	Estonia	0.09	0.07	0.10	43
	Latvia	0.18	0.14	0.11	-21
	Lithuania	0.04	0.05	0.06	20
<b>L03AX</b>	<b>Other immunostimulants</b>				
	Estonia	0.06	0.09	0.09	
	Latvia	0.08	0.09	0.07	-20
	Lithuania	0.07	0.07	0.09	29
<b>L03AX03</b>	<b>BCG vaccine</b>				
	Estonia	-	-	-	
	Latvia	0.02	0.02	0.01	-65
	Lithuania	0.02	0.01	0.04	300
<b>L03AX13</b>	<b>glatiramer acetate</b>				
	Estonia	0.06	0.09	0.09	
	Latvia	0.06	0.07	0.06	-10
	Lithuania	0.06	0.06	0.05	-17
<b>L04</b>	<b>IMMUNOSUPPRESSANTS</b>				
	Estonia	3.03	3.38	3.91	16
	Latvia	0.59	0.67	0.73	9
	Lithuania	0.79	0.99	1.07	8
<b>L04A</b>	<b>IMMUNOSUPPRESSANTS</b>				
	Estonia	3.03	3.38	3.91	16
	Latvia	0.59	0.67	0.73	9
	Lithuania	0.79	0.99	1.07	8
<b>L04AA</b>	<b>Selective immunosuppressants</b>				
	Estonia	0.54	0.57	0.63	11
	Latvia	0.29	0.31	0.37	19
	Lithuania	0.23	0.23	0.26	13
<b>L04AA06</b>	<b>mycophenolic acid</b>				
	Estonia	0.18	0.20	0.21	5
	Latvia	0.13	0.18	0.22	23
	Lithuania	0.15	0.16	0.18	13

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
<b>L04AA10</b>	<b>sirolimus</b>				
	Estonia	0.02	0.02	0.02	
	Latvia	0.02	0.01	0.01	-14
	Lithuania	0.01	0.01	0.01	
<b>L04AA13</b>	<b>leflunomide</b>				
	Estonia	0.34	0.34	0.39	15
	Latvia	0.15	0.12	0.13	13
	Lithuania	0.07	0.06	0.07	17
<b>L04AA24</b>	<b>abatacept</b>				
	Estonia	-	-	<0.01	
	Latvia	<0.01	<0.01	0.01	
	Lithuania	-	-	-	
<b>L04AA27</b>	<b>fingolimod</b>				
	Estonia	-	<0.01	0.01	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
<b>L04AB</b>	<b>Tumor necrosis factor alpha (TNF-<math>\alpha</math>) inhibitors</b>				
	Estonia	0.27	0.36	0.46	28
	Latvia	0.07	0.11	0.10	-6
	Lithuania	0.17	0.27	0.20	-26
<b>L04AB01</b>	<b>etanercept</b>				
	Estonia	0.09	0.10	0.12	20
	Latvia	0.04	0.05	0.06	15
	Lithuania	0.02	0.09	0.11	22
<b>L04AB02</b>	<b>infliximab</b>				
	Estonia	0.09	0.12	0.16	33
	Latvia	0.03	0.06	0.04	-24
	Lithuania	0.12	0.12	0.04	-67
<b>L04AB04</b>	<b>adalimumab</b>				
	Estonia	0.08	0.11	0.14	27
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	0.03	0.05	0.04	-20
<b>L04AB05</b>	<b>certolizumab pegol</b>				
	Estonia	<0.01	0.01	0.01	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	<0.01	0.01	0.01	
<b>L04AB06</b>	<b>golimumab</b>				
	Estonia	<0.01	0.02	0.04	100
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
<b>L04AC</b>	<b>Interleukin inhibitors</b>				
	Estonia	-	0.02	0.04	100
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	



ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
<b>L04AC05</b>	<b>ustekinumab</b>				
	Estonia	<0.01	0.01	0.01	
	Latvia	-	-	-	
	Lithuania	-	-	-	
<b>L04AC07</b>	<b>tocilizumab</b>				
	Estonia	<0.01	0.02	0.03	50
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
<b>L04AD</b>	<b>Calcineurin inhibitors</b>				
	Estonia	0.23	0.25	0.28	12
	Latvia	0.16	0.17	0.17	
	Lithuania	0.14	0.14	0.16	14
<b>L04AD01</b>	<b>ciclosporin</b>				
	Estonia	0.23	0.23	0.22	-4
	Latvia	0.15	0.12	0.12	
	Lithuania	0.14	0.13	0.12	-8
<b>L04AD02</b>	<b>tacrolimus</b>				
	Estonia	<0.01	0.02	0.05	150
	Latvia	0.02	0.05	0.05	4
	Lithuania	<0.01	0.01	0.04	300
<b>L04AX</b>	<b>Other immunosuppressants</b>				
	Estonia	1.98	2.17	2.51	16
	Latvia	0.07	0.09	0.09	6
	Lithuania	0.25	0.35	0.45	29
<b>L04AX01</b>	<b>azathioprine</b>				
	Estonia	0.22	0.23	0.28	22
	Latvia	0.06	0.08	0.08	3
	Lithuania	0.12	0.13	0.14	8
<b>L04AX02</b>	<b>thalidomide</b>				
	Estonia	0.01	0.01	0.03	200
	Latvia	-	-	-	
	Lithuania	-	-	-	
<b>L04AX03</b>	<b>methotrexate</b>				
	Estonia	1.75	1.91	2.18	14
	Latvia	0.01	0.01	0.01	30
	Lithuania	0.13	0.22	0.31	41
<b>L04AX04</b>	<b>lenalidomide</b>				
	Estonia	<0.01	0.02	0.03	50
	Latvia	-	-	-	
	Lithuania	-	-	<0.01	


ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
<b>M</b>	<b>MUSCULO-SKELETAL SYSTEM</b>				
	Estonia	60.22	63.49	69.42	9
	Latvia	58.56	63.75	68.19	7
	Lithuania	59.36	66.09	69.33	5
<b>M01</b>	<b>ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS</b>				
	Estonia	52.62	55.84	61.02	9
	Latvia	50.77	54.55	58.04	6
	Lithuania	53.39	60.00	62.28	4
<b>M01A</b>	<b>ANTIINFLAMMATORY AND ANTI-RHEUMATIC PRODUCTS, NON-STERIODS</b>				
	Estonia	52.60	55.83	61.00	9
	Latvia	50.75	54.54	58.02	6
	Lithuania	53.37	59.98	62.25	4
<b>M01AB</b>	<b>Acetic acid derivatives and related substances</b>				
	Estonia	13.48	13.38	13.43	
	Latvia	25.84	26.76	28.68	7
	Lithuania	23.61	23.94	25.88	8
<b>M01AB01</b>	<b>indometacin</b>				
	Estonia	0.27	0.23	0.23	
	Latvia	0.40	0.34	0.34	-2
	Lithuania	1.70	1.76	1.90	8
<b>M01AB05</b>	<b>diclofenac</b>				
	Estonia	13.12	13.09	13.12	
	Latvia	21.48	22.19	23.85	7
	Lithuania	18.84	19.03	20.49	8
<b>M01AB15</b>	<b>ketorolac</b>				
	Estonia	-	-	-	
	Latvia	1.26	1.22	1.29	6
	Lithuania	2.35	2.43	2.60	7
<b>M01AB16</b>	<b>aceclofenac</b>				
	Estonia	-	-	0.02	
	Latvia	0.92	1.19	1.41	19
	Lithuania	-	-	0.11	
<b>M01AB55</b>	<b>diclofenac, combinations</b>				
	Estonia	0.08	0.07	0.06	-14
	Latvia	1.77	1.83	1.80	-2
	Lithuania	0.73	0.73	0.77	5
<b>M01AC</b>	<b>Oxicams</b>				
	Estonia	5.67	6.02	5.98	-1
	Latvia	3.45	3.99	4.19	5
	Lithuania	5.51	6.29	6.98	11
<b>M01AC01</b>	<b>piroxicam</b>				
	Estonia	0.15	0.20	0.18	-10
	Latvia	0.13	0.14	0.11	-18
	Lithuania	0.80	0.83	0.89	7

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
<b>M01AC05</b>	<b>lornoxicam</b>				
	Estonia	0.95	0.98	0.94	-4
	Latvia	0.64	0.79	0.90	14
	Lithuania	0.93	0.99	1.15	16
<b>M01AC06</b>	<b>meloxicam</b>				
	Estonia	4.57	4.83	4.86	1
	Latvia	2.68	3.06	3.17	3
	Lithuania	3.77	4.47	4.94	11
<b>M01AE</b>	<b>Propionic acid derivatives</b>				
	Estonia	21.79	24.36	27.82	14
	Latvia	15.86	18.49	19.89	8
	Lithuania	18.79	23.10	22.36	-3
<b>M01AE01</b>	<b>ibuprofen</b>				
	Estonia	20.55	22.52	23.38	4
	Latvia	15.50	17.98	19.30	7
	Lithuania	17.68	20.34	18.30	-10
<b>M01AE02</b>	<b>naproxen</b>				
	Estonia	<0.01	0.18	0.43	139
	Latvia	-	-	-	
	Lithuania	-	1.23	1.95	59
<b>M01AE03</b>	<b>ketoprofen</b>				
	Estonia	0.84	0.91	1.05	15
	Latvia	0.20	0.25	0.29	16
	Lithuania	0.68	0.69	0.75	9
<b>M01AE09</b>	<b>flurbiprofen</b>				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	0.01	0.02	0.02	
	Lithuania	-	-	-	
<b>M01AE12</b>	<b>oxaprozin</b>				
	Estonia	-	-	-	
	Latvia	-	-	-	
	Lithuania	0.01	-	-	
<b>M01AE17</b>	<b>dexketoprofen</b>				
	Estonia	0.40	0.44	0.58	32
	Latvia	0.16	0.25	0.29	17
	Lithuania	0.42	0.58	0.80	38
<b>M01AE51</b>	<b>ibuprofen, combinations (ibuprofen + pseudoephedrine)</b>				
	Estonia	-	-	-	
	Latvia	-	-	-	
	Lithuania	0.01	<0.01	-	
<b>M01AE52</b>	<b>naproxen and esomeprazole</b>				
	Estonia	-	0.31	2.38	668
	Latvia	-	-	-	
	Lithuania	-	0.25	0.56	124

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
<b>M01AG</b>	<b>Fenamates</b>				
	Estonia	0.01	0.01	<0.01	
	Latvia	-	-	-	
	Lithuania	-	-	-	
<b>M01AG02</b>	<b>tolfenamic acid</b>				
	Estonia	0.01	0.01	<0.01	
	Latvia	-	-	-	
	Lithuania	-	-	-	
<b>M01AH</b>	<b>Coxibs</b>				
	Estonia	2.29	2.88	3.73	30
	Latvia	0.33	0.53	1.12	110
	Lithuania	0.81	1.33	1.41	6
<b>M01AH01</b>	<b>celecoxib</b>				
	Estonia	0.14	0.19	0.37	95
	Latvia	0.04	0.04	0.07	102
	Lithuania	0.38	0.52	0.49	-6
<b>M01AH05</b>	<b>etoricoxib</b>				
	Estonia	2.15	2.68	3.35	25
	Latvia	0.28	0.50	1.05	111
	Lithuania	0.44	0.81	0.92	14
<b>M01AX</b>	<b>Other antiinflammatory and antirheumatic agents, non-steroids</b>				
	Estonia	9.36	9.18	10.04	9
	Latvia	5.28	4.76	4.14	-13
	Lithuania	4.65	5.32	5.61	5
<b>M01AX01</b>	<b>nabumetone</b>				
	Estonia	0.47	0.46	0.50	9
	Latvia	0.03	0.02	0.01	-32
	Lithuania	0.07	0.07	0.07	
<b>M01AX05</b>	<b>glucosamine</b>				
	Estonia	8.89	8.73	9.54	9
	Latvia	1.81	1.68	1.70	1
	Lithuania	0.72	1.01	1.03	2
<b>M01AX17</b>	<b>nimesulide</b>				
	Estonia	-	-	-	
	Latvia	3.45	3.06	2.43	-21
	Lithuania	3.85	4.24	4.50	6
<b>M01C</b>	<b>SPECIFIC ANTIRHEUMATIC AGENTS</b>				
	Estonia	0.02	0.01	0.02	100
	Latvia	0.02	0.02	0.02	54
	Lithuania	0.02	0.02	0.03	50
<b>M01CC</b>	<b>Penicillamine and similar agents</b>				
	Estonia	0.02	0.01	0.02	100
	Latvia	0.02	0.02	0.02	54
	Lithuania	0.02	0.02	0.03	50

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
<b>M01CC01</b>	<b>penicillamine</b>				
	Estonia	0.02	0.01	0.02	100
	Latvia	0.02	0.02	0.02	54
	Lithuania	0.02	0.02	0.03	50
<b>M03</b>	<b>MUSCLE RELAXANTS</b>				
	Estonia	0.58	0.62	0.69	11
	Latvia	2.69	2.85	3.24	13
	Lithuania	1.52	1.61	1.96	22
<b>M03B</b>	<b>MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS</b>				
	Estonia	0.58	0.62	0.69	11
	Latvia	2.69	2.85	3.24	13
	Lithuania	1.52	1.61	1.96	22
<b>M03BX</b>	<b>Other centrally acting agents</b>				
	Estonia	0.58	0.62	0.69	11
	Latvia	2.69	2.85	3.24	13
	Lithuania	1.45	1.53	1.88	23
<b>M03BX01</b>	<b>baclofen</b>				
	Estonia	0.13	0.13	0.14	8
	Latvia	0.14	0.16	0.13	-16
	Lithuania	0.20	0.21	0.25	19
<b>M03BX02</b>	<b>tizanidine</b>				
	Estonia	0.45	0.49	0.54	10
	Latvia	0.12	0.12	0.13	6
	Lithuania	-	-	-	
<b>M03BX04</b>	<b>tolperisone</b>				
	Estonia	0.01	0.01	<0.01	
	Latvia	2.43	2.57	2.98	16
	Lithuania	1.25	1.32	1.63	23

### Consumption of non-steroidal antiinflammatory and antirheumatic products (M01A)




ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
<b>M04</b>	<b>ANTIGOUT PREPARATIONS</b>				
	Estonia	2.44	2.54	2.91	15
	Latvia	0.88	1.04	1.34	29
	Lithuania	1.06	1.22	1.59	30
<b>M04A</b>	<b>ANTIGOUT PREPARATIONS</b>				
	Estonia	2.44	2.54	2.91	15
	Latvia	0.88	1.04	1.34	29
	Lithuania	1.06	1.22	1.59	30
<b>M04AA</b>	<b>Preparations inhibiting uric acid production</b>				
	Estonia	2.43	2.53	2.90	15
	Latvia	0.88	1.04	1.34	29
	Lithuania	1.06	1.22	1.59	30
<b>M04AA01</b>	<b>allopurinol</b>				
	Estonia	2.43	2.53	2.90	15
	Latvia	0.88	1.03	1.26	22
	Lithuania	1.06	1.21	1.51	25
<b>M04AA03</b>	<b>febuxostat</b>				
	Estonia	-	-	-	
	Latvia	<0.01	0.01	0.08	992
	Lithuania	-	0.01	0.09	800
<b>M04AB</b>	<b>Preparations increasing uric acid excretion</b>				
	Estonia	0.02	0.01	0.01	
	Latvia	-	-	-	
	Lithuania	-	-	-	
<b>M04AB03</b>	<b>benzbromarone</b>				
	Estonia	0.02	0.01	0.01	
	Latvia	-	-	-	
	Lithuania	-	-	-	
<b>M05</b>	<b>DRUGS FOR TREATMENT OF BONE DISEASES</b>				
	Estonia	4.58	4.49	4.80	7
	Latvia	4.22	5.30	5.56	5
	Lithuania	3.38	3.26	3.57	10
<b>M05B</b>	<b>DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION</b>				
	Estonia	4.58	4.49	4.80	7
	Latvia	4.22	5.30	5.56	5
	Lithuania	3.38	3.26	3.57	10
<b>M05BA</b>	<b>Bisphosphonates</b>				
	Estonia	2.09	1.86	2.41	30
	Latvia	2.61	2.99	3.30	10
	Lithuania	1.80	1.71	1.76	3
<b>M05BA02</b>	<b>clodronic acid</b>				
	Estonia	-	-	-	
	Latvia	0.06	0.06	0.06	-4
	Lithuania	-	-	-	

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
<b>M05BA04</b>	<b>alendronic acid</b>				
	Estonia	0.65	0.56	0.92	64
	Latvia	<0.01	0.01	0.01	-13
	Lithuania	0.40	0.37	0.36	-3
<b>M05BA06</b>	<b>ibandronic acid</b>				
	Estonia	0.93	0.80	0.97	21
	Latvia	0.96	0.92	1.05	15
	Lithuania	0.73	0.73	0.81	11
<b>M05BA07</b>	<b>risedronic acid</b>				
	Estonia	0.52	0.49	0.52	6
	Latvia	1.59	2.00	2.18	9
	Lithuania	0.68	0.61	0.58	-5
<b>M05BB</b>	<b>Bisphosphonates, combinations</b>				
	Estonia	2.42	2.52	2.19	-13
	Latvia	1.19	1.82	1.66	-9
	Lithuania	0.94	0.95	0.80	-16
<b>M05BB03</b>	<b>alendronic acid and colecalciferol</b>				
	Estonia	2.42	2.52	2.19	-13
	Latvia	1.19	1.82	1.66	-9
	Lithuania	0.48	0.45	0.28	-38
<b>M05BB04</b>	<b>risedronic acid, calcium and colecalciferol, sequential</b>				
	Estonia	-	-	-	
	Latvia	-	-	-	
	Lithuania	0.46	0.50	0.51	2
<b>M05BX</b>	<b>Other drugs affecting bone structure and mineralization</b>				
	Estonia	0.06	0.10	0.19	90
	Latvia	0.42	0.49	0.61	23
	Lithuania	0.64	0.59	1.02	73
<b>M05BX03</b>	<b>strontium ranelate</b>				
	Estonia	0.06	0.09	0.09	
	Latvia	0.42	0.47	0.53	12
	Lithuania	0.64	0.53	0.58	9
<b>M05BX04</b>	<b>denosumab</b>				
	Estonia	<0.01	0.01	0.10	900
	Latvia	<0.01	0.02	0.08	277
	Lithuania	<0.01	0.07	0.43	514
<b>M09</b>	<b>OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM</b>				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	<0.01	<0.01	0.01	
	Lithuania	0.01	0.01	0.01	
<b>M09A</b>	<b>OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM</b>				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	<0.01	<0.01	0.01	
	Lithuania	0.01	0.01	0.01	

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
M09AX	Other drugs for disorders of the musculo-skeletal system	Estonia	<0.01	<0.01	<0.01
		Latvia	<0.01	<0.01	0.01
		Lithuania	0.01	0.01	0.01
M09AX01	hyaluronic acid	Estonia	<0.01	<0.01	<0.01
		Latvia	<0.01	<0.01	0.01
		Lithuania	0.01	0.01	0.01

### Consumption of drugs for treatment of bone disease (M05B)






ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
<b>N</b>	<b>NERVOUS SYSTEM</b>				
	Estonia	85.46	90.70	97.78	8
	Latvia	79.26	80.45	82.26	2
	Lithuania	118.85	123.86	136.40	10
<b>N02</b>	<b>ANALGESICS</b>				
	Estonia	12.56	13.29	14.13	6
	Latvia	13.63	12.22	11.08	-9
	Lithuania	14.58	13.71	14.11	3
<b>N02A</b>	<b>OPIOIDS</b>				
	Estonia	2.74	2.92	3.19	9
	Latvia	2.12	2.31	2.63	14
	Lithuania	2.93	1.71	1.84	8
<b>N02AA</b>	<b>Natural opium alkaloids</b>				
	Estonia	1.01	1.13	1.24	10
	Latvia	0.42	0.46	0.60	30
	Lithuania	0.27	0.29	0.32	10
<b>N02AA01</b>	<b>morphine</b>				
	Estonia	0.18	0.16	0.16	
	Latvia	0.09	0.09	0.10	3
	Lithuania	0.18	0.18	0.20	11
<b>N02AA05</b>	<b>oxycodone</b>				
	Estonia	0.15	0.13	0.12	-8
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
<b>N02AA08</b>	<b>dihydrocodeine</b>				
	Estonia	0.03	0.04	0.04	
	Latvia	0.09	0.09	0.09	6
	Lithuania	-	-	-	
<b>N02AA59</b>	<b>codeine, combinations excl. psycholeptics</b>				
	Estonia	0.65	0.80	0.92	15
	Latvia	0.24	0.28	0.41	46
	Lithuania	0.10	0.11	0.13	18
<b>N02AB</b>	<b>Phenylpiperidine derivatives</b>				
	Estonia	0.07	0.07	0.08	14
	Latvia	0.37	0.43	0.49	15
	Lithuania	0.62	0.64	0.67	5
<b>N02AB02</b>	<b>pethidine</b>				
	Estonia	0.02	0.02	0.02	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	0.03	0.03	0.03	
<b>N02AB03</b>	<b>fentanyl</b>				
	Estonia	0.05	0.05	0.06	20
	Latvia	0.37	0.42	0.49	15
	Lithuania	0.60	0.62	0.64	3


ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
<b>N02AX</b>	<b>Other opioids</b>				
	Estonia	1.66	1.72	1.86	8
	Latvia	1.32	1.42	1.54	9
	Lithuania	2.04	0.78	0.85	9
<b>N02AX02</b>	<b>tramadol</b>				
	Estonia	1.63	1.68	1.82	8
	Latvia	1.32	1.41	1.53	8
	Lithuania	2.04	0.78	0.85	9
<b>N02AX52</b>	<b>tramadol, combinations</b>				
	Estonia	0.03	0.03	0.04	33
	Latvia	<0.01	0.01	0.01	37
	Lithuania	-	<0.01	<0.01	
<b>N02B</b>	<b>OTHER ANALGESICS AND ANTIPIRETTICS</b>				
	Estonia	9.52	10.02	10.52	5
	Latvia	11.41	9.79	8.30	-15
	Lithuania	11.38	11.67	11.88	2
<b>N02BA</b>	<b>Salicylic acid and derivatives</b>				
	Estonia	2.26	2.13	2.13	
	Latvia	6.46	4.69	3.51	-25
	Lithuania	1.63	1.61	1.99	24
<b>N02BA01</b>	<b>acetylsalicylic acid</b>				
	Estonia	1.30	1.31	1.27	-3
	Latvia	0.72	0.71	0.62	-12
	Lithuania	1.39	1.40	1.39	-1
<b>N02BA03</b>	<b>choline salicylate</b>				
	Estonia	-	-	-	
	Latvia	-	-	-	
	Lithuania	0.14	0.10	0.08	-20

### Consumption of opioids (N02A)



ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
<b>N02BA51</b>	<b>acetylsalicylic acid, combinations excl. psycholeptics</b>				
	Estonia	0.95	0.82	0.86	5
	Latvia	5.74	3.98	2.89	-28
	Lithuania	0.11	0.11	0.52	373
<b>N02BB</b>	<b>Pyrazolones</b>				
	Estonia	0.04	0.02	0.01	-50
	Latvia	0.84	0.82	0.76	-7
	Lithuania	1.13	1.10	1.09	-1
<b>N02BB02</b>	<b>metamizole sodium</b>				
	Estonia	0.04	0.02	0.01	-50
	Latvia	0.84	0.82	0.76	-7
	Lithuania	1.13	1.10	1.09	-1
<b>N02BE</b>	<b>Anilides</b>				
	Estonia	7.21	7.84	8.37	7
	Latvia	4.09	4.26	4.02	-6
	Lithuania	8.62	8.96	8.79	-2
<b>N02BE01</b>	<b>paracetamol</b>				
	Estonia	4.77	5.16	5.67	10
	Latvia	1.64	1.81	1.72	-5
	Lithuania	2.74	3.14	3.03	-4
<b>N02BE51</b>	<b>paracetamol, combinations excl. psycholeptics</b>				
	Estonia	2.44	2.68	2.70	1
	Latvia	2.45	2.45	2.29	-6
	Lithuania	5.89	5.82	5.76	-1
<b>N02BG</b>	<b>Other analgesics and antipyretics</b>				
	Estonia	0.01	0.02	0.02	
	Latvia	0.01	0.01	0.01	44
	Lithuania	<0.01	0.01	0.01	
<b>N02BG07</b>	<b>flupirtine</b>				
	Estonia	0.01	0.02	0.02	
	Latvia	0.01	0.01	0.01	44
	Lithuania	<0.01	0.01	0.01	
<b>N02C</b>	<b>ANTIMIGRAINE PREPARATIONS</b>				
	Estonia	0.30	0.35	0.42	20
	Latvia	0.10	0.13	0.15	20
	Lithuania	0.27	0.33	0.40	21
<b>N02CC</b>	<b>Selective serotonin (5HT1) agonists</b>				
	Estonia	0.30	0.35	0.42	20
	Latvia	0.10	0.13	0.15	20
	Lithuania	0.27	0.33	0.40	21
<b>N02CC01</b>	<b>sumatriptan</b>				
	Estonia	0.26	0.30	0.35	17
	Latvia	0.09	0.11	0.13	20
	Lithuania	0.23	0.28	0.35	25

Consumption of other analgesics and antipyretics (N02B)




ATC code	ATC group / INN	DDD/1000/day			Relative change %	
		2010	2011	2012		
N02CC02	naratriptan	Estonia	<0.01	<0.01	<0.01	
		Latvia	-	-	-	
		Lithuania	0.01	0.01	0.01	
N02CC03	zolmitriptan	Estonia	0.03	0.03	0.03	
		Latvia	-	-	-	
		Lithuania	0.02	0.02	0.02	
N02CC04	rizatriptan	Estonia	<0.01	0.01	0.01	
		Latvia	-	-	-	
		Lithuania	<0.01	<0.01	<0.01	
N02CC06	eletriptan	Estonia	-	-	-	
		Latvia	0.01	0.01	0.01	6
		Lithuania	<0.01	0.01	<0.01	
N02CC07	frovatriptan	Estonia	<0.01	0.01	0.02	100
		Latvia	<0.01	0.01	0.01	24
		Lithuania	<0.01	0.01	0.01	
N03	ANTIEPILEPTICS	Estonia	6.20	6.29	6.93	10
		Latvia	6.53	6.97	7.22	4
		Lithuania	7.81	8.20	9.09	11
N03A	ANTIEPILEPTICS	Estonia	6.20	6.29	6.93	10
		Latvia	6.53	6.97	7.22	4
		Lithuania	7.81	8.20	9.09	11

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
<b>N03AA</b>	<b>Barbiturates and derivatives</b>				
	Estonia	0.55	0.50	0.53	6
	Latvia	-	-	-	
	Lithuania	-	-	-	
<b>N03AA02</b>	<b>phenobarbital</b>				
	Estonia	0.48	0.44	0.46	5
	Latvia	-	-	-	
	Lithuania	-	-	-	
<b>N03AA03</b>	<b>primidone</b>				
	Estonia	0.07	0.06	0.07	17
	Latvia	-	-	-	
	Lithuania	-	-	-	
<b>N03AB</b>	<b>Hydantoin derivatives</b>				
	Estonia	0.06	0.06	0.05	-17
	Latvia	-	-	-	
	Lithuania	-	-	-	
<b>N03AB02</b>	<b>phenytoin</b>				
	Estonia	0.06	0.06	0.05	-17
	Latvia	-	-	-	
	Lithuania	-	-	-	
<b>N03AD</b>	<b>Succinimide derivatives</b>				
	Estonia	0.01	0.01	0.01	
	Latvia	-	-	-	
	Lithuania	-	-	-	
<b>N03AD01</b>	<b>ethosuximide</b>				
	Estonia	0.01	0.01	0.01	
	Latvia	-	-	-	
	Lithuania	-	-	-	
<b>N03AE</b>	<b>Benzodiazepine derivatives</b>				
	Estonia	0.67	0.67	0.74	10
	Latvia	1.86	1.86	1.83	-1
	Lithuania	2.30	2.32	2.42	4
<b>N03AE01</b>	<b>clonazepam</b>				
	Estonia	0.67	0.67	0.74	10
	Latvia	1.86	1.86	1.83	-1
	Lithuania	2.30	2.32	2.42	4
<b>N03AF</b>	<b>Carboxamide derivatives</b>				
	Estonia	2.88	2.80	2.98	6
	Latvia	1.85	2.00	2.04	2
	Lithuania	2.54	2.64	2.92	11
<b>N03AF01</b>	<b>carbamazepine</b>				
	Estonia	2.11	2.02	2.14	6
	Latvia	1.49	1.63	1.68	3
	Lithuania	1.19	1.25	1.44	15

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
<b>N03AF02</b>	<b>oxcarbazepine</b>				
	Estonia	0.77	0.78	0.84	8
	Latvia	0.36	0.36	0.36	
	Lithuania	1.36	1.39	1.48	6
<b>N03AG</b>	<b>Fatty acid derivatives</b>				
	Estonia	1.16	1.18	1.27	8
	Latvia	1.49	1.59	1.65	3
	Lithuania	1.66	1.73	1.89	9
<b>N03AG01</b>	<b>valproic acid</b>				
	Estonia	1.15	1.17	1.26	8
	Latvia	1.49	1.59	1.65	3
	Lithuania	1.62	1.70	1.87	10
<b>N03AG04</b>	<b>vigabatrin</b>				
	Estonia	<0.01	0.01	0.01	
	Latvia	-	-	-	
	Lithuania	-	-	-	
<b>N03AG06</b>	<b>tiagabine</b>				
	Estonia	-	-	-	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	0.03	0.03	0.03	
<b>N03AX</b>	<b>Other antiepileptics</b>				
	Estonia	0.86	1.08	1.35	25
	Latvia	1.33	1.52	1.70	12
	Lithuania	1.31	1.5	1.86	24
<b>N03AX09</b>	<b>lamotrigine</b>				
	Estonia	0.27	0.30	0.36	20
	Latvia	0.49	0.54	0.54	
	Lithuania	0.49	0.54	0.67	24
<b>N03AX11</b>	<b>topiramate</b>				
	Estonia	0.18	0.17	0.18	6
	Latvia	0.22	0.22	0.22	
	Lithuania	0.31	0.33	0.36	9
<b>N03AX12</b>	<b>gabapentin</b>				
	Estonia	0.18	0.26	0.37	42
	Latvia	0.50	0.63	0.78	23
	Lithuania	0.25	0.26	0.28	8
<b>N03AX14</b>	<b>levetiracetam</b>				
	Estonia	0.02	0.10	0.16	60
	Latvia	<0.01	0.01	0.02	153
	Lithuania	0.01	0.02	0.04	100
<b>N03AX16</b>	<b>pregabalin</b>				
	Estonia	0.21	0.24	0.27	13
	Latvia	0.11	0.12	0.14	13
	Lithuania	0.25	0.37	0.52	41

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
<b>N03AX21</b>	<b>retigabine</b>				
	Estonia	-	-	<0.01	
	Latvia	<0.01	<0.01	0.01	
	Lithuania	-	-	-	
<b>N04</b>	<b>ANTI-PARKINSON DRUGS</b>				
	Estonia	3.50	3.57	3.81	7
	Latvia	4.18	4.23	4.35	3
	Lithuania	4.41	4.67	5.27	13
<b>N04A</b>	<b>ANTICHOLINERGIC AGENTS</b>				
	Estonia	0.61	0.61	0.59	-3
	Latvia	1.93	1.94	1.95	
	Lithuania	1.58	1.59	1.73	9
<b>N04AA</b>	<b>Tertiary amines</b>				
	Estonia	0.61	0.61	0.59	-3
	Latvia	1.93	1.94	1.95	
	Lithuania	1.58	1.59	1.73	9
<b>N04AA01</b>	<b>trihexyphenidyl</b>				
	Estonia	0.61	0.61	0.59	-3
	Latvia	1.93	1.94	1.95	
	Lithuania	1.58	1.59	1.73	9
<b>N04B</b>	<b>DOPAMINERGIC AGENTS</b>				
	Estonia	2.88	2.96	3.21	8
	Latvia	2.25	2.29	2.39	5
	Lithuania	2.83	3.07	3.54	15
<b>N04BA</b>	<b>Dopa and dopa derivatives</b>				
	Estonia	1.28	1.26	1.34	6
	Latvia	0.68	0.71	0.79	10
	Lithuania	1.36	1.40	1.54	10

### Consumption of antiepileptics (N03)



ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
<b>N04BA02</b>	<b>levodopa and decarboxylase inhibitor</b>				
	Estonia	1.06	1.03	1.08	5
	Latvia	0.59	0.61	0.67	10
	Lithuania	1.00	1.06	1.20	13
<b>N04BA03</b>	<b>levodopa, decarboxylase inhibitor and COMT inhibitor</b>				
	Estonia	0.22	0.23	0.26	13
	Latvia	0.10	0.10	0.12	14
	Lithuania	0.36	0.34	0.35	3
<b>N04BB</b>	<b>Adamantane derivatives</b>				
	Estonia	0.33	0.32	0.36	13
	Latvia	0.61	0.63	0.65	2
	Lithuania	0.75	0.78	0.84	8
<b>N04BB01</b>	<b>amantadine</b>				
	Estonia	0.33	0.32	0.36	13
	Latvia	0.61	0.63	0.65	2
	Lithuania	0.75	0.78	0.84	8
<b>N04BC</b>	<b>Dopamine agonists</b>				
	Estonia	0.77	0.82	0.84	2
	Latvia	0.36	0.42	0.47	11
	Lithuania	0.71	0.79	0.99	25
<b>N04BC01</b>	<b>bromocriptine</b>				
	Estonia	-	-	-	
	Latvia	0.02	0.02	0.02	2
	Lithuania	-	-	-	
<b>N04BC04</b>	<b>ropinirole</b>				
	Estonia	0.45	0.43	0.44	2
	Latvia	0.28	0.33	0.35	7
	Lithuania	0.44	0.46	0.63	37
<b>N04BC05</b>	<b>pramipexole</b>				
	Estonia	0.32	0.39	0.40	3
	Latvia	0.06	0.08	0.11	31
	Lithuania	0.27	0.34	0.35	3
<b>N04BD</b>	<b>Monoamine oxidase B inhibitors</b>				
	Estonia	0.50	0.55	0.67	22
	Latvia	0.59	0.52	0.49	-5
	Lithuania	<0.01	0.09	0.16	78
<b>N04BD01</b>	<b>selegiline</b>				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	0.59	0.52	0.49	-6
	Lithuania	-	-	-	
<b>N04BD02</b>	<b>rasagiline</b>				
	Estonia	0.50	0.55	0.67	22
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	<0.01	0.09	0.16	78




ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
<b>N04BX</b>	<b>Other dopaminergic agents</b>				
	Estonia	-	-	-	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	<0.01	<0.01	0.01	
<b>N04BX02</b>	<b>entacapone</b>				
	Estonia	-	-	-	
	Latvia	-	-	-	
	Lithuania	<0.01	<0.01	0.01	
<b>N05</b>	<b>PSYCHOLEPTICS</b>				
	Estonia	33.97	35.67	38.05	7
	Latvia	24.87	26.63	27.84	5
	Lithuania	51.00	53.47	59.38	11
<b>N05A</b>	<b>ANTIPSYCHOTICS</b>				
	Estonia	6.10	6.38	6.93	9
	Latvia	8.52	8.79	9.03	3
	Lithuania	9.41	10.12	11.49	14
<b>N05AA</b>	<b>Phenothiazines with aliphatic side-chain</b>				
	Estonia	0.23	0.18	0.20	11
	Latvia	0.15	0.16	0.18	14
	Lithuania	0.15	0.15	0.15	
<b>N05AA01</b>	<b>chlorpromazine</b>				
	Estonia	0.15	0.11	0.12	9
	Latvia	-	-	-	
	Lithuania	-	-	-	
<b>N05AA02</b>	<b>levomepromazine</b>				
	Estonia	0.09	0.07	0.08	14
	Latvia	0.15	0.16	0.18	14
	Lithuania	0.15	0.15	0.15	
<b>N05AB</b>	<b>Phenothiazines with piperazine structure</b>				
	Estonia	0.07	0.07	0.07	
	Latvia	-	-	-	
	Lithuania	0.13	0.09	0.08	-11
<b>N05AB02</b>	<b>fluphenazine</b>				
	Estonia	0.01	0.01	0.01	
	Latvia	-	-	-	
	Lithuania	0.13	0.09	0.08	-11
<b>N05AB03</b>	<b>perphenazine</b>				
	Estonia	0.06	0.07	0.06	-14
	Latvia	-	-	-	
	Lithuania	-	-	-	
<b>N05AD</b>	<b>Butyrophenone derivatives</b>				
	Estonia	1.19	1.15	1.16	1
	Latvia	2.86	2.85	3.00	5
	Lithuania	2.17	2.22	2.35	6

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
<b>N05AD01</b>	<b>haloperidol</b>				
	Estonia	0.82	0.79	0.80	1
	Latvia	2.62	2.59	2.72	5
	Lithuania	1.81	1.86	1.95	5
<b>N05AD03</b>	<b>melperone</b>				
	Estonia	0.37	0.36	0.36	
	Latvia	0.24	0.27	0.28	3
	Lithuania	0.36	0.35	0.40	14
<b>N05AE</b>	<b>Indole derivatives</b>				
	Estonia	0.14	0.17	0.17	
	Latvia	0.30	0.32	0.28	-13
	Lithuania	0.24	0.18	0.27	50
<b>N05AE03</b>	<b>sertindole</b>				
	Estonia	0.13	0.13	0.13	
	Latvia	0.09	0.12	0.10	-18
	Lithuania	-	-	-	
<b>N05AE04</b>	<b>ziprasidone</b>				
	Estonia	0.02	0.04	0.04	
	Latvia	0.22	0.20	0.18	-10
	Lithuania	0.24	0.18	0.27	50
<b>N05AF</b>	<b>Thioxanthene derivatives</b>				
	Estonia	0.79	0.75	0.74	-1
	Latvia	1.62	1.68	1.72	3
	Lithuania	0.86	0.96	0.97	1
<b>N05AF01</b>	<b>flupentixol</b>				
	Estonia	0.17	0.17	0.17	
	Latvia	0.28	0.29	0.31	6
	Lithuania	0.18	0.20	0.22	10
<b>N05AF03</b>	<b>chlorprothixene</b>				
	Estonia	0.29	0.27	0.27	
	Latvia	0.71	0.74	0.78	5
	Lithuania	0.32	0.38	0.34	-11
<b>N05AF05</b>	<b>zuclopenthixol</b>				
	Estonia	0.33	0.32	0.30	-6
	Latvia	0.64	0.65	0.64	-1
	Lithuania	0.35	0.39	0.41	5
<b>N05AH</b>	<b>Diazepines, oxazepines, thiazepines and oxepines</b>				
	Estonia	2.63	2.95	3.41	16
	Latvia	2.14	2.35	2.42	3
	Lithuania	3.54	4.07	4.82	18
<b>N05AH02</b>	<b>clozapine</b>				
	Estonia	0.48	0.51	0.54	6
	Latvia	0.63	0.57	0.50	-12
	Lithuania	0.37	0.39	0.42	8

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
<b>N05AH03</b>	<b>olanzapine</b>				
	Estonia	0.99	1.08	1.25	16
	Latvia	0.57	0.72	0.82	14
	Lithuania	1.71	1.90	2.30	21
<b>N05AH04</b>	<b>quetiapine</b>				
	Estonia	1.16	1.37	1.62	18
	Latvia	0.94	1.06	1.10	3
	Lithuania	1.46	1.79	2.10	17
<b>N05AL</b>	<b>Benzamides</b>				
	Estonia	0.10	0.10	0.10	
	Latvia	0.44	0.44	0.43	-3
	Lithuania	1.34	1.41	1.68	19
<b>N05AL01</b>	<b>sulpiride</b>				
	Estonia	0.05	0.05	0.05	
	Latvia	0.14	0.14	0.14	
	Lithuania	0.06	0.07	0.08	14
<b>N05AL03</b>	<b>tiapride</b>				
	Estonia	-	-	-	
	Latvia	-	-	-	
	Lithuania	0.90	0.96	1.19	24
<b>N05AL05</b>	<b>amisulpride</b>				
	Estonia	0.05	0.06	0.05	-17
	Latvia	0.30	0.30	0.29	-4
	Lithuania	0.38	0.38	0.41	8
<b>N05AN</b>	<b>Lithium</b>				
	Estonia	0.16	0.16	0.17	6
	Latvia	-	-	-	
	Lithuania	-	-	-	
<b>N05AN01</b>	<b>lithium</b>				
	Estonia	0.16	0.16	0.17	6
	Latvia	-	-	-	
	Lithuania	-	-	-	
<b>N05AX</b>	<b>Other antipsychotics</b>				
	Estonia	0.79	0.83	0.91	10
	Latvia	1.00	0.99	1.00	1
	Lithuania	0.98	1.05	1.18	12
<b>N05AX08</b>	<b>risperidone</b>				
	Estonia	0.49	0.50	0.55	10
	Latvia	0.73	0.73	0.75	2
	Lithuania	0.74	0.81	0.90	11
<b>N05AX12</b>	<b>aripiprazole</b>				
	Estonia	0.30	0.33	0.36	9
	Latvia	0.27	0.26	0.26	
	Lithuania	0.24	0.24	0.26	8


ATC code	ATC group / INN	DDD/1000/day			Relative change %	
		2010	2011	2012		
N05AX13	paliperidone	Estonia	-	-	-	
		Latvia	-	-	-	
		Lithuania	-	-	0.02	
N05B	ANXIOLYTICS	Estonia	13.10	13.33	13.83	4
		Latvia	11.66	12.62	13.67	8
		Lithuania	36.40	37.16	40.53	9
N05BA	Benzodiazepine derivatives	Estonia	13.10	13.33	13.83	4
		Latvia	11.44	12.37	13.40	8
		Lithuania	36.34	37.10	40.46	9
N05BA01	diazepam	Estonia	6.10	6.14	6.46	5
		Latvia	3.26	3.37	3.51	4
		Lithuania	5.95	5.84	6.08	4
N05BA02	chlordiazepoxide	Estonia	<0.01	<0.01	<0.01	
		Latvia	0.21	0.21	0.19	-10
		Lithuania	0.14	0.12	0.12	
N05BA03	medazepam	Estonia	-	-	-	
		Latvia	0.10	0.11	0.11	-2
		Lithuania	0.92	0.90	0.80	-11
N05BA04	oxazepam	Estonia	0.05	0.04	0.05	25
		Latvia	0.85	0.81	0.80	-1
		Lithuania	0.35	0.33	0.33	

### Consumption of antipsychotics (N05A)




ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
<b>N05BA05</b>	<b>potassium clorazepate</b>				
	Estonia	-	-	-	
	Latvia	-	-	-	
	Lithuania	0.70	0.71	0.77	8
<b>N05BA06</b>	<b>lorazepam</b>				
	Estonia	<0.01	<0.01	0.01	
	Latvia	0.48	0.59	0.75	28
	Lithuania	18.77	18.57	19.97	8
<b>N05BA08</b>	<b>bromazepam</b>				
	Estonia	1.41	1.40	1.43	2
	Latvia	2.32	2.54	2.85	12
	Lithuania	4.83	5.21	5.91	13
<b>N05BA12</b>	<b>alprazolam</b>				
	Estonia	5.55	5.74	5.89	3
	Latvia	4.23	4.73	5.18	10
	Lithuania	4.69	5.43	6.49	20
<b>N05BE</b>	<b>Azaspirodecanedione derivatives</b>				
	Estonia	<0.01	-	-	
	Latvia	0.22	0.26	0.27	7
	Lithuania	0.06	0.06	0.06	
<b>N05BE01</b>	<b>buspiron</b>				
	Estonia	<0.01	-	-	
	Latvia	0.22	0.26	0.27	7
	Lithuania	0.06	0.06	0.06	
<b>N05C</b>	<b>HYPNOTICS AND SEDATIVES</b>				
	Estonia	14.77	15.96	17.29	8
	Latvia	4.69	5.21	5.13	-2
	Lithuania	5.19	6.19	7.36	19

### Consumption of anxiolytics (N05B)



ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
<b>N05CD</b>	<b>Benzodiazepine derivatives</b>				
	Estonia	2.08	1.94	1.45	-25
	Latvia	1.15	1.11	0.38	-66
	Lithuania	1.74	1.85	1.75	-5
<b>N05CD02</b>	<b>nitrazepam</b>				
	Estonia	1.77	1.60	1.03	-36
	Latvia	0.89	0.84	0.05	-94
	Lithuania	1.12	1.01	0.65	-36
<b>N05CD04</b>	<b>estazolam</b>				
	Estonia	-	-	-	
	Latvia	-	-	-	
	Lithuania	0.05	0.05	0.06	20
<b>N05CD05</b>	<b>triazolam</b>				
	Estonia	0.04	0.04	0.05	25
	Latvia	0.11	0.10	0.14	33
	Lithuania	0.41	0.60	0.83	38
<b>N05CD08</b>	<b>midazolam</b>				
	Estonia	0.27	0.30	0.37	23
	Latvia	0.15	0.17	0.19	15
	Lithuania	0.16	0.19	0.21	11
<b>N05CF</b>	<b>Benzodiazepine related drugs</b>				
	Estonia	12.62	13.94	15.76	13
	Latvia	3.54	4.10	4.75	16
	Lithuania	3.44	4.32	5.59	29
<b>N05CF01</b>	<b>zopiclone</b>				
	Estonia	10.63	11.67	13.09	12
	Latvia	2.46	2.84	3.30	16
	Lithuania	1.62	2.09	2.91	39
<b>N05CF02</b>	<b>zolpidem</b>				
	Estonia	1.99	2.27	2.67	18
	Latvia	1.08	1.27	1.45	14
	Lithuania	1.82	2.23	2.68	20
<b>N05CH</b>	<b>Melatonin receptor agonists</b>				
	Estonia	0.07	0.08	0.09	13
	Latvia	-	-	-	
	Lithuania	0.01	0.01	0.02	100
<b>N05CH01</b>	<b>melatonin</b>				
	Estonia	0.07	0.08	0.09	13
	Latvia	-	-	-	
	Lithuania	0.01	0.01	0.02	100
<b>N06</b>	<b>PSYCHOANALEPTICS</b>				
	Estonia	21.39	23.49	25.55	9
	Latvia	17.53	17.16	17.66	3
	Lithuania	30.18	33.10	37.01	12

## Consumption of hypnotics and sedatives (N05C)




ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
<b>N06A</b>	<b>ANTIDEPRESSANTS</b>				
	Estonia	15.83	17.81	19.91	12
	Latvia	7.72	8.65	9.47	9
	Lithuania	19.16	20.76	23.40	13
<b>N06AA</b>	<b>Non-selective monoamine reuptake inhibitors</b>				
	Estonia	2.05	1.99	2.06	4
	Latvia	1.60	1.59	1.64	3
	Lithuania	1.42	1.42	1.46	3
<b>N06AA04</b>	<b>clomipramine</b>				
	Estonia	0.07	0.06	0.07	17
	Latvia	0.20	0.20	0.20	-2
	Lithuania	0.07	0.07	0.07	
<b>N06AA09</b>	<b>amitriptyline</b>				
	Estonia	1.47	1.44	1.50	4
	Latvia	1.20	1.20	1.25	4
	Lithuania	1.29	1.30	1.34	3
<b>N06AA10</b>	<b>nortriptyline</b>				
	Estonia	0.51	0.48	0.49	2
	Latvia	0.20	0.19	0.19	
	Lithuania	0.06	0.06	0.06	
<b>N06AB</b>	<b>Selective serotonin reuptake inhibitors</b>				
	Estonia	10.18	11.46	12.79	12
	Latvia	4.65	5.44	6.00	10
	Lithuania	12.03	13.25	14.94	13
<b>N06AB03</b>	<b>fluoxetine</b>				
	Estonia	2.31	2.42	2.55	5
	Latvia	0.28	0.31	0.32	2
	Lithuania	0.45	0.50	0.53	6

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
<b>N06AB04</b>	<b>citalopram</b>				
	Estonia	1.86	1.65	1.66	1
	Latvia	0.43	0.48	0.54	14
	Lithuania	1.17	1.09	1.12	3
<b>N06AB05</b>	<b>paroxetine</b>				
	Estonia	1.59	1.70	1.87	10
	Latvia	1.50	1.72	1.88	9
	Lithuania	2.13	2.40	2.65	10
<b>N06AB06</b>	<b>sertraline</b>				
	Estonia	1.45	1.64	2.03	24
	Latvia	0.68	0.63	0.70	11
	Lithuania	3.99	4.09	4.40	8
<b>N06AB08</b>	<b>fluvoxamine</b>				
	Estonia	0.01	0.01	<0.01	
	Latvia	0.12	0.12	0.14	16
	Lithuania	0.22	0.19	0.17	-11
<b>N06AB10</b>	<b>escitalopram</b>				
	Estonia	2.96	4.03	4.67	16
	Latvia	1.64	2.17	2.42	11
	Lithuania	4.08	5.00	6.08	22
<b>N06AX</b>	<b>Other antidepressants</b>				
	Estonia	3.60	4.35	5.05	16
	Latvia	1.46	1.62	1.82	13
	Lithuania	5.71	6.08	7.00	15
<b>N06AX05</b>	<b>trazodone</b>				
	Estonia	-	-	-	
	Latvia	-	-	-	
	Lithuania	0.09	0.10	0.11	10
<b>N06AX11</b>	<b>mirtazapine</b>				
	Estonia	1.21	1.41	1.52	8
	Latvia	0.48	0.55	0.59	7
	Lithuania	2.94	3.14	3.32	6
<b>N06AX12</b>	<b>bupropion</b>				
	Estonia	0.17	0.18	0.21	17
	Latvia	0.13	0.14	0.15	8
	Lithuania	0.17	0.17	0.19	12
<b>N06AX14</b>	<b>tianeptine</b>				
	Estonia	0.65	0.79	0.90	14
	Latvia	0.23	0.26	0.34	30
	Lithuania	0.44	0.47	0.45	-4
<b>N06AX16</b>	<b>venlafaxine</b>				
	Estonia	1.02	1.26	1.62	29
	Latvia	0.39	0.43	0.47	8
	Lithuania	0.77	0.77	0.82	6



ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
<b>N06AX17</b>	<b>milnacipran</b>				
	Estonia	0.03	0.04	0.04	
	Latvia	0.01	0.01	<0.01	
	Lithuania	-	-	-	
<b>N06AX21</b>	<b>duloxetine</b>				
	Estonia	0.48	0.61	0.70	15
	Latvia	0.17	0.17	0.17	3
	Lithuania	1.05	1.06	1.20	13
<b>N06AX22</b>	<b>agomelatine</b>				
	Estonia	0.03	0.06	0.07	17
	Latvia	0.05	0.05	0.09	68
	Lithuania	0.25	0.37	0.92	149
<b>N06B</b>	<b>PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS</b>				
	Estonia	0.43	0.48	0.56	17
	Latvia	6.03	6.25	6.35	2
	Lithuania	8.23	8.45	9.44	12
<b>N06BA</b>	<b>Centrally acting sympathomimetics</b>				
	Estonia	0.07	0.17	0.27	59
	Latvia	0.01	0.01	0.01	15
	Lithuania	0.01	0.01	0.01	
<b>N06BA04</b>	<b>methylphenidate</b>				
	Estonia	0.07	0.17	0.26	53
	Latvia	<0.01	0.01	0.01	15
	Lithuania	0.01	0.01	0.01	
<b>N06BA09</b>	<b>atomoxetine</b>				
	Estonia	<0.01	<0.01	0.02	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	

### Consumption of antidepressants (N06A)



ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
<b>N06BC</b>	<b>Xanthine derivatives</b>				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	<0.01	0.01	<0.01	
	Lithuania	-	-	-	
<b>N06BC01</b>	<b>caffeine</b>				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	<0.01	0.01	<0.01	
	Lithuania	-	-	-	
<b>N06BX</b>	<b>Other psychostimulants and nootropics</b>				
	Estonia	0.35	0.31	0.29	-6
	Latvia	6.02	6.23	6.34	2
	Lithuania	8.22	8.45	9.43	12
<b>N06BX02</b>	<b>pyritinol</b>				
	Estonia	-	-	-	
	Latvia	0.04	0.04	0.03	-10
	Lithuania	-	-	-	
<b>N06BX03</b>	<b>piracetam</b>				
	Estonia	0.31	0.27	0.26	-4
	Latvia	1.78	1.87	1.90	2
	Lithuania	0.57	0.61	0.74	21
<b>N06BX18</b>	<b>vinpocetine</b>				
	Estonia	0.04	0.04	0.03	-25
	Latvia	4.20	4.32	4.40	2
	Lithuania	7.66	7.84	8.69	11
<b>N06D</b>	<b>ANTI-DEMENTIA DRUGS</b>				
	Estonia	5.14	5.20	5.07	-3
	Latvia	3.79	2.27	1.85	-19
	Lithuania	2.80	3.89	4.18	7
<b>N06DA</b>	<b>Anticholinesterases</b>				
	Estonia	0.07	0.13	0.22	69
	Latvia	<0.01	0.04	0.06	55
	Lithuania	0.54	0.68	0.85	25
<b>N06DA02</b>	<b>donepezil</b>				
	Estonia	0.07	0.13	0.22	69
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	0.54	0.68	0.85	25
<b>N06DA04</b>	<b>galantamine</b>				
	Estonia	<0.01	-	<0.01	
	Latvia	<0.01	0.04	0.06	58
	Lithuania	-	-	-	
<b>N06DX</b>	<b>Other anti-dementia drugs</b>				
	Estonia	5.06	5.07	4.85	-4
	Latvia	3.79	2.23	1.79	-20
	Lithuania	2.25	3.21	3.33	4

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
<b>N06DX01</b>	<b>memantine</b>				
	Estonia	0.07	0.06	0.06	
	Latvia	0.06	0.06	0.07	14
	Lithuania	0.33	0.40	0.47	18
<b>N06DX02</b>	<b>Ginkgo folium</b>				
	Estonia	5.00	5.01	4.78	-5
	Latvia	3.73	2.17	1.72	-21
	Lithuania	1.92	2.81	2.87	2
<b>N07</b>	<b>OTHER NERVOUS SYSTEM DRUGS</b>				
	Estonia	7.84	8.39	9.33	11
	Latvia	12.51	13.24	14.12	7
	Lithuania	10.87	10.72	11.54	8
<b>N07A</b>	<b>PARASYMPATHOMIMETICS</b>				
	Estonia	0.29	0.30	0.30	
	Latvia	0.08	0.09	0.09	
	Lithuania	0.02	0.02	0.02	
<b>N07AA</b>	<b>Anticholinesterases</b>				
	Estonia	0.29	0.29	0.30	3
	Latvia	0.08	0.09	0.09	
	Lithuania	0.02	0.02	0.02	
<b>N07AA01</b>	<b>neostigmine</b>				
	Estonia	0.04	0.04	0.04	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	0.02	0.02	0.02	
<b>N07AA02</b>	<b>pyridostigmine</b>				
	Estonia	0.24	0.24	0.25	4
	Latvia	0.08	0.09	0.09	-2
	Lithuania	-	-	-	
<b>N07AA51</b>	<b>neostigmine, combinations</b>				
	Estonia	0.01	0.01	0.01	
	Latvia	-	-	-	
	Lithuania	-	-	-	
<b>N07B</b>	<b>DRUGS USED IN ADDICTIVE DISORDERS</b>				
	Estonia	2.38	2.61	2.82	8
	Latvia	0.20	0.22	0.24	11
	Lithuania	0.83	0.80	0.82	3
<b>N07BA</b>	<b>Drugs used in nicotine dependence</b>				
	Estonia	0.83	0.94	1.07	14
	Latvia	0.17	0.18	0.20	7
	Lithuania	0.36	0.37	0.39	5
<b>N07BA01</b>	<b>nicotine</b>				
	Estonia	0.82	0.92	1.04	13
	Latvia	0.15	0.17	0.18	7
	Lithuania	0.35	0.36	0.38	6

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
<b>N07BA03</b>	<b>varenicline</b>				
	Estonia	0.01	0.02	0.02	
	Latvia	0.01	0.01	0.01	15
	Lithuania	0.01	0.01	0.02	100
<b>N07BB</b>	<b>Drugs used in alcohol dependence</b>				
	Estonia	0.16	0.16	0.18	13
	Latvia	0.01	0.01	0.01	16
	Lithuania	0.01	0.02	0.01	-50
<b>N07BB01</b>	<b>disulfiram</b>				
	Estonia	0.15	0.15	0.18	20
	Latvia	-	-	-	
	Lithuania	-	<0.01	-	
<b>N07BB04</b>	<b>naltrexone</b>				
	Estonia	0.01	0.01	0.01	
	Latvia	0.01	0.01	0.01	16
	Lithuania	0.01	0.02	0.01	-50
<b>N07BC</b>	<b>Drugs used in opioid dependence</b>				
	Estonia	1.39	1.52	1.57	3
	Latvia	0.02	0.03	0.03	29
	Lithuania	0.46	0.41	0.42	2
<b>N07BC01</b>	<b>buprenorphine</b>				
	Estonia	<0.01	<0.01	-	
	Latvia	0.01	0.01	0.02	97
	Lithuania	<0.01	<0.01	0.01	
<b>N07BC02</b>	<b>methadone</b>				
	Estonia	1.37	1.51	1.55	3
	Latvia	-	-	-	
	Lithuania	0.46	0.41	0.41	
<b>N07BC51</b>	<b>buprenorphine, combinations</b>				
	Estonia	0.01	0.01	0.01	
	Latvia	0.02	0.02	0.02	
	Lithuania	-	-	-	
<b>N07C</b>	<b>ANTIVERTIGO PREPARATIONS</b>				
	Estonia	5.18	5.48	6.20	13
	Latvia	12.22	12.92	13.78	7
	Lithuania	10.01	9.90	10.69	8
<b>N07CA</b>	<b>Antivertigo preparations</b>				
	Estonia	5.18	5.48	6.20	13
	Latvia	12.22	12.92	13.78	7
	Lithuania	10.01	9.90	10.69	8
<b>N07CA01</b>	<b>betahistine</b>				
	Estonia	3.15	3.70	4.35	18
	Latvia	6.43	7.54	8.93	18
	Lithuania	2.71	3.62	4.53	25

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
<b>N07CA02</b>	<b>cinnarizine</b>				
	Estonia	2.03	1.79	1.85	3
	Latvia	3.95	3.58	3.25	-9
	Lithuania	5.22	3.98	3.72	-7
<b>N07CA52</b>	<b>cinnarizine, combinations</b>				
	Estonia	-	-	-	
	Latvia	1.84	1.80	1.60	-11
	Lithuania	2.08	2.30	2.44	6
<b>N07X</b>	<b>OTHER NERVOUS SYSTEM DRUGS</b>				
	Estonia	-	<0.01	0.01	
	Latvia	<0.01	0.01	0.01	-13
	Lithuania	<0.01	<0.01	0.01	
<b>N07XX</b>	<b>Other nervous system drugs</b>				
	Estonia	-	<0.01	0.01	
	Latvia	<0.01	0.01	0.01	-13
	Lithuania	<0.01	<0.01	0.01	
<b>N07XX02</b>	<b>riluzole</b>				
	Estonia	-	<0.01	0.01	
	Latvia	<0.01	0.01	0.01	-18
	Lithuania	<0.01	<0.01	0.01	

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
<b>P</b>	<b>ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS</b>				
	Estonia	0.80	0.78	0.84	8
	Latvia	0.67	0.71	0.74	4
	Lithuania	0.60	0.73	0.77	5
<b>P01</b>	<b>ANTIPROTOZOALS</b>				
	Estonia	0.68	0.64	0.69	8
	Latvia	0.35	0.37	0.37	2
	Lithuania	0.27	0.39	0.38	-3
<b>P01A</b>	<b>AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES</b>				
	Estonia	<0.01	-	-	
	Latvia	0.23	0.25	0.24	-1
	Lithuania	-	-	-	
<b>P01AB</b>	<b>Nitroimidazole derivatives</b>				
	Estonia	-	-	-	
	Latvia	0.23	0.25	0.24	-1
	Lithuania	0.10	0.20	0.17	-15
<b>P01AB01</b>	<b>metronidazole</b>				
	Estonia	-	-	-	
	Latvia	0.22	0.25	0.24	-1
	Lithuania	0.09	0.19	0.16	-16
<b>P01AB02</b>	<b>tinidazole</b>				
	Estonia	-	-	-	
	Latvia	-	-	-	
	Lithuania	0.01	0.01	0.01	
<b>P01AB03</b>	<b>ornidazole</b>				
	Estonia	-	-	-	
	Latvia	0.01	<0.01	<0.01	
	Lithuania	-	-	-	
<b>P01B</b>	<b>ANTIMALARIALS</b>				
	Estonia	0.68	0.64	0.68	6
	Latvia	0.13	0.12	0.13	9
	Lithuania	0.17	0.18	0.21	17
<b>P01BA</b>	<b>Aminoquinolines</b>				
	Estonia	0.66	0.63	0.66	5
	Latvia	0.12	0.12	0.13	10
	Lithuania	0.17	0.18	0.21	17
<b>P01BA02</b>	<b>hydroxychloroquine</b>				
	Estonia	0.66	0.63	0.66	5
	Latvia	0.12	0.12	0.13	10
	Lithuania	0.17	0.18	0.21	17
<b>P01BB</b>	<b>Biguanides</b>				
	Estonia	0.01	0.01	0.01	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	<0.01	<0.01	<0.01	

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
<b>P01BB51</b>	<b>proguanil, combinations</b>				
	Estonia	0.01	0.01	0.01	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	<0.01	<0.01	<0.01	
<b>P01BC</b>	<b>Methanolquinolines</b>				
	Estonia	0.01	<0.01	0.01	
	Latvia	-	-	-	
	Lithuania	-	-	-	
<b>P01BC02</b>	<b>mefloquine</b>				
	Estonia	0.01	<0.01	0.01	
	Latvia	-	-	-	
	Lithuania	-	-	-	
<b>P02</b>	<b>ANTHELMINTICS</b>				
	Estonia	0.13	0.14	0.15	7
	Latvia	0.31	0.34	0.36	6
	Lithuania	0.33	0.35	0.38	9
<b>P02C</b>	<b>ANTINEMATODAL AGENTS</b>				
	Estonia	0.13	0.14	0.15	7
	Latvia	0.31	0.34	0.36	6
	Lithuania	0.33	0.35	0.38	9
<b>P02CA</b>	<b>Benzimidazole derivatives</b>				
	Estonia	0.12	0.14	0.15	7
	Latvia	0.17	0.18	0.19	3
	Lithuania	0.27	0.28	0.32	14
<b>P02CA01</b>	<b>mebendazole</b>				
	Estonia	0.12	0.14	0.15	7
	Latvia	0.17	0.18	0.19	3
	Lithuania	0.27	0.28	0.32	14
<b>P02CC</b>	<b>Tetrahydropyrimidine derivatives</b>				
	Estonia	-	-	-	
	Latvia	0.13	0.15	0.16	8
	Lithuania	0.05	0.06	0.06	
<b>P02CC01</b>	<b>pyrantel</b>				
	Estonia	-	-	-	
	Latvia	0.13	0.15	0.16	8
	Lithuania	0.05	0.06	0.06	
<b>P02CE</b>	<b>Imidazothiazole derivatives</b>				
	Estonia	<0.01	<0.01	-	
	Latvia	0.01	0.01	0.01	11
	Lithuania	0.01	0.01	0.01	
<b>P02CE01</b>	<b>levamisole</b>				
	Estonia	<0.01	<0.01	-	
	Latvia	0.01	0.01	0.01	11
	Lithuania	0.01	0.01	0.01	

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
<b>R</b>	<b>RESPIRATORY SYSTEM</b>				
	Estonia	60.26	62.67	69.05	10
	Latvia	53.92	53.11	56.54	6
	Lithuania	55.88	57.48	63.31	10
<b>R01</b>	<b>NASAL PREPARATIONS</b>				
	Estonia	26.28	26.65	29.88	12
	Latvia	22.74	20.94	23.94	14
	Lithuania	20.32	20.51	23.27	13
<b>R01A</b>	<b>DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE</b>				
	Estonia	24.20	24.56	27.92	14
	Latvia	22.42	20.64	23.62	14
	Lithuania	19.69	19.85	22.49	13
<b>R01AA</b>	<b>Sympathomimetics, plain</b>				
	Estonia	19.10	18.87	20.94	11
	Latvia	18.90	16.80	19.33	15
	Lithuania	14.71	14.34	16.41	14
<b>R01AA05</b>	<b>oxymetazoline</b>				
	Estonia	0.21	0.07	-	
	Latvia	0.39	0.12	0.29	129
	Lithuania	0.15	0.04	0.35	775
<b>R01AA07</b>	<b>xylometazoline</b>				
	Estonia	18.69	18.64	20.87	12
	Latvia	15.27	15.99	16.84	5
	Lithuania	14.25	14.03	15.64	11
<b>R01AA08</b>	<b>naphazoline</b>				
	Estonia	0.20	0.17	0.07	-59
	Latvia	3.24	0.68	2.20	221
	Lithuania	0.31	0.27	0.42	56
<b>R01AB</b>	<b>Sympathomimetics, combinations excl. corticosteroids</b>				
	Estonia	-	-	0.74	
	Latvia	-	-	-	
	Lithuania	2.59	2.80	2.94	5
<b>R01AB01</b>	<b>phenylephrine and dimetinden</b>				
	Estonia	-	-	-	
	Latvia	-	-	-	
	Lithuania	2.45	2.45	2.60	6
<b>R01AB06</b>	<b>xylometazoline</b>				
	Estonia	-	-	0.74	
	Latvia	-	-	-	
	Lithuania	0.15	0.35	0.34	-3
<b>R01AC</b>	<b>Antiallergic agents, excl. corticosteroids</b>				
	Estonia	0.22	0.17	0.24	41
	Latvia	0.05	0.05	0.08	55
	Lithuania	0.07	0.08	0.12	50



ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
<b>R01AC03</b>	<b>azelastine</b>				
	Estonia	0.22	0.17	0.24	41
	Latvia	0.05	0.05	0.08	55
	Lithuania	0.07	0.08	0.12	50
<b>R01AD</b>	<b>Corticosteroids</b>				
	Estonia	4.88	5.52	6.00	9
	Latvia	3.47	3.79	4.20	11
	Lithuania	2.32	2.63	3.02	15
<b>R01AD01</b>	<b>beclometasone</b>				
	Estonia	0.35	0.23	0.21	-9
	Latvia	0.24	0.21	0.21	-2
	Lithuania	0.32	0.18	0.01	-94
<b>R01AD05</b>	<b>budesonide</b>				
	Estonia	1.48	1.10	1.09	-1
	Latvia	1.45	1.43	1.44	
	Lithuania	0.30	0.26	0.26	
<b>R01AD08</b>	<b>fluticasone</b>				
	Estonia	0.93	0.75	0.76	1
	Latvia	0.70	0.70	0.74	6
	Lithuania	0.40	0.39	0.41	5
<b>R01AD09</b>	<b>mometasone</b>				
	Estonia	1.83	2.29	2.33	2
	Latvia	0.57	0.89	1.12	25
	Lithuania	1.10	1.31	1.71	31
<b>R01AD12</b>	<b>fluticasone furoate</b>				
	Estonia	0.30	1.16	1.61	39
	Latvia	0.51	0.55	0.70	27
	Lithuania	0.20	0.49	0.64	31
<b>R01B</b>	<b>NASAL DECONGESTANTS FOR SYSTEMIC USE</b>				
	Estonia	2.08	2.08	1.96	-6
	Latvia	0.32	0.30	0.32	8
	Lithuania	0.63	0.66	0.78	18
<b>R01BA</b>	<b>Sympathomimetics</b>				
	Estonia	2.08	2.08	1.96	-6
	Latvia	0.32	0.30	0.32	8
	Lithuania	0.63	0.66	0.78	18
<b>R01BA02</b>	<b>pseudoephedrine</b>				
	Estonia	1.04	1.08	1.20	11
	Latvia	-	-	-	
	Lithuania	0.02	0.02	0.01	-50
<b>R01BA52</b>	<b>pseudoephedrine, combinations</b>				
	Estonia	1.04	1.01	0.76	-25
	Latvia	0.32	0.30	0.32	8
	Lithuania	0.53	0.56	0.67	20


ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
<b>R01BA53</b>	<b>phenylephrine, combinations</b>				
	Estonia	-	-	-	
	Latvia	-	-	-	
	Lithuania	0.08	0.08	0.10	25
<b>R02</b>	<b>THROAT PREPARATIONS</b>				
	Estonia	0.25	0.23	0.38	65
	Latvia	0.88	0.92	0.81	-12
	Lithuania	2.36	2.47	2.71	10
<b>R02A</b>	<b>THROAT PREPARATIONS</b>				
	Estonia	0.25	0.23	0.38	65
	Latvia	0.88	0.92	0.81	-12
	Lithuania	2.36	2.47	2.71	10
<b>R02AA</b>	<b>Antiseptics</b>				
	Estonia	0.25	0.21	0.32	52
	Latvia	0.88	0.92	0.81	-12
	Lithuania	2.12	2.22	2.43	9
<b>R02AA01</b>	<b>ambazone</b>				
	Estonia	-	-	-	
	Latvia	-	-	-	
	Lithuania	0.18	0.11	0.11	
<b>R02AA02</b>	<b>dequalinium</b>				
	Estonia	0.24	0.21	0.31	48
	Latvia	0.56	0.59	0.52	-12
	Lithuania	0.37	0.40	0.47	18
<b>R02AA05</b>	<b>chlorhexidine</b>				
	Estonia	0.02	<0.01	<0.01	
	Latvia	0.32	0.33	0.29	-11
	Lithuania	0.26	0.20	0.15	-25
<b>R02AA06</b>	<b>cetylpyridinium</b>				
	Estonia	-	-	-	
	Latvia	-	-	-	
	Lithuania	0.12	0.21	0.29	38
<b>R02AA16</b>	<b>benzalkonium</b>				
	Estonia	-	-	-	
	Latvia	-	-	-	
	Lithuania	0.05	0.09	0.10	11
<b>R02AA20</b>	<b>various antiseptics</b>				
	Estonia	-	-	-	
	Latvia	-	-	-	
	Lithuania	1.15	1.21	1.31	8
<b>R02AX</b>	<b>Other throat preparations</b>				
	Estonia	-	0.02	0.06	200
	Latvia	-	-	-	
	Lithuania	-	0.01	0.04	300

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
R02AX01	flurbiprofen				
	Estonia	-	0.02	0.06	200
	Latvia	-	-	-	
	Lithuania	-	0.01	0.04	300
R03	DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES				
	Estonia	18.21	18.64	20.16	8
	Latvia	17.73	17.77	17.71	
	Lithuania	18.99	18.79	20.91	11
R03A	ADRENERGICS, INHALANTS				
	Estonia	11.87	12.28	13.66	11
	Latvia	11.81	11.65	12.38	6
	Lithuania	12.82	12.72	14.62	15
R03AC	Selective beta-2-adrenoreceptor agonists				
	Estonia	5.23	5.10	5.46	7
	Latvia	5.99	6.16	6.40	4
	Lithuania	6.12	6.46	7.19	11
R03AC02	salbutamol				
	Estonia	2.68	2.64	2.75	4
	Latvia	5.13	5.25	5.54	5
	Lithuania	4.93	5.32	6.03	13
R03AC04	fenoterol				
	Estonia	0.44	0.39	0.38	-3
	Latvia	0.62	0.59	0.58	-2
	Lithuania	0.05	0.05	0.04	-20
R03AC12	salmeterol				
	Estonia	0.46	0.38	0.34	-11
	Latvia	0.08	0.18	0.14	-26
	Lithuania	0.49	0.43	0.39	-9
R03AC13	formoterol				
	Estonia	1.64	1.60	1.46	-9
	Latvia	0.15	0.12	0.09	-21
	Lithuania	0.66	0.67	0.72	7
R03AC18	indacaterol				
	Estonia	-	0.09	0.53	489
	Latvia	<0.01	0.02	0.06	246
	Lithuania	-	-	-	
R03AK	Adrenergics and other drugs for obstructive airway diseases				
	Estonia	6.64	7.18	8.20	14
	Latvia	5.83	5.49	5.97	9
	Lithuania	6.70	6.26	7.44	19
R03AK03	fenoterol and other drugs for obstructive airway diseases				
	Estonia	0.62	0.75	0.78	4
	Latvia	2.02	1.29	1.28	-1
	Lithuania	-	-	-	

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
<b>R03AK06</b>	<b>salmeterol and other drugs for obstructive airway diseases</b>				
	Estonia	3.21	3.36	3.75	12
	Latvia	2.58	2.78	2.96	7
	Lithuania	3.64	3.08	3.89	26
<b>R03AK07</b>	<b>formoterol and other drugs for obstructive airway diseases</b>				
	Estonia	2.80	3.08	3.67	19
	Latvia	1.22	1.42	1.72	21
	Lithuania	3.06	3.18	3.55	12
<b>R03B</b>	<b>OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS</b>				
	Estonia	3.56	3.53	3.58	1
	Latvia	2.36	2.44	1.43	-41
	Lithuania	3.49	3.49	3.64	4
<b>R03BA</b>	<b>Glucocorticoids</b>				
	Estonia	2.40	2.31	1.84	-20
	Latvia	1.71	1.77	1.33	-25
	Lithuania	1.57	1.58	1.56	-1
<b>R03BA01</b>	<b>beclometasone</b>				
	Estonia	0.91	0.72	0.12	-83
	Latvia	0.88	0.89	0.25	-72
	Lithuania	0.13	0.13	0.01	-92
<b>R03BA02</b>	<b>budesonide</b>				
	Estonia	1.23	1.29	1.34	4
	Latvia	0.43	0.45	0.37	-19
	Lithuania	0.65	0.66	0.68	3
<b>R03BA05</b>	<b>fluticasone</b>				
	Estonia	0.26	0.30	0.37	23
	Latvia	0.40	0.43	0.72	67
	Lithuania	0.79	0.80	0.87	9
<b>R03BB</b>	<b>Anticholinergics</b>				
	Estonia	1.16	1.22	1.74	43
	Latvia	0.65	0.67	0.11	-84
	Lithuania	1.93	1.91	2.08	9
<b>R03BB01</b>	<b>ipratropium bromide</b>				
	Estonia	1.16	1.22	1.19	-2
	Latvia	-	-	-	
	Lithuania	<0.01	<0.01	<0.01	
<b>R03BB04</b>	<b>tiotropium bromide</b>				
	Estonia	<0.01	<0.01	0.55	
	Latvia	0.65	0.67	0.11	-84
	Lithuania	1.92	1.91	2.08	9
<b>R03C</b>	<b>ADRENERGICS FOR SYSTEMIC USE</b>				
	Estonia	0.29	0.29	0.26	-10
	Latvia	0.22	0.23	0.22	-3
	Lithuania	0.34	0.34	0.32	-6

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
<b>R03CC</b>	<b>Selective beta-2-adrenoreceptor agonists</b>				
	Estonia	0.29	0.29	0.26	-10
	Latvia	0.22	0.23	0.22	-3
	Lithuania	0.34	0.33	0.31	-6
<b>R03CC02</b>	<b>salbutamol</b>				
	Estonia	0.29	0.29	0.26	-10
	Latvia	0.22	0.23	0.22	-3
	Lithuania	0.34	0.33	0.31	-6
<b>R03D</b>	<b>OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES</b>				
	Estonia	2.50	2.53	2.66	5
	Latvia	3.34	3.45	3.68	7
	Lithuania	2.34	2.24	2.33	4
<b>R03DA</b>	<b>Xanthines</b>				
	Estonia	1.63	1.56	1.65	6
	Latvia	2.58	2.57	2.63	2
	Lithuania	1.48	1.45	1.49	3
<b>R03DA04</b>	<b>theophylline</b>				
	Estonia	1.58	1.51	1.60	6
	Latvia	2.20	2.20	2.25	2
	Lithuania	0.78	0.77	0.80	4
<b>R03DA05</b>	<b>aminophylline</b>				
	Estonia	0.06	0.05	0.05	
	Latvia	0.38	0.37	0.38	1
	Lithuania	0.70	0.68	0.69	1
<b>R03DC</b>	<b>Leukotriene receptor antagonists</b>				
	Estonia	0.86	0.98	1.00	2
	Latvia	0.76	0.88	1.01	15
	Lithuania	0.86	0.79	0.84	6
<b>R03DC03</b>	<b>montelukast</b>				
	Estonia	0.86	0.98	1.00	2
	Latvia	0.76	0.88	1.01	15
	Lithuania	0.86	0.79	0.84	6
<b>R03DX</b>	<b>Other systemic drugs for obstructive airway diseases</b>				
	Estonia	-	<0.01	<0.01	
	Latvia	<0.01	<0.01	0.04	
	Lithuania	-	-	-	
<b>R03DX07</b>	<b>roflumilast</b>				
	Estonia	-	-	-	
	Latvia	<0.01	<0.01	0.04	
	Lithuania	-	-	-	
<b>R05</b>	<b>COUGH AND COLD PREPARATIONS</b>				
	Estonia	6.18	6.95	7.13	3
	Latvia	6.03	6.60	6.90	4
	Lithuania	6.93	7.79	7.79	

## Consumption of antiasthmatics (R03)



ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
R05C	EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS				
	Estonia	6.06	6.83	7.01	3
	Latvia	5.86	6.48	6.78	5
	Lithuania	6.85	7.69	7.73	1
R05CA	Expectorants				
	Estonia	0.18	0.19	0.24	26
	Latvia	0.04	0.04	0.03	-24
	Lithuania	0.06	0.06	0.03	-50
R05CA03	guaifenesin				
	Estonia	0.18	0.19	0.24	26
	Latvia	0.04	0.04	0.03	-24
	Lithuania	0.06	0.06	0.03	-50
R05CB	Mucolytics				
	Estonia	5.87	6.64	6.77	2
	Latvia	5.82	6.44	6.75	5
	Lithuania	6.64	7.52	7.59	1
R05CB01	acetylcysteine				
	Estonia	2.79	3.20	3.39	6
	Latvia	1.75	1.78	2.10	18
	Lithuania	2.64	2.69	2.76	3
R05CB02	bromhexine				
	Estonia	1.14	0.97	0.84	-13
	Latvia	2.17	2.24	2.20	-2
	Lithuania	0.87	0.79	0.79	
R05CB03	carbocisteine				
	Estonia	0.08	0.09	0.22	144
	Latvia	0.12	0.11	0.10	-10
	Lithuania	0.10	0.12	0.14	17

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
R05CB06	<b>ambroxol</b>				
	Estonia	1.85	2.36	2.32	-2
	Latvia	1.78	2.30	2.35	2
	Lithuania	3.02	3.91	3.89	-1
R05CB13	<b>dornase alfa (desoxyribonuclease)</b>				
	Estonia	0.01	0.01	0.01	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	0.01	0.01	0.01	
R05D	<b>COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS</b>				
	Estonia	0.10	0.10	0.09	-10
	Latvia	0.17	0.13	0.12	-8
	Lithuania	0.08	0.10	0.07	-30
R05DA	<b>Opium alkaloids and derivatives</b>				
	Estonia	<0.01	-	-	
	Latvia	0.13	0.13	0.12	-8
	Lithuania	0.02	0.03	-	
R05DA08	<b>pholcodine</b>				
	Estonia	-	-	-	
	Latvia	-	-	-	
	Lithuania	0.02	0.03	-	
R05DA09	<b>dextromethorphan</b>				
	Estonia	-	-	-	
	Latvia	0.13	0.13	0.12	-8
	Lithuania	<0.01	-	-	
R05DB	<b>Other cough suppressants</b>				
	Estonia	0.10	0.10	0.09	-10
	Latvia	0.04	<0.01	<0.01	
	Lithuania	0.06	0.07	0.07	
R05DB09	<b>oxeladin</b>				
	Estonia	0.10	0.10	0.09	-10
	Latvia	0.04	<0.01	<0.01	
	Lithuania	0.06	0.07	0.07	
R05F	<b>COUGH SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS</b>				
	Estonia	0.01	0.02	0.03	50
	Latvia	-	-	-	
	Lithuania	-	-	-	
R05FA	<b>Opium derivatives and expectorants</b>				
	Estonia	0.01	0.02	0.03	50
	Latvia	-	-	-	
	Lithuania	-	-	-	
R05FA02	<b>opium derivatives and expectorants</b>				
	Estonia	0.01	0.02	0.03	50
	Latvia	-	-	-	
	Lithuania	-	-	-	

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
<b>R06</b>	<b>ANTI-HISTAMINES FOR SYSTEMIC USE</b>				
	Estonia	9.34	10.20	11.50	13
	Latvia	6.36	6.74	7.05	5
	Lithuania	7.28	7.92	8.63	9
<b>R06A</b>	<b>ANTI-HISTAMINES FOR SYSTEMIC USE</b>				
	Estonia	9.34	10.20	11.50	13
	Latvia	6.36	6.74	7.05	5
	Lithuania	7.28	7.92	8.63	9
<b>R06AA</b>	<b>Aminoalkyl ethers</b>				
	Estonia	0.53	0.62	0.61	-2
	Latvia	2.00	2.09	1.95	-7
	Lithuania	1.58	1.74	1.83	5
<b>R06AA04</b>	<b>clemastine</b>				
	Estonia	0.53	0.62	0.61	-2
	Latvia	2.00	2.09	1.95	-7
	Lithuania	1.58	1.74	1.83	5
<b>R06AC</b>	<b>Substituted ethylene diamines</b>				
	Estonia	-	-	-	
	Latvia	0.49	0.50	0.52	5
	Lithuania	-	-	-	
<b>R06AC03</b>	<b>chloropyramine</b>				
	Estonia	-	-	-	
	Latvia	0.49	0.50	0.52	5
	Lithuania	-	-	-	
<b>R06AE</b>	<b>Piperazine derivatives</b>				
	Estonia	4.34	4.71	5.54	18
	Latvia	1.91	2.02	2.34	16
	Lithuania	2.06	2.04	2.36	16
<b>R06AE07</b>	<b>cetirizine</b>				
	Estonia	3.95	4.36	5.12	17
	Latvia	1.57	1.67	2.03	22
	Lithuania	1.92	1.91	2.24	17
<b>R06AE09</b>	<b>levocetirizine</b>				
	Estonia	0.39	0.35	0.42	20
	Latvia	0.34	0.35	0.31	-12
	Lithuania	0.14	0.13	0.12	-8
<b>R06AX</b>	<b>Other antihistamines for systemic use</b>				
	Estonia	4.47	4.87	5.35	10
	Latvia	1.96	2.13	2.23	5
	Lithuania	3.62	4.14	4.44	7
<b>R06AX13</b>	<b>loratadine</b>				
	Estonia	2.58	2.73	3.18	16
	Latvia	1.15	1.24	1.22	-2
	Lithuania	2.34	2.75	2.75	
<b>R06AX17</b>	<b>ketotifen</b>				
	Estonia	0.01	0.01	<0.01	
	Latvia	0.27	0.25	0.24	-2
	Lithuania	0.01	-	-	




ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
<b>R06AX22</b>	<b>ebastine</b>				
	Estonia	0.98	1.10	1.12	2
	Latvia	0.11	0.10	0.10	-4
	Lithuania	0.77	0.88	0.83	-6
<b>R06AX26</b>	<b>fexofenadine</b>				
	Estonia	-	-	-	
	Latvia	0.03	0.02	<0.01	
	Lithuania	0.22	0.15	-	
<b>R06AX27</b>	<b>desloratadine</b>				
	Estonia	0.91	1.01	0.99	-2
	Latvia	0.40	0.51	0.66	29
	Lithuania	0.28	0.34	0.71	109
<b>R06AX28</b>	<b>rupatadine</b>				
	Estonia	-	0.02	0.05	150
	Latvia	<0.01	0.01	0.02	198
	Lithuania	-	0.03	0.15	400
<b>R07</b>	<b>OTHER RESPIRATORY SYSTEM PRODUCTS</b>				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	0.18	0.14	0.14	-5
	Lithuania	-	-	-	
<b>R07A</b>	<b>OTHER RESPIRATORY SYSTEM PRODUCTS</b>				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	0.18	0.14	0.14	-5
	Lithuania	-	-	-	
<b>R07AB</b>	<b>Respiratory stimulants</b>				
	Estonia	-	-	-	
	Latvia	0.18	0.14	0.14	-5
	Lithuania	-	-	-	
<b>R07AB02</b>	<b>nikethamide</b>				
	Estonia	-	-	-	
	Latvia	0.18	0.14	0.14	-5
	Lithuania	-	-	-	

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
<b>S</b>	<b>SENSORY ORGANS</b>				
	Estonia	21.43	20.38	24.00	18
	Latvia	17.09	19.17	21.34	11
	Lithuania	15.10	16.51	19.52	18
<b>S01</b>	<b>OPHTHALMOLOGICALS</b>				
	Estonia	21.43	20.38	24.00	18
	Latvia	17.09	19.17	21.34	11
	Lithuania	15.10	16.51	19.52	18
<b>S01E</b>	<b>ANTIGLAUCOMA PREPARATIONS AND MIOTICS</b>				
	Estonia	21.43	20.38	24.00	18
	Latvia	17.09	19.17	21.34	11
	Lithuania	15.10	16.51	19.52	18
<b>S01EA</b>	<b>Sympathomimetics in glaucoma therapy</b>				
	Estonia	-	<0.01	<0.01	
	Latvia	0.67	0.65	0.79	21
	Lithuania	0.28	0.69	1.19	72
<b>S01EA05</b>	<b>brimonidine</b>				
	Estonia	-	<0.01	<0.01	
	Latvia	0.67	0.65	0.79	21
	Lithuania	0.28	0.69	1.19	72
<b>S01EB</b>	<b>Parasympathomimetics</b>				
	Estonia	0.08	0.07	0.07	
	Latvia	0.04	0.04	0.01	-70
	Lithuania	0.01	<0.01	-	
<b>S01EB01</b>	<b>pilocarpine</b>				
	Estonia	0.01	<0.01	0.01	
	Latvia	0.04	0.04	0.01	-70
	Lithuania	0.01	<0.01	-	
<b>S01EB51</b>	<b>pilocarpine, combinations</b>				
	Estonia	0.08	0.07	0.06	-14
	Latvia	-	-	-	
	Lithuania	-	-	-	
<b>S01EC</b>	<b>Carbonic anhydrase inhibitors</b>				
	Estonia	1.69	1.66	1.93	16
	Latvia	1.38	1.55	1.70	10
	Lithuania	1.77	1.84	2.66	45
<b>S01EC01</b>	<b>acetazolamide</b>				
	Estonia	0.05	0.05	0.06	20
	Latvia	0.11	0.11	0.10	-6
	Lithuania	0.07	0.07	0.07	
<b>S01EC03</b>	<b>dorzolamide</b>				
	Estonia	0.59	0.60	0.72	20
	Latvia	0.55	0.61	0.63	2
	Lithuania	0.65	0.71	0.86	21

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
<b>S01EC04</b>	<b>brinzolamide</b>				
	Estonia	1.05	1.01	1.15	14
	Latvia	0.72	0.83	0.97	17
	Lithuania	1.05	1.07	1.72	61
<b>S01ED</b>	<b>Beta blocking agents</b>				
	Estonia	12.68	12.12	14.79	22
	Latvia	9.83	10.82	12.10	12
	Lithuania	7.06	7.26	7.91	9
<b>S01ED01</b>	<b>timolol</b>				
	Estonia	6.10	5.75	7.54	31
	Latvia	4.70	4.99	5.86	17
	Lithuania	2.10	1.94	1.98	2
<b>S01ED02</b>	<b>betaxolol</b>				
	Estonia	1.25	1.13	1.17	4
	Latvia	0.90	0.89	0.79	-12
	Lithuania	0.80	0.73	0.72	-1
<b>S01ED51</b>	<b>timolol, combinations</b>				
	Estonia	5.34	5.23	6.08	16
	Latvia	4.22	4.94	5.45	10
	Lithuania	4.16	4.59	5.21	14
<b>S01EE</b>	<b>Prostaglandin analogues</b>				
	Estonia	6.97	6.52	7.22	11
	Latvia	5.17	6.11	6.74	10
	Lithuania	5.99	6.73	7.77	15
<b>S01EE01</b>	<b>latanoprost</b>				
	Estonia	5.18	4.57	4.94	8
	Latvia	4.59	5.45	6.02	10
	Lithuania	4.71	4.84	5.45	13
<b>S01EE03</b>	<b>bimatoprost</b>				
	Estonia	-	-	<0.01	
	Latvia	0.09	0.15	0.22	48
	Lithuania	<0.01	0.29	0.66	128
<b>S01EE04</b>	<b>travoprost</b>				
	Estonia	1.79	1.95	2.19	12
	Latvia	0.44	0.41	0.34	-16
	Lithuania	1.28	1.59	1.57	-1
<b>S01EE05</b>	<b>tafluprost</b>				
	Estonia	-	0.01	0.09	800
	Latvia	0.05	0.10	0.16	58
	Lithuania	-	<0.01	0.09	

### Consumption of antiglaucoma preparations and miotics (S01E)



ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
V	VARIOUS				
	Estonia	0.08	0.09	0.12	33
	Latvia	0.06	0.05	0.05	2
	Lithuania	0.05	0.05	0.06	20
V03	ALL OTHER THERAPEUTIC PRODUCTS				
	Estonia	0.08	0.09	0.12	33
	Latvia	0.06	0.05	0.05	2
	Lithuania	0.05	0.05	0.06	20
V03A	ALL OTHER THERAPEUTIC PRODUCTS				
	Estonia	0.08	0.09	0.12	33
	Latvia	0.06	0.05	0.05	2
	Lithuania	0.05	0.05	0.06	20
V03AE	Drugs for treatment of hyperkalemia and hyperphosphatemia				
	Estonia	0.03	0.04	0.06	50
	Latvia	0.01	0.01	0.02	39
	Lithuania	0.01	0.02	0.02	
V03AE01	polystyrene sulfonate				
	Estonia	0.02	0.03	0.03	
	Latvia	0.01	0.01	0.01	58
	Lithuania	0.01	0.01	0.02	100
V03AE02	sevelamer				
	Estonia	<0.01	<0.01	0.01	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
V03AE03	lanthanum carbonate				
	Estonia	<0.01	0.01	0.02	100
	Latvia	<0.01	0.01	0.01	22
	Lithuania	-	-	-	
V03AE04	calcium acetate and magnesium carbonate				
	Estonia	-	-	-	
	Latvia	-	-	-	
	Lithuania	<0.01	<0.01	0.01	
V03AF	Detoxifying agents for antineoplastic treatment				
	Estonia	0.05	0.05	0.06	20
	Latvia	0.04	0.04	0.03	-12
	Lithuania	0.04	0.04	0.04	
V03AF03	calcium folinate				
	Estonia	0.05	0.05	0.04	-20
	Latvia	0.04	0.04	0.03	-12
	Lithuania	0.04	0.03	0.03	
V03AF10	sodium levofolate				
	Estonia	-	-	0.02	
	Latvia	-	-	-	
	Lithuania	<0.01	<0.01	0.01	

## 8. Top 15 most used prescription-only medicines

ESTONIA			
No	ATC	Active substance	DDD/1000/day
1	C09AA05	ramipril	62.86
2	C08CA01	amlodipine	37.05
3	C07AB02	metoprolol	22.31
4	C10AA07	rosuvastatin	19.42
5	C09AA02	enalapril	18.91
6	A02BC01	omeprazole	18.73
7	A10BA02	metformin	17.57
8	C09CA07	telmisartan	16.72
9	C09BA02	enalapril and diuretics	14.82
10	H03AA01	levothyroxine sodium	13.32
11	C07AB12	nebivolol	13.28
12	M01AB05	diclofenac	13.12
13	N05CF01	zopiclone	13.09
14	C09AA09	fosinopril	12.81
15	C01EB15	trimetazidine	11.33

LATVIA			
No	ATC	Active substance	DDD/1000/day
1	C09BA04	perindopril and diuretics	33.16
2	C10AA05	atorvastatin	30.31
3	M01AB05	diclofenac	23.85
4	C09AA02	enalapril	22.92
5	C09AA04	perindopril	21.00
6	C08CA01	amlodipine	20.28
7	C09BB04	perindopril and amlodipine	19.59
8	C09AA05	ramipril	19.47
9	A02BC01	omeprazole	17.95
10	C07AB07	bisoprolol	17.12
11	C07AB02	metoprolol	13.52
12	C09BA02	enalapril and diuretics	13.27
13	A10BA02	metformin	13.22
14	C09BA06	quinapril and diuretics	11.30
15	H03AA01	levothyroxine sodium	10.59

LITHUANIA			
No	ATC	Active substance	DDD/1000/day
1	C09AA05	ramipril	38.90
2	C07AB12	nebivolol	30.26
3	C01EB15	trimetazidine	22.92
4	C09AA04	perindopril	21.32
5	M01AB05	diclofenac	20.49
6	N05BA06	lorazepam	19.97
7	C09BA04	perindopril and diuretics	19.64
8	C09CA03	valsartan	19.45
9	C07AB02	metoprolol	18.34
10	C02AC05	moxonidine	17.18
11	C08CA13	lercanidipine	15.42
12	C09CA07	telmisartan	12.50
13	C09AA02	enalapril	11.75
14	H03AA01	levothyroxine sodium	11.58
15	C09BB04	perindopril and amlodipine	11.41

## 9. Top 15 most used ATC 3rd level groups

ESTONIA			
No	ATC	ATC group	DDD/1000/day
1	C09A	ACE INHIBITORS, PLAIN	95.73
2	B01A	ANTITHROMBOTIC AGENTS	78.83
3	C08C	SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS	65.60
4	M01A	ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STERIODS	61.00
5	C07A	BETA BLOCKING AGENTS	40.38
6	C10A	LIPID MODIFYING AGENTS, PLAIN	39.18
7	C09C	ANGIOTENSIN II ANTAGONISTS, PLAIN	38.46
8	A10B	BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS	37.44
9	A02B	DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)	30.48
10	C09B	ACE INHIBITORS, COMBINATIONS	29.35
11	R01A	DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE	27.92
12	G03A	HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE	27.40
13	S01E	ANTIGLAUCOMA PREPARATIONS AND MIOTICS	24.00
14	N06A	ANTIDEPRESSANTS	19.91
15	C09D	ANGIOTENSIN II ANTAGONISTS, COMBINATIONS	19.83

LATVIA			
No	ATC	ATC group	DDD/1000/day
1	C09B	ACE INHIBITORS, COMBINATIONS	84.88
2	B01A	ANTITHROMBOTIC AGENTS	74.04
3	C09A	ACE INHIBITORS, PLAIN	69.13
4	M01A	ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STERIODS	58.02
5	C10A	LIPID MODIFYING AGENTS, PLAIN	41.68
6	C07A	BETA BLOCKING AGENTS	40.12
7	C08C	SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS	36.73
8	A10B	BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS	31.86
9	A02B	DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)	28.26
10	R01A	DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE	23.62
11	S01E	ANTIGLAUCOMA PREPARATIONS AND MIOTICS	21.34
12	N07C	ANTIVERTIGO PREPARATIONS	13.78
13	N05B	ANXIOLYTICS	13.67
14	R03A	ADRENERGICS, INHALANTS	12.38
15	A10A	INSULINS AND ANALOGUES	11.05

LITHUANIA			
No	ATC	ATC group	DDD/1000/day
1	C09A	ACE INHIBITORS, PLAIN	111.79
2	B01A	ANTITHROMBOTIC AGENTS	63.49
3	M01A	ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STERIODS	62.25
4	C07A	BETA BLOCKING AGENTS	57.95
5	C09C	ANGIOTENSIN II ANTAGONISTS, PLAIN	44.24
6	C09B	ACE INHIBITORS, COMBINATIONS	44.18
7	N05B	ANXIOLYTICS	40.53
8	C08C	SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS	33.70
9	A02B	DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)	31.87
10	A10B	BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS	25.58
11	C01E	OTHER CARDIAC PREPARATIONS	25.23
12	N06A	ANTIDEPRESSANTS	23.40
13	R01A	DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE	22.49
14	S01E	ANTIGLAUCOMA PREPARATIONS AND MIOTICS	19.52
15	C02A	ANTIADRENERGIC AGENTS, CENTRALLY ACTING	17.25

## 10. TOP 15 of over-the-counter medicines

ESTONIA			
No	ATC	Active substance	DDD/1000/day
1	B01AC30	acetylsalicylic acid combinations	51.55
2	R01AA07	xylometazoline	20.87
3	M01AE01	ibuprofen	19.71
4	B01AC06	acetylsalicylic acid	13.40
5	N02BE01	paracetamol	5.49
6	A06AD11	lactulose	5.44
7	N06DX02	ginkgo folium	4.78
8	R05CB01	acetylcysteine	3.38
9	A06AB02	bisacodyl	3.24
10	A06AB08	sodium picosulfate	2.75
11	R06AE07	cetirizine	2.37
12	R05CB06	ambroxol	2.32
13	G04CX02	sabalis serrulatae fructus	2.29
14	R06AX13	loratadine	2.18
15	A03AD02	drotaverine	1.42

LATVIA			
No	ATC	Active substance	DDD/1000/day
1	B01AC06	acetylsalicylic acid	64.61
2	M01AE01	ibuprofen	18.45
3	R01AA07	xylometazoline	16.84
4	A01AA01	sodium fluoride	6.33
5	A03AD02	drotaverine	4.22
6	A09AA02	multienzymes (lipase, protease etc.)	4.04
7	A03BA04	belladonna total alkaloids	3.16
8	B03AD02	ferrous fumarate	3.11
9	N02BA51	acetylsalicylic acid, combinations excl. psycholeptics	2.89
10	A02BA02	ranitidine	2.83
11	A06AB02	bisacodyl	2.72
12	R05CB06	ambroxol	2.35
13	N02BE51	paracetamol, combinations excl. psycholeptics	2.29
14	R01AA08	naphazoline	2.20
15	R05CB02	bromhexine	2.20

LITHUANIA			
No	ATC	Active substance	DDD/1000/day
1	B01AC06	acetylsalicylic acid	47.53
2	R01AA07	xylometazoline	15.64
3	M01AE01	ibuprofen	7.42
4	N02BE51	paracetamol, combinations excl. psycholeptics	5.76
5	R05CB06	ambroxol	3.89
6	A03AD02	drotaverine	3.23
7	A02BA02	ranitidine	3.23
8	N02BE01	paracetamol	3.02
9	R05CB01	acetylcysteine	2.76
10	A06AD11	lactulose	2.42
11	A06AB02	bisacodyl	2.27
12	A06AB08	sodium picosulfate	2.24
13	N06DX02	ginkgo folium	1.97
14	A02BC02	pantoprazole	1.57
15	N02BA01	acetylsalicylic acid	1.39



## 11. Contacts



■ **Estonian State Agency of Medicines  
(Ravimiamet)**

1 Nooruse Street  
50411 Tartu  
Estonia  
info@ravimiamet.ee  
www.ravimiamet.ee



Zāļu valsts aģentūra

■ **Latvian State Agency of Medicines  
(Zāļu valsts aģentūra)**

15 Jersikas Street  
LV-1003 Riga  
Latvia  
info@zva.gov.lv  
www.zva.gov.lv



■ **Lithuanian State Medicines Control Agency  
(Valstybinė vaistų kontrolės tarnyba)**

139A Žirmūnų Street  
09120 Vilnius  
Lithuania  
vukt@vukt.lt  
www.vukt.lt

## 12. References

1. WHO Collaborating Centre for Drug Statistics Methodology. ATC/DDD methodology. ([http://www.whocc.no/atc\\_ddd\\_methodology/purpose\\_of\\_the\\_atc\\_ddd\\_system](http://www.whocc.no/atc_ddd_methodology/purpose_of_the_atc_ddd_system))
2. Estonian Statistics on Medicines. (<http://www.ravimiamet.ee/en/statistics-medicines>)
3. Statistics on medicines consumption of Latvia ([http://www.zva.gov.lv/doc\\_upl/Zalu\\_paterina\\_statistika\\_2012-20130604.pdf](http://www.zva.gov.lv/doc_upl/Zalu_paterina_statistika_2012-20130604.pdf))
4. Medicines consumption 2012 in Lithuania. (<http://www.vvkt.lt/Annual-Reports>)
5. Estonian Health Insurance. Health Insurance in Estonia. (<http://www.haigekassa.ee/eng/health-insurance-in-estonia>)
6. Statistics Estonia. (<http://www.stat.ee>)
7. Pudersell, K., Vetka, A., Rootslane, L., Mathiesen, M., Vendla, K., Laasalu, K.: PPRI Pharma Profile Estonia 2007. June; Pharmaceutical Pricing and Reimbursement Information; Commissioned by the European Commission, Directorate-General Health and Consumer Protection and Austrian Federal Ministry of Health, Family and Youth. (<http://whocc.goeg.at/Publications/CountryReports>)
8. Central Statistical Bureau of Latvia. (<http://data.csb.gov.lv/DATABASEEN/ledz/databasetree.asp>)
9. World Health Organization. Global Health Expenditure Database. (<http://apps.who.int/nha/database/PreDataExplorer.aspx?d=1>)
10. The World Bank. Health expenditure per capita. (<http://data.worldbank.org/indicator/SH.XPD.PCAP/countries>)
11. The Centre for Disease Prevention and Control of Latvia. (<http://www.spkc.gov.lv>)
12. The National Health Service of Latvia. (<http://www.vmnvd.gov.lv>)
13. Garuoliene K., Alonderis T., Marcinkevičius M. Pharmaceutical policy and the effects of the economic crisis: Lithuania. *Eurohealth*. 2011; 17(1): 1-4.



